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a. Osteoporosis and osteoporotic fractures 
Osteoporosis is a chronic disease characterised by loss of bone mass and 
microarchitectural deterioration of the bones, culminating in bone fragility and ultimately 
an increased risk of fractures, named osteoporotic (OP) fractures.1,2 It is estimated that 
around 22% of women and 7% of men aged 50 years and above were afflicted with 
osteoporosis in Europe in 2010.3 There are two main variants of the disease by aetiology. 
Primary osteoporosis occurs predominantly along with the natural ageing process or due 
to hormonal changes, as observed in elderly individuals and postmenopausal women. 
Secondary osteoporosis occurs due to another medical condition or medication use, such 
as inflammatory rheumatic diseases including rheumatoid arthritis (RA), endocrine 
abnormalities (thyroid disorders, hyperparathyroidism, hypogonadism, hypopituitarism, 
or type I diabetes mellitus), inflammatory bowel disease, exposure to glucocorticoids 
(GCs), prolonged immobility (e.g. due to spinal cord injury, Parkinson’s disease, stroke, or 
muscular dystrophy), and organ transplantation.4 According to the definition by the 
World Health Organisation (WHO), diagnosis of osteoporosis is based on the bone 
mineral density (BMD) measurement by dual-energy X-ray absorptiometry (DXA).5 A BMD 
T-score of 2.5 standard deviations (SDs) below the mean BMD of the young adults from 
the reference population defines osteoporosis, while a BMD T-score between -1 and -2.5 
SDs compared with the reference mean shows osteopenia, and a BMD T-score above -1 
SD denotes normality.  
The main manifestation of osteoporosis are OP fractures. Various definitions exist for OP 
fractures in the literature, however most identify these as fractures occurring from a low-
energy trauma, such as falling from a standing position.6-8 The WHO/FRAX definition 
considers hip, clinically symptomatic vertebral, humerus, and forearm (radius/ulna) as 
major OP fractures (MOFs).9,10 But still, other anatomical sites such as pelvis, ribs, distal 
femur, clavicle, scapula, sternum, tibia and fibula are considered as an OP fracture site.6 
Vertebral fracture is the most common OP fracture, where one in every five men or 
women aged 50+ years is affected by at least one vertebral fracture.11 The diagnosis of a 
vertebral fracture is based on vertebral deformity on radiographs or clinical features. Two 
thirds of vertebral fractures remain to be asymptomatic and might only be accidentally 
found on chest radiographs for other reasons.12 Hip fracture is the 2nd most common OP 
fracture, with observed increasing rates in older age and also with postmenopausal 
status in women. In 2010, the lifetime probability of hip fracture from the age of 50 years 
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estimated to be 15% among women and 5% in men.8 It is the most severe among OP 
fractures with substantial need for hospitalisation and treatment, and high morbidity, 
mortality and substantial societal costs.13 Forearm fracture is the other common OP 
fracture, associated with much less morbidity and mortality, compared with hip and 
vertebral fractures. The term ‘advanced severe osteoporosis’ has been proposed, when 
there is a hip fracture or at least two other non-hip fractures in addition to the BMD T-
score ≤-2.5 SDs.14 
 
b. Secular trends in osteoporotic fractures 
The absolute number of hip fractures is generally increasing due to the worldwide 
increase in life expectancies and ageing trajectory. In the UK, the incidence rate (IR) of 
hip fracture between 2008 and 2012 was 33.5 per 10,000 person years (PYs) among 
women aged 50+ years and 13.4 per 10,000 PYs among men aged 50+.15 However, the 
trend in age-standardised IRs is different across the globe. Most reports from North 
European and North American countries (i.e., those with the highest IRs of hip fracture) 
indicate rising trends until the 1980s/1990s and then a decrease in the subsequent two 
decades.16-19 In contrast, increasing trends in age-standardised IRs of hip fracture have 
been observed in the Asian countries over a similar time period, highlighting a contrast in 
the reported trends between the West and the East.20-23 There are fewer reports on the 
secular trend in OP fractures other than hip. These studies from the UK and the US 
reported a mostly increasing trend in humerus and vertebral fractures and a decline in 
other fracture sites.15,24 
Considering the impending ageing trajectory and the increase in absolute number of OP 
fractures, the burden of these fractures on patients and healthcare systems will become 
more critical in the near future. The associated costs of OP fractures in Europe, including 
the costs of acute treatment of fracture, the costs of pharmacologic prevention and long-
term care, was estimated to be €37.4 billion in 2010, where more than half was caused by 
hip fracture alone.3,25 These costs are expected to double by 2050.26 The changing trends 
of OP fractures in various countries and the huge expected economic burden 
accompanied with OP fractures in the near future led the International Osteoporosis 
Foundation (IOF) working group on Fracture Epidemiology to ask for updates on secular 
trends in IRs of OP fractures.16 As there were few reports globally on the secular trend in 





this thesis, the IRs of hip and other MOFs among adults aged 50+ years in Denmark 
between 1995 and 2010. 
 
c. Mortality after fracture and the role of bisphosphonates 
High mortality is a devastating outcome of an OP fracture. More than one third of men 
and more than one fifth of women suffering a hip fracture will die within one year.19 This 
1-year all-cause mortality after hip fracture is 3.5-fold higher in males and 2.4-fold higher in 
females compared with controls without a fracture.27 Of those patients who sustained an 
OP fracture, around 51% of men and 39% of women will die within five years.28 A significant 
contributor to this high mortality is a subsequent fracture and mortality after that.28,29  
Anti-osteoporotic treatment such as bisphosphonates (BPs) can prevent a subsequent 
fracture in patients with osteoporosis.30 There is conflicting evidence from randomised 
controlled trials (RCTs) that BPs can reduce mortality after hip fracture.31-33 Observational 
studies have also found contrasting results regarding the effect of BPs on mortality risk 
after fracture, although their findings might be flawed due to methodological 
limitations.34-36 There is no established biological mechanism for BPs to reduce mortality 
aside from secondary fracture prevention. However, some evidence points to anti-
atherosclerotic effects of BPs, such as reducing arterial wall calcification or decreasing 
lipid profiles.37-40 This pile of evidence brought scepticism for any beneficial effect of BPs 
on mortality risk after fracture. Therefore, we examined the association between oral BP 
use and all-cause mortality after OP fractures in a large nationwide cohort study. 
 
d. Oral glucocorticoids, risk factor for osteoporotic fractures 
Oral GCs are one of the oldest and most important anti-inflammatory medications that 
are widely used for a constellation of chronic inflammatory conditions including 
rheumatic, respiratory, dermatologic, neurologic, and gastrointestinal diseases. 
Epidemiologic studies showed that the prevalence of oral GC use at any time point was 
about 1% in the general population of the UK and the US.41,42 But besides their potent anti-
inflammatory effects, oral GCs incur considerable side effects to the patient. 
Osteoporosis and OP fractures are amongst the best-established side effects.43-45 The 
reason behind this GC-induced higher fracture rate is apoptosis of osteoblasts and 
osteocytes and reduced bone formation, elevated bone resorption and hence lowered 
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Previous studies have shown that the OP fracture risk associated with oral GC use is dose-
dependent.44,47,48 The existing evidence signifies a potential role for both daily dose and 
cumulative dose of oral GCs in raising the OP fracture risk, but with more emphasis on 
daily dose.44,47,48 However, taking oral GCs for short periods, even in high daily doses, 
would not substantially increase the fracture risk when the cumulative use is less than 1 g 
prednisolone equivalent dose (PED).47 Many patients with chronic inflammatory 
conditions use oral GCs intermittently in short periods, or sometimes for a longer time, 
due to the repeated relapses of the underlying disease. There is already limited data on 
the OP fracture risk associated with various exposure patterns of oral GCs. Thus, we 
sought to examine the association between daily dose and cumulative exposure to oral 
GCs and OP fracture risk by using a large national registry. 
 
e. Rheumatoid arthritis and its pharmacotherapy, risk factors for 
osteoporotic fractures  
RA is a chronic autoimmune inflammatory musculoskeletal disease with an unknown 
aetiology. It affects around 0.5-1.0% of adult population in developed countries and is 
more prevalent among elderly individuals and women.49 The hallmark of RA is the 
presence of synovitis, which in a subgroup of patients can result in joint damage of mainly 
the small joints of hands and feet.50 Patients experience pain, morning stiffness, and 
limited range of motion in the affected joints. In addition, extra-articular manifestations 
such as rheumatoid nodules can be detected in clinical examination. In the majority of 
patients, laboratory tests reveal presence of serum rheumatoid factor (RF), 
anticitrullinated protein antibody (ACPA), and elevated levels of erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP). In more advanced cases, bone and 
cartilage erosions are observed in imaging. These manifestations drive the clinical 
diagnosis of RA but are also part of the RA classification criteria available for research 
purposes.51  
The treatment for RA should start as early as possible to prevent further damage and to 
avoid complications and comorbidities. Analgesics and non-steroidal anti-inflammatory 
drugs (NSAIDs) are prescribed to control the pain and stiffness in patients. The European 
Alliance of Associations for Rheumatology (EULAR) recommends starting a conventional 
synthetic disease-modifying antirheumatic drug (csDMARD, such as methotrexate, 
leflunomide, sulfasalazine, or hydroxychloroquine) as first-line therapy, in combination 





absence of clinical improvement at 3- and 6-months targets, change to other csDMARDs 
or adding a biological DMARD (bDMARD) or a targeted synthetic DMARD (tsDMARD, i.e., 
Janus kinase inhibitors, such as tofacitinib, baricitinib, and filgotinib) should be 
considered. The bDMARDs recommended for RA include tumour necrosis factor (TNF) 
inhibitors (i.e., adalimumab, infliximab, certolizumab, etanercept, and golimumab), 
costimulation inhibitors (such as abatacept), interleukin (IL)-6 blockers (tocilizumab, 
sarilumab, clazakizumab or sirukumab), and anti-B-cell agent rituximab. Despite the 
growing number of new medications, a considerable number of patients do not achieve 
optimal disease control, which is partly due to adverse effects of the medications.53 
The inflammatory process of RA can contribute to comorbidities such as osteoporosis, in 
addition to cardiovascular disease, depression, and disability (especially in severe cases or 
with under-treatment).54,55 Previous studies showed that patients with RA have a 1.5-fold 
increased risk of OP fractures compared with controls without a history of RA, which was 
more prominent in the hip/femur and spine (significant adjusted relative risks 2.0 and 2.4, 
respectively).56 The increased fracture risk in RA is also dependent on the duration of RA 
disease, persistent disease activity, and the pharmacotherapy that RA patients receive, 
particularly GCs. 
Using GCs in RA is advised to be short-term and preferably in lower doses to minimise the 
risk of adverse effects.52 There is evidence from RCTs that low-dose GC therapy in RA 
could even have protective effects on bone: taking 7.5 mg prednisolone once daily had 
reduced BMD loss in hand or hip compared to placebo.57,58 Plausible biological 
explanations might not only be the regulation of the adverse impact of RA-related 
systemic inflammation on bone metabolism, but also the beneficial effect of increased 
physical performance due to the improved functional status of patient. Based on this 
reasoning, low-dose GC therapy may also bring about beneficial effects on OP fractures. 
To date, there are few observational studies that examined the association between low-
dose GC therapy (≤7.5 mg PED/day) and OP fracture risk in RA patients.59-61 Most of these 
studies have found higher fracture rates with low-dose GC use compared with non-use. 
These findings are in contrast to the aforementioned RCTs on BMD and might be spurious 
due to methodological limitations. Thus, we aimed to investigate the use of low-dose oral 
GCs on OP fracture risk among patients with RA, in a large cohort study that considers 
various thresholds of low-dose oral GC use and different OP fracture sites. 
Apart from GCs, other medications frequently prescribed for patients with RA might also 
be associated with OP fractures. Proton pump inhibitors (PPIs) are routinely co-




 15  
There is evidence from observational studies that PPIs might increase hip and vertebral 
fracture risk.62-65 This increased fracture risk by PPIs was attributed to induced 
hypochlorhydria by PPIs and reduced calcium absorption, or to unmeasured bias or 
confounding according to other authors.66,67 To the best of our knowledge, the 
association between concomitant use of oral GCs and PPIs and risk of fracture was never 
studied among patients with RA, and only once in the general population but yet with no 
definite conclusions.67 Furthermore, with the increasing life expectancies and ageing 
populations, use of PPIs could become more ubiquitous, as it is commonly used among 
elderly patients. So, we investigated the association between concomitant use of oral GCs 
and PPIs and the risk of OP fractures among patients with RA with a well-designed cohort 
study. 
A more recently developed class of drugs for RA treatment, the bDMARDs, have been 
postulated by the literature to be related to fragility fractures as they are potent 
suppressors of disease activity. Certain types of inflammatory cytokines in RA have 
important roles in activation and maturation of osteoclasts and finally bone resorption, 
including macrophage colony-stimulating factor, TNF-α, IL-1, IL-6, and IL-17.68 They are 
ultimately responsible for an increase in the ratio of receptor activator of nuclear factor-
κB ligand to osteoprotegerin (RANKL/OPG ratio), which directly results in bone loss. 
Previous clinical trials reported inconsistent results for a protective effect on bone health 
in RA patients by maintaining BMD in hands, hip or vertebrae after using infliximab or 
adalimumab (TNF-α inhibitors).69-72 But, the studies on the association between various 
bDMARDs and fracture risk in RA or similar chronic arthropathies failed to show such a 
beneficial role for bDMARDs.73-76 Lack of RCTs due to ethical considerations, paucity of 
observational studies, and the contrasting results of the existing literature have led the 
IOF working group on Chronic Inflammation and Bone Structure to affirm the unmet 
need for additional and high quality data on the association between bDMARDs and OP 
fracture risk in RA.68 Therefore, we aimed to investigate the effect of bDMARDs on OP 
fracture risk compared with no treatment with biologicals in patients with RA in a 
nationwide cohort study. 
 
f. Pharmacoepidemiology, applications and limitations  
Pharmacoepidemiology is an interdisciplinary field to study the effectiveness and side 
effects of medications in real-world settings.77 It brings together various fields such as 





methods to design and conduct studies, and then to interpret the results. 
Pharmacoepidemiological studies and methodologies are used for post-authorisation 
drug evaluations. This ideally allows to have enough time for some of the longer-term or 
rarer adverse effects (or sometimes beneficial effects) of drugs to develop in real 
patients, for whom the drug was originally intended. This is in contrast with pre-
authorisation RCTs that have stringent inclusion and exclusion criteria without enough 
generalisability to the real-world populations. In this thesis, we tried to address the 
previously mentioned knowledge gaps in the literature by means of the 
pharmacoepidemiological methodologies. It is also very advantageous to use 
observational pharmacoepidemiological studies for studying a debilitating and 
uncommon outcome such as OP fracture. One can name various reasons that make it 
practically impossible to conduct RCTs to study OP fractures, such as ethical 
considerations, generalisability issues, high costs, and a necessity for a long follow-up 
time and a large sample size. 
To answer the study objectives in this thesis, a couple of validated and robust electronic 
healthcare databases (EHDs) were used, and some established or state-of-the-art study 
designs were employed. For three studies, data were used from the British Clinical 
Practice Research Datalink, CPRD GOLD. This is one of the world’s largest primary care 
databases, which covered 11.3 million patients from 674 practices in the UK in 2013.78 The 
other three studies were based on data from the Danish National Patient Registry (DNPR, 
with information on all hospitalisation and outpatient records), and the DANBIO (a 
specific register for certain inflammatory rheumatic diseases such as RA in Denmark), 
both with comprehensive nationwide coverage and quality research data.79,80 For the 
study on trends of OP fractures, a series of cross-sectional analyses was used. A case-
control design was utilised to investigate the oral GCs-fracture association in the general 
population of Denmark. For the other studies, we made use of a retrospective cohort 
design. 
Pharmacoepidemiological studies as a form of observational research investigate the 
real-world evidence, and in theory cannot randomise patients to various treatment arms, 
as in RCTs that are considered gold standard for studying the causal effects of 
interventions. To mimic the randomisation performed in RCTs, one needs proper and 
sometimes complicated study designs and methodologies, which in turn can end up in 
important limitations.81 It is key to be aware of these limitations when designing the 
study and to find ways to avoid or minimise them. An in-depth methodological evaluation 
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of this thesis. There, we explain different sorts of confounding and bias that we might 
have encountered in our studies, the strategies to minimise or avoid them, and any 
remaining impact on the final results. 
  
g. Objectives of this thesis 
The overall objective of this thesis was to study the OP fractures and their relation to 
mortality, medication use and RA. There are two sub-objectives in this thesis, each 
represented with a corresponding section: 1) investigating various attributes of OP 
fractures in the general population, including a recent secular trend, the mortality after 
fracture in association with oral BP use, and the association between various exposure 
patterns of oral GCs and OP fracture risk; 2) evaluating the role of medications (low-dose 
oral GCs, concomitant oral GCs and PPIs, and bDMARDs) in OP fracture risk among 
patients with RA. 
 
h. Outline of chapters 
This thesis contains two sections and eight chapters. Section 1 addresses the 1st sub-
objective of this thesis regarding the various attributes of OP fractures in the general 
population. Under this section, Chapter 2 describes recent secular trends in OP fractures 
in Denmark, and in Chapter 3 the association between oral BP use and mortality risk after 
an OP fracture has been studied using the CPRD. Still, Chapter 4 addresses the role of 
various exposure patterns of oral GC use in OP fracture risk in the general population of 
Denmark. Section 2 answers the 2nd sub-objective of this thesis, entailing three chapters 
representing three cohort studies conducted among patients with RA, which investigate 
the association between various medication use and OP fracture risk. In Chapter 5, we 
studied the effect of low-dose oral GC therapy on OP fracture risk in patients with RA 
using the CPRD. In Chapter 6, the association between concomitant use of oral GCs and 
PPIs in RA and risk of OP fractures in the CPRD has been investigated. In Chapter 7, we 
aimed to compare OP fracture risk with use of bDMARDs to no treatment with biologicals 
in patients with RA using the nationwide Danish registries. The thesis is concluded with 
Chapter 8, as the general discussion of the main findings of the accomplished studies, 
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The trend in osteoporotic fractures is varied across the globe, and there is no updated 
information in the case of Denmark for all major osteoporotic fractures (MOFs). Thus, we 




A series of cross-sectional analyses was done using the Danish National Health Service 
Register. Participants were 50+ adults in the full country Denmark with a MOF between 
1995 and 2010. Gender-specific IRs of MOFs per 10,000 person years (PYs) were 
estimated, in addition to IRs of individual fracture sites (hip, vertebrae, humerus, and 
radius/ulna), and women-to men IR ratios for MOFs. 
 
Results 
A general decline was observed in IRs of MOFs for the whole population (from 169.8 per 
10,000 PYs in 1995, to 148.0 in 2010), which was more pronounced among women. Thirty-
one and nineteen percent of decline was observed in hip fracture rates among women 
and men, respectively. The trend in clinical vertebral fracture was slightly decreasing for 
women and increasing for men. The women-to-men rate ratio of MOFs decreased 
noticeably from 2.93 to 2.72 during study period. 
 
Conclusions 
We observed declining trends in MOFs and hip fracture for both sexes. However, a lower 
rate of decrease of hip fracture and an increasing trend in vertebral fracture was noticed 
among men. Considering our observations and the major economic burden that 








Secular trends in major osteoporotic fractures among 50+ adults in Denmark between 1995 and 2010 
 27 
b. Introduction 
This article was published in error in Archives of Osteoporosis and has now been 
retracted.1 Osteoporosis is a systemic metabolic skeletal disease where reduced bone 
mineral density would make patients susceptible to fractures, called osteoporotic (OP) 
fractures. Based on literature consensus, major osteoporotic fractures (MOFs) include 
mostly hip, clinical vertebral, humerus, and forearm (radius/ulna) fractures, which 
altogether are a leading cause of morbidity and mortality worldwide.2 OP fractures 
incurred 5.8 million lost Disability-Adjusted Life Years (DALYs) worldwide in the year 
2000, of which 51% was represented by two WHO world regions Europe and the 
Americas.3 The occurrence of a MOF would not only impact the well-being and function 
of a patient, including an elevated mortality risk, but also has substantial economic 
consequences.4-9 It is estimated that in the year 2011, the associated costs of OP fractures 
were €36 billion in Europe, and €1.6 billion in Denmark (including both direct and 
productivity costs), and these costs are estimated to double by 2050.10,11 
The predicted increase in OP fractures has been reported in numerous countries, 
including the USA, China, and in worldwide projections (especially developing countries), 
and is in large part due to the impending ageing trajectory.12-14 A recent study in the UK 
with a relatively long follow-up time (1990–2012) revealed mostly a rising or steady trend 
for most OP fractures in both men and women.15 However, despite the expected 
increase, a number of studies have identified a levelling, or decline in hip fractures in 
recent years.16-21 This led the International Osteoporosis Foundation (IOF) working group 
on fracture to request for updates on secular trends in hip and other OP fracture 
incidence rates (IRs).22 In Danish studies, age-adjusted hip fracture IRs increased between 
1977 and 1999, yet a decline, particularly in women, has been observed since 1997.23-25 This 
trend of increasing fractures up to the 1990s, with a levelling of fracture rates in the past 
two decades, has been noted by others.18,19,26 Apart from two single year studies which 
surveyed the IRs of forearm and OP fractures in 2010 and 2011, respectively, and two 
reports on hip fracture trend until 2006 and 2010, there has never been a country-specific 
report on secular incidence trends in all OP fractures for Denmark.24,25,27,28 Thus, the aim 
of this study was to investigate the IRs of MOFs among adults aged 50 years or older in 








c. Methods  
Data Source 
We used data from the registry of the Danish National Health Service. The extensive 
registers in Denmark cover all contacts to the health sector for all citizens, without age 
restriction. This includes approximately 5.2 million individuals in 1995 and 5.5 million in 
2010.29 The unique 10-digit civil registry number allocated to each Danish citizen was used 
to link the population-based registries and generate a complete hospital discharge history 
for each patient. Data on vital status for the Danish population have been collected since 
1968 in the Civil Registration System, and all inpatient contacts have been registered in 
the Danish National Hospital Discharge Register (NHDR) since 1977.30 The NHDR covers all 
inpatient contacts since 1977, and beginning in 1995, the NHDR captures also all 
outpatient visits to hospitals, outpatient clinics, and emergency room visits. The validity 
of the Danish National fracture records has been previously verified.31 
 
Study Design 
We included patients, aged 50 years or older, who were diagnosed with a fracture in the 
period between 1995 and 2010. MOFs were identified in accordance with the WHO/FRAX 
definition as hip, clinical symptomatic vertebral, humerus, or forearm (radius/ulna) 
fracture.32,33 They were clustered by site using the following International Classification of 
Diseases and Related Health Problems 10th Edition (ICD-10) codes: hip (S72.0-S72.2), 
clinical symptomatic vertebral (S12, S22.0, S22.1, S32.0, T08), humerus (S42.2-S42.4), and 
forearm (S52). As it is possible that the original fracture and follow-up visits or procedures 
may have the same ICD-10 code, we introduced a washout period to avoid double 
counting fractures in individuals. As 1995 was the first year of observation, we also 
applied a 1-year washout period prior to 1995. Thus, if a patient had a hip fracture code 
(ICD-10 S72.2) in 1995 and also had the same code in 1994, we did not include this in our 
analysis as we could not be certain that it was a new hip fracture or a recurring follow-up. 
After 1995, we took the first recorded fracture code in each calendar year and assessed if 
the patient had a previous code for the same fracture, or unspecified fracture, in the prior 
365 days. If there were no codes for a prior fracture of the same type, or unspecified, in 
the prior 365 days, it was deemed an eligible new fracture, otherwise it was excluded. 
Additionally, for MOF, the first occurrence of a hip, clinical symptomatic vertebral, 
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Statistical Analysis 
Population demographics for the background population in calendar years 1995–2010 
were obtained online from Statistics Denmark.29 IRs (number of fractures/10,000 person 
years [PYs]), and corresponding 95% confidence intervals (95% CI), were calculated by 
dividing all cases of first recorded fractures during the calendar year over the average 
number of persons alive in that calendar year. For example, to calculate the denominator 
for the year 2010, we first summed the number of people alive on 1 January 2010 and 
those alive on 1 January 2011, then divided this sum by two. Gender-specific IRs were 
estimated in addition to site-specific fracture rates. While we did not produce age-specific 
rates, we were able to standardise the IRs to the annual Danish population over the age 
50, using the Statistics Denmark data. This permits a comparison to a similar age 
distribution. Women-to-men incidence rate ratios (IRRs) were calculated for MOFs and 
determined by dividing the IR for women over the IR for men. The IRs were plotted over 
time both for MOFs, as well as specific fracture sites, and the plots were examined by 




We identified a total of 422,380 MOFs in Danish adults over 50 between 1995 and 2010, 
where a sum of 101,177 fractures occurred among men, and 321,203 cases among women 
(Table 2.1); thus, females sustained 76.0% of all MOFs. There was a 4.5% relative increase in 
the total number of MOFs from 1995 to 2010, although apart from a spike in 2010, the 
numbers were dropping until 2009. The mean age at first occurrence of a MOF was 74.1 
years, and the age distribution was constant across all years. 
A general decline was observed in the IRs of MOFs for the whole population, where IRs 
dropped from 169.8 per 10,000 PYs in 1995 to 148.0 in 2010 (Table 2.1), as visualised in 
Figure 2.1. Among women, the rates for the MOF dropped during this 16-year study period 
from 242.8 to 211.5; however, it is worth mentioning that the rates had dropped even 
lower in the years 2008 and 2009 (IRs 188.3 and 186.2, respectively). For men, the MOF 
rates exhibited a smaller decrease from 82.9 in 1995 to 77.6 in 2010. The women-to-men 
rate ratio of MOFs decreased noticeably from 2.93 (95% CI, 2.85–3.01) in 1995 to 2.72 (95% 







                                                                                                                                                                                                                                                                                                           
 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.1. Incidence rates of major osteoporotic fractures for Danish adults aged 50+, stratified by sex 
and calendar year, 1995-2010. 95% confidence intervals are shown by small bars for each graph line and 
calendar year.  
IR: incidence rates, PYs: person years. 
 
Regarding hip fractures, a total of 152,571 cases were identified, where 72.3% (110,349) of 
all hip fractures occurred in women, and 27.7% (42,222) occurred in men. The mean age 
for occurrence of hip fracture among the whole population was 80.0 years. The overall 
hip fracture IRs decreased during the study period, i.e., 1995 to 2010 from 64.1 per 10,000 
PYs to 45.5, respectively, and this decrease was more prominent in women (Figure 2.2a). 
We observed a 31% decline in hip fracture rates (from 87.2 to 59.9 per 10,000 PYs) among 
women and 19% decline (from 36.5 to 29.6 per 10,000 PYs) among men. 
The IRs over time for the other MOF subsites are provided in Figure 2.2b–d. The trend for 
clinical vertebral fracture remained steady between 1995 and 2010, yet there was a 
slightly decreasing trend for women and an increasing trend for men (Figure 2.2b). 
Overall, humerus fracture rates remained stable, and this steady state was observed 
among both men and women (Figure 2.2c). Regarding forearm fractures, there is a 
declining trend for the whole study population from 1995 to 2009 (IRs dropped from 73.0 
in 1995 to 55.5 in 2009), but there was a spike in 2010 (IRs 69.1) (Figure 2.2d). Women 
followed a similar trend to the overall trend regarding radius/ulna fracture, while for men, 
a smaller decrease was observed. The mean age of occurrence was 72.4 years for clinical 
vertebral fracture, 73.6 years for humerus fracture, and 69.6 years for radius/ulna 
fracture. Furthermore, females sustained 61.5% of all clinical vertebral fractures, 76.4% of 




































Figure 2.2. Incidence rates of major osteoporotic fracture subsites (a hip, b clinical vertebral, c 
humerus, d radius/ulna) for Danish adults aged 50+, stratified by sex and calendar year, 1995–2010.  




In this study, we observed a reduction in IRs of MOFs from 1995 to 2010 in 50+ adults in 
Denmark, where the striking finding was a reduction in hip fracture rates in both men and 
women. Among women, the IRs of all MOFs have been declining, with exception of a 
rather steady state for humerus. But in men, apart from the gradually reducing hip and 
forearm fracture rates, steady rates for humerus fracture and a rising trend in vertebral 
fracture were noticed. The results of study by Driessen et al. in 2011 complement our 
observed decreasing trend in MOFs for Denmark.28 Considering the ageing population, 
these findings are interesting, as we identify a decreasing incidence of MOFs between 
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1995 and 2011. Yet, importantly, there appears to be differences between males and 
females, particularly for hip fractures, in Denmark. 
In general, our findings are in line with the present literature affirming a decrease in hip 
fracture rates in both men and women. We observed a 31% decline (from 87.2 to 59.9 per 
10,000 PYs) among women and 19% decline (from 36.5 to 29.6) among men. Driessen et 
al. estimated even lower IRs for hip fracture in Denmark in the year 2011, as 57.1 per 
10,000 PYs for women, and 29.2 for men.28 In numerous studies from different countries, 
a levelling or decrease in age- and sex-specific hip fracture rates especially in the past two 
decades has been noticed too.16-21,24 For instance, Leslie et al. showed that there was a 
32% reduction in hip fracture rates among women in Canada (118.6 to 80.9 per 100,000 
PYs), and 25% in men (68.2 to 51.1) between 1985 and 2005.16 Additionally, Brauer et al. 
reported dropped rates from 964.2 per 100,000 PYs in 1986 to 793.5 in 2005 among 65+ 
women, and from 392.4 to 369.0 among 65+ men in the USA.17 In most cases as we 
observed, the decrease was more profound among women, which could be hypothesised 
due to the higher number of women under anti-osteoporotic treatment or who received 
lifestyle modifications.  
There are few studies that have looked at both hip and other MOFs. A study in the USA 
made comparisons after 20 years (1989–1991 and 2009–2011), and the reported decrease 
in hip fracture rates in both sexes and an increase in vertebral fractures in men were 
concordant with our results.34 Another study in Canada (1986–2006) identified a similar 
result to ours regarding a global decrease in hip fracture rates and a decrease of forearm 
fractures among women.35 
On the other hand, there are studies whose results are not concordant with our findings. 
Van der Velde et al. reported an increase of hip fracture rates in men and a steady state 
for women in the UK;15 the differences could be due to a different version of ICD used for 
fracture classification (ICD-9 vs. 10) or a different kind of database (medical record-based 
Clinical Practice Research Datalink [CPRD]). A Japanese study showed not only 
substantially lower rates for limb OP fractures, and higher rates of vertebral cases, but 
also an increasing trend in hip fractures since the 1990s.36 Two other studies from Japan 
and Singapore showed similar results with increasing tendencies for hip fracture over the 
1990s and 2000s.37,38 Interestingly, there was a notable difference between East and 
West regarding change of rates of hip fracture in the past decades, where the exact 





Our study period (i.e., the 1990s and 2000s) was a crucial time span as it saw extensive 
developments in management of osteoporosis, including bisphosphonates coming to the 
market, awareness of osteoporosis management grew, and treatment guidelines 
underwent a number of revisions.41,42 Based on the guidelines for osteoporosis treatment 
in Denmark, the suggested daily intake of calcium for men with osteoporosis is lower 
than postmenopausal women at risk (800–1000 mg vs. 1000–1200 mg, respectively), but 
the first line treatment for both sexes is alendronate, and in case of severe disease, 
anabolic treatment is indicated.43,44 Nevertheless, osteoporosis has been traditionally 
considered a women’s only disease, and it could be hypothesised that a decrease in hip 
fractures due to preventive medication may be stronger among women than men. 
Numerous studies have already shown the effectiveness of anti-osteoporotic therapy 
(including bisphosphonates) on fracture prevention; however, there are studies which 
reported only a small role of these medication in the reduction of hip fracture rates.24,45-47 
So, the extent to which anti-osteoporotic therapy may affect rates of OP fractures, or 
whether it could have a role in the present discrepancies among men and women, 
requires further investigation. 
Beside anti-osteoporotic therapy, there might be other factors which contributed to the 
mostly declining OP fracture trend in Denmark. An increasing proportion of 50+ 
individuals was born after the World War II, and grew up under better nutritional states 
and physical activities (sport classes introduced at schools, etc.), which might help to 
improve their peak bone mass. Also, the next generations are being guided by physicians 
on the importance of bone health as we age, and this could end up in positive effects 
including better use of Ca/Vit D supplements, and more adherence to anti-osteoporotic 
therapies. These among others resulted in a lower rate of fracture despite an ageing 
population. Still, interventions such as more ubiquitous use of devices that reduce risk of 
falling in frail and elderly, such as walk aids, could play a role. These hypothesised factors 
are beyond the scope of this study and need further investigation. 
As stated above, the economic burden of OP fractures is substantial and many reports 
suggest this will increase over the coming years mostly because of an ageing 
population.2,4-9 Studies showed that healthcare expenditures associated with an OP 
fracture in the USA are twice as high compared to patients only affected with 
osteoporosis and are threefold higher compared to the general population.9 It has also 
been shown that the hospital costs of OP fractures were higher compared to similar 
ageing ailments such as myocardial infarction, stroke, or breast cancer.5 From €1.6 billion 
total costs of OP fractures in Denmark in 2011, just €628 million (40.2%) was spent for 
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men;10 but based on our results, there was an increase in the total number of fractures in 
Denmark, the OP fracture rates are not declining among men with the same rate 
observed in women, and the women to men ratio for MOF rates were noticeably 
decreased from 2.93 to 2.72 between 1995 and 2010. Considering all these, it could be 
expected that healthcare expenditures for osteoporosis and OP fractures among men 
might be a more serious burden in the near future. 
This study had many strengths. The database used provided the opportunity of studying 
all fracture cases reported to hospitals in Denmark in this time period, and it has already 
proved to be reliable and valid.31 This is one of the few studies that examined not only hip 
but all MOFs. Again, the duration of study is one of the longest in literature with 16 years 
of follow- up time. We were also able to stratify IRs by fracture sites. All these resulted in 
a comprehensive study that could be used for national and international policy-making 
purposes, including improvements of healthcare services, and better estimation of OP 
fracture-associated costs. 
We had also some limitations in this study. To minimise double counting, we excluded 
fractures of the same type within 1 year. While this decision was made to improve the 
likelihood that we would capture new fractures as opposed to follow-up visits, we 
recognise that this may have resulted in an underestimation of the true fracture rate as 
we may have excluded some new fractures. In case of clinical vertebral fracture, this 
underestimation could be even worse, as the evidence suggests the majority of vertebral 
fractures do not immediately come to clinical attention.48 On the other hand, there is this 
possibility that we overestimated the clinical vertebral fractures, because with 
advancement of spine imaging utilisation in recent years, there are more chances to 
detect old previously unrecognised fractures, and so, some prevalent vertebral fracture 
might be misclassified as incident fractures. Also, our IRs were not adjusted beyond the 
factors explained in this article, as we were not able to examine the influence of any 
further mediating or confounding factor on the observed trends. Similarly, we have 
limited explanatory information for seemingly anomalous spikes. For example, the only 
explanation for the spike observed in trends of radius/ulna fracture in the year 2010 
(Figure 2.2d) was the record-breaking freezing winter happened in Europe in 2010 
(potentially resulting in higher number of falls),49 as no other coding or reporting issue 
was detected. 
In conclusion, we did a series of cross-sectional analyses showing the secular trends of 
MOF rates in Denmark between 1995 and 2010. The results showed a general decline in 





in line with the study by Driessen et al. in Denmark for the year 2011, and many other 
studies in Nordic and Western countries. Also, we noticed a lower rate of decrease of hip 
fracture trends and an increasing trend in rates of vertebral fracture among men, which 
was accompanied by a reducing women-to-men IRR in the study period. Considering 
these observations and the major economic burden that accompanies this devastating 
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a. Abstract 
Background 
Bisphosphonates (BPs) might have extra benefits in reducing mortality because of their 
anti-atherosclerotic effects, but studies reported conflicting results. We investigated the 
association between oral BP use and mortality risk following a major osteoporotic 
fracture (MOF) in the United Kingdom. 
 
Methods 
This was a population-based cohort study. In total, 163,273 adults aged 50 years and older 
with a MOF were included between 2000 and 2018 from the Clinical Practice Research 
Datalink in the United Kingdom. Cox proportional-hazards models were used to estimate 
the risk of all-cause mortality in current (0‒6 months), recent (7‒12 months), and past (>1 
year) exposures to oral BPs after non-hip MOF and hip fracture. In addition, stratification 
by sex, BP type, and duration of follow-up was performed. 
 
Results 
Compared with never users of oral BPs, current BP use was associated with a 7% higher 
all-cause mortality risk after non-hip MOF, whereas a 28% lower all-cause mortality risk 
was observed after hip fracture. Past BP exposure was associated with a 14% and 42% 
lower risk after non-hip MOF and hip fracture, respectively. When considering only the 
first 5 years of follow-up, mortality risk associated with current BP use was significantly 
lower for both fracture groups, and the greatest reduction in mortality risk was observed 
within the first year. Women had slightly lower risk compared with men. 
 
Conclusions 
We found a slight increased risk of all-cause mortality with current BP exposure after a 
non-hip MOF; however, a protective effect was observed following a hip fracture. Both 
the timing and the effect size of an association based on the anti-atherosclerotic 
hypothesis of BPs are not supported by our results. The decreasing trend of the mortality 
risk with shorter durations of follow-up suggests that the observed association is likely 
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b. Introduction 
Major osteoporotic fractures (MOFs) are the main consequence of osteoporosis, with 
devastating results for the affected patients, including a significant increased risk of 
mortality.1 Occurrence of a hip fracture markedly increases the risk of subsequent 
fractures (relative risks of 2‒7 compared with the general population).2,3 This may 
increase mortality after fracture even more.4 Approximately 33% of men and 22% of 
women suffering a hip fracture will die within 1 year, and 51% of men and 39% of women 
sustaining an MOF will die within 5 years.5-7 But the reasons of this high mortality risk and 
the ways to prevent it are still not fully understood. 
Secondary fracture prevention with anti-osteoporotic treatment, such as 
bisphosphonates (BPs), can prevent subsequent fractures.8,9 Given the strong association 
between fracture and mortality in older individuals, it has been hypothesised that use of 
BPs may lower the risk of mortality after a fracture. Apart from preventing secondary 
fractures, the main underlying potential mechanism that could explain the mortality-
reducing benefits of BPs is protection against cardiovascular events. This may mostly be 
the result of lowering lipid profile and decreasing arterial wall calcification.10-14 However, 
data from randomised clinical trials (RCTs) yield conflicting evidence.15,16 Although a post 
hoc analysis of the Health Outcomes and Reduced Incidence with Zoledronic Acid Once 
Yearly (HORIZON) trial showed a 28% statistically significant mortality reduction among 
users of zoledronic acid after hip fracture,15 the design, analysis, and conduct of this study 
have been heavily criticised.17 
Because the underlying mechanism for mortality reduction is likely similar for various BPs, 
we sought to further test the hypothesis of an association between all-cause mortality 
and the initiation of oral BPs following a MOF in a large representative real-life cohort 
study. Thus, the aim of this study was to examine if oral BP treatment was associated 
with a lower all-cause mortality risk after a non-hip MOF or hip fracture.  
 
c. Methods  
Data Source 
This was a cohort study using the Clinical Practice Research Datalink (CPRD; 
www.cprd.com). The CPRD contains medical records of 674 practices in the United 
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includes patient demographics, lifestyle parameters, medical history, laboratory test 
results, prescription details, specialist referrals, hospital admissions, and major outcomes 
since 1987. Previous studies showed a high validity of using CPRD data regarding MOFs.19 
 
Study Population 
The study population included all patients aged 50 years and older with a record of their 
first fracture between 01 January 2000 and 31 December 2018. The index date (start of 
study follow-up) was defined as the date of first recorded MOF (i.e., a fracture of the 
hip/femur, vertebrae, humerus, or radius/ulna). We further classified fractures by hip or 
non-hip MOF (i.e., vertebral, humerus, radius/ulna, or femur excluding hip). Patients with 
any fracture prior to age 50 years and those with use of oral BPs prior to the index date 
were excluded (adhering to new-user design). Also, to allow for at least 1 year of follow-
up, we excluded those with an index fracture in 2018. 
 
Exposure and Outcome 
The exposure of interest was the use of oral BPs after index date, which was assessed 
time-dependently. First, the total follow-up time for each patient was established by 
considering the time he/she had entered the study (i.e., index date) and the time follow-
up ends, which could be the end of study period, the date of transfer out of the practice 
area, or death (the outcome of interest), whichever came first. The total follow-up time 
was then divided into 180-day “periods” starting from the index date. Exposure status to 
BPs was defined as the following: “current exposure” means that the patient has 
received his most recent BP prescription during the past 6 months before the start of a 
period. “Recent exposure” means that the patient has taken his most recent BP 
prescription 7‒12 months before, and “past exposure” means that the patient has 
stopped taking BPs for >1 year before. Using this model, patient exposure is then 
classified in a dynamic time-dependent manner, meaning they can move between 
exposure groups (current, recent, past) throughout time. However, once a patient is 
classified as a current user, he cannot return to the never user group. The total person-
time in each category is accounted for and contributes to the Cox proportional-hazards 
model. In addition, BP use was broken down into nitrogen-containing BPs (n-BP, 
alendronate, and risedronate) and the non-nitrogen-containing BP (non-n-BP) etidronate. 
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Potential Confounders 
Age was considered time dependently, whereas sex, smoking status, alcohol use, and 
body mass index were determined at index date. A history of the following comorbidities 
was assessed at the start of each interval: cerebrovascular disease, chronic kidney 
disease, chronic obstructive pulmonary disease, dementia, diabetes mellitus, epilepsy, 
heart failure, ischaemic heart disease, major infections (sepsis, meningitis, upper and 
lower respiratory tract infections), or malignant neoplasms (excluding nonmelanoma skin 
cancers). In addition, the use of following medications in the 6 months prior was 
included: antihypertensives, anti-Parkinson’s medications, glucocorticoids, loop diuretics, 
psychotropic drugs (antipsychotics, anxiolytics, hypnotics, and sedatives), and statins. 
Confounders were included in the final model if they changed the beta coefficient of the 




Cox proportional-hazards models were used to assess the risk of all-cause mortality 
following fracture associated with current BP use vs never use (using the SAS PHREG 
procedure). To avoid immortal time bias, all patient time in each exposure status was 
incorporated into the model and all patient time prior to first BP use was defined as never 
use. Analyses were stratified by index fracture type (non-hip MOF vs hip) and sex.  
In secondary analyses, current BP exposure was stratified by type of oral BP (n-BP or non-
n-BP). A sensitivity analysis assessed 1-year and 5-year all-cause mortality risk, censoring 
the total follow-up period at 1 or 5 years, respectively. 
Data were analysed using SAS v 9.3 (SAS Institute Inc, Cary, NC). This study was reviewed 
and approved by the Independent Scientific Advisory Committee of the Clinical Practice 




A total of 163,273 patients were included in our cohort with a first MOF between 2000 
and 2018 (Figure 3.1). Of the eligible fractures, 119,107 (72.9%) were non-hip MOF and 
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MOF and hip fracture were 70 and 81 years, respectively. Female patients accounted for 
74% of the non-hip MOF and 69% of hip fracture patients. A similar pattern of smoking was 
observed among both fracture groups, with less than one quarter of patients being 
current smokers. Frequent comorbidity and comedication included major infections and 
antihypertensives. The non-hip MOF comprised 16,378 vertebral fractures (13.8%), 5294 
femur fractures (4.4%), 33,665 humerus fractures (28.3%), and 63,770 radius/ulna fractures 
(53.5%). The follow-up time for BP users was 7.6 years in the non-hip MOF and 5.7 years in 
the hip fracture group. The average duration of BP use was 3.3 years among non-hip MOF 















Figure 3.1. Flowchart on establishment of patient population. All patients aged over 50 years from the 
CPRD in the UK who had a major osteoporotic fracture between 2000 and 2018, and started 
bisphosphonate use after the (index, first) fracture are included in the study. 






Ineligible patients because of 
death before fracture, and fracture 
date outside of study period, 
before UTS, or during 2018 
n= 7521 
Excluding patients with prior BP 
use or prior fracture (before index 
date and prior to 2000) 
n= 21,115 
Total 50+ patients with a MOF 
from CPRD between 2000-2018  
n= 191,909 
Total eligible patients with a 
fracture during valid data 
collection 
n= 184,388 
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Table 3.1. Baseline characteristics of participants according to index fracture site.  
 Non-hip MOF  Hip fracture 
 N % - SD N % - SD 
Number of events 119,107  44,166  
Mean follow-up (years, SD) 6.7 4.8 3.9 4.0 
Mean age (SD) 70.1 11.9 80.5 10.3 
Female 88,415 74.2 30,645 69.4 
Mean BMI (SD) 26.6 5.5 24.3 4.9 
Smoking status     
Never 70,241 59.0 25,593 57.9 
Past 17,856 15.0 6878 15.6 
Current 29,056 24.4 9443 21.4 
Missing 1954 1.6 2252 5.1 
Alcohol use     
Yes 80,188 67.3 22,786 51.6 
No 28,937 24.3 13,921 31.5 
Missing 9982 8.4 7459 16.9 
Comorbidities*     
Cerebrovascular disease 10,825 9.1 7908 17.9 
Chronic kidney disease 11,168 9.4 7850 17.8 
COPD 8269 6.9 4198 9.5 
Dementia 4395 3.7 6142 13.9 
Diabetes mellitus 12,820 10.8 6247 14.1 
Epilepsy 3630 3.0 1520 3.4 
Heart failure 3284 2.8 2626 5.9 
Ischaemic heart disease 15,268 12.8 8218 18.6 
Major infection 31,928 26.8 10,660 24.1 
Malignant neoplasm 14,816 12.4 7568 17.1 
Prior fracture 0 0.0 0 0.0 
Medications†     
Antihypertensives‡ 49,832 41.8 22,195 50.3 
Anti-Parkinson’s 1428 1.2 1325 3.0 
BP history 0 0.0 0 0.0 
Loop diuretics 13,933 11.7 9790 22.2 
Glucocorticoids 5944 5.0 2325 5.3 
Psychotropics 16,299 13.7 9580 21.7 
Statins 30,354 25.5 11,820 26.8 
Fracture at baseline     
Hip n/a n/a 44,166 100 
Vertebral 16,378 13.8 n/a n/a 
Femur 5294 4.4 n/a n/a 
Humerus 33,665 28.3 n/a n/a 
Radius/Ulna 63,770 53.5 n/a n/a 
BMI: body mass index, BP: bisphosphonates, COPD: Chronic obstructive pulmonary disease, MOF: 
Major osteoporotic fracture, SD: Standard deviation. 
* Disease comorbidities happened ever before. 
† Medications taken 6 months before index fracture. 
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Table 3.2 shows that current use of oral BPs was associated with a 7% higher risk of all-
cause mortality among patients with an index non-hip MOF compared with never use 
(adjusted hazard ratio [adj. HR] 1.07, 95% confidence interval [CI] 1.03‒1.10). Mortality risk 
in the recent exposure group was also higher compared with the reference group (adj. 
HR 1.25, 95% CI 1.16‒1.36), but past exposure was associated with statistically significant 
lower risk (adj. HR 0.86, 95% CI 0.83‒0.90). Among patients who had sustained a hip 
fracture, current BP exposure was associated with a significant 28% lower mortality risk 
compared with never BP exposure (adj. HR 0.72, 95% CI 0.70‒0.75), whereas recent and 
past exposures were associated with 21% and 42% lower risk, respectively. The HR of past 
exposure was statistically lower compared with recent and current exposure. In general, 
mortality risk tended to be slightly lower among women as compared with men. 
Stratifying our analysis by nitrogen-containing BPs showed similar results to the primary 
analysis. Analyses with the non-n-BP etidronate lacked statistical power due to low 
frequency of exposure (data not shown). 
The 5-year analysis showed a significant reduction in mortality risk with current BP 
exposure after non-hip MOF (adj. HR 0.91, 95% CI 0.87‒0.95) compared with never use 
(Table 3.3). Following a hip fracture, all-cause mortality risk associated with current 
exposure shifted further from the null value with a significant 39% reduction compared to 
never use (adj. HR 0.61, 95% CI 0.59‒0.64). 
The 1-year mortality risk (data not shown) in the non-hip MOF group showed a 34% lower 
risk of all-cause mortality with current BP exposure (adj. HR 0.66, 95% CI 0.60‒0.72), 
whereas it was not lower with recent exposure (adj. HR 0.23, 95% CI 0.03‒1.61). The 1-year 
risk of all-cause mortality among hip fracture patients was considerably lower for current 
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Table 3.2. Risk of all-cause mortality following an index fracture (non-hip MOF and hip), stratified by 
fracture type, gender and oral BP exposure status.  
 Events IR per 
1000 PYs 
Age (/Sex) adjusted 
Analysis HR (95%CI)* 
Final adjusted 
Model HR (95%CI)† 
Non-hip MOF     
BP Never exposure‡    21,940 34.6 Reference Reference 
BP Past exposure 2341 36.1 0.85 (0.81-0.89) 0.86 (0.83-0.90)§ 
BP Recent exposure 627 57.9 1.40 (1.30-1.52) 1.25 (1.16-1.36)§ 
BP Current exposure¶ 5219 57.4 1.32 (1.28-1.37) 1.07 (1.03-1.10)§ 
Females**     
BP Never exposure    14,535 31.4 Reference Reference 
BP Past exposure 1933 33.2 0.82 (0.78-0.86) 0.85 (0.81-0.89)§ 
BP Recent exposure 480 50.2 1.30 (1.19-1.43) 1.19 (1.09-1.31)§ 
BP Current exposure¶ 4003 50.1 1.25 (1.21-1.30) 1.04 (1.01-1.08)§ 
Males**     
BP Never exposure    7405 43.2 Reference Reference 
BP Past exposure 408 61.7 0.93 (0.84-1.03) 0.88 (0.80-0.98)§ 
BP Recent exposure 147 115.1 1.81 (1.53-2.13) 1.47 (1.25-1.73)§ 
BP Current exposure¶ 1216 109.7 1.61 (1.52-1.72) 1.14 (1.07-1.21)§ 
     
Hip Fracture     
BP Never exposure‡ 16,977 152.3 Reference Reference 
BP Past exposure 1440 62.5 0.51 (0.48-0.53) 0.58 (0.55-0.62) 
BP Recent exposure 398 96.2 0.75 (0.68-0.83) 0.79 (0.71-0.87)†† 
BP Current exposure¶ 3778 103.5 0.76 (0.73-0.78) 0.72 (0.70-0.75)†† 
Females**     
 BP Never exposure   10,942 145.1 Reference Reference 
 BP Past exposure 1123 59.3 0.50 (0.47-0.54) 0.58 (0.54-0.61)§ 
 BP Recent exposure 305 91.8 0.76 (0.68-0.85) 0.81 (0.72-0.90)§ 
 BP Current exposure¶ 2738 92.4 0.71 (0.68-0.74) 0.69 (0.66-0.72)§ 
Males**     
 BP Never exposure    6035 167.5 Reference Reference 
 BP Past exposure 317 77.0 0.49 (0.43-0.55) 0.58 (0.52-0.65) 
 BP Recent exposure 93 114.5 0.69 (0.56-0.85) 0.73 (0.59-0.89) 
 BP Current exposure¶ 1040 151.2 0.87 (0.81-0.93) 0.80 (0.75-0.85)†† 
BP: Bisphosphonate, CI: Confidence interval, HR: hazard ratio, IR: Incidence rate, MOF: Major osteoporotic fracture, 
PYs: person years. Statistically significant hazard ratios are shown in bold. 
* Adjusted only for age where stratified by sex.  
† Adjusted for sex, body mass index, smoking status and alcohol use at baseline, and the following variables time-
dependently: age and use of antihypertensives, anti-Parkinson's medications, loop diuretics, glucocorticoids, 
psychotropics, statins in the previous 6-months, and history of malignant neoplasm, dementia (for hip fracture 
group), and chronic obstructive pulmonary disease (for non-hip MOF group). 
‡ Never exposure denotes to no known use of oral BPs, whereas past, recent, and current exposures refer to 
taking oral BPs in the time window >12 months, 6-12 months, and 0-6 month prior to the start of a period, 
respectively.  
§ HR from each BP exposure status is statistically different from the other exposure status in the same model, by 
Wald test, P <0.05. 
¶ Not stratified by nitrogen containing agents due to small cell sizes and reporting restrictions in the CPRD for 
privacy reasons. 
** Patients from each sex are compared only with same sex cohorts.  
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Table 3.3. Five-year risk of all-cause mortality following an index fracture (non-hip MOF and hip), by 
oral BP exposure status.  
 Events IR per 
1000 PYs 
Age/Sex adjusted 
Analysis HR (95%CI) 
Final adjusted 
Model* HR (95%CI) 
Non-hip MOF     
BP Never exposure†    16,162 42.5 Reference Reference 
BP Past exposure 753 43.2 0.73 (0.68-0.79) 0.76 (0.70-0.82) 
BP Recent exposure 342 55.9 1.00 (0.90-1.12) 0.98 (0.88-1.09)‡ 
BP Current exposure 3135 56.5 1.03 (0.99-1.07) 0.91 (0.87-0.95)‡ 
Hip Fracture     
BP Never exposure†    14,946 183.1 Reference Reference 
BP Past exposure 644 75.7 0.43 (0.40-0.47) 0.50 (0.47-0.55) 
BP Recent exposure 279 95.7 0.56 (0.50-0.64) 0.62 (0.55-0.70)‡ 
BP Current exposure 2831 103.3 0.60 (0.58-0.63) 0.61 (0.59-0.64)‡ 
BP: Bisphosphonate, CI: Confidence interval, HR: hazard ratio, IR: Incidence rate, MOF: Major osteoporotic fracture, 
PYs: person years. Statistically significant hazard ratios are shown in bold. 
* Adjusted for sex, body mass index, smoking status and alcohol use at baseline, and the following variables 
time-dependently: age and use of antihypertensives, anti-Parkinson's medications, loop diuretics, 
glucocorticoids, psychotropics, statins in the previous 6 months, and history of malignant neoplasm, dementia 
(for hip fracture group), and chronic obstructive pulmonary disease (for non-hip MOF group). 
† Never exposure denotes to no known use of oral BPs, while past, recent, and current exposures refer to taking 
oral BPs in the time window >12 months, 6-12 months, and 0-6 month prior to the start of a period, respectively.  




This study identified that current oral BP exposure was associated with a 7% higher all-
cause mortality risk after a non-hip MOF and with a 28% lower mortality risk after a hip 
fracture. When the follow-up time was censored at 1 and 5 years, a significant protective 
effect was observed in both fracture groups, with a trend away from the null with 
decreasing follow-up time: mortality risk with current BP use in the non-hip MOF group 
first dropped to a 9% reduction in the 5-year and then to 34% reduction in the 1-year 
analysis. In the case of hip fracture, mortality risk with current BP use first dropped to a 
39% reduction in the 5-year and then to 59% in the 1-year analysis.  
Our finding of a higher mortality risk among non-hip MOF patients with current BP 
exposure is not in line with findings from 2 meta-analyses of RCTs in 2010 (n=25,072) and 
2018 (n=63,371), which showed no association between all-cause mortality and BP use vs 
placebo, yielding a pooled relative risk of 0.91 (95% CI 0.80‒1.03) and 0.95 (95% CI 0.86‒
1.04), respectively.20,21 However, the 28% lower mortality risk after hip fracture with 
current BP exposure in our study could be in line with those from the HORIZON trial, 
which showed a 28% reduced risk of all-cause mortality after 16 months of zoledronic acid 
use (HR 0.72; 95% CI 0.56‒0.93), and was included in both meta-analyses.15 However, RCTs 
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have normally evaluated BP use in individual patients in a time-fixed model, while we 
assessed person-time within exposure states in a time-dependent analysis. 
Our results in patients with hip fractures are in line with those from other observational 
studies in the field. In a recent cohort study by van Geel et al, a 21% reduction in mortality 
risk (HR 0.79, 95% CI 0.64‒0.97) was reported with oral BP use compared to calcium and 
vitamin D use among fracture patients.22 Using Danish national health register data, 
Bondo et al observed survival benefits for patients who had taken BP both before and 
after hip fracture, although their results may be distorted due to channelling or immortal 
time bias.23 Sambrook et al found 27% mortality reduction for oral BP use compared to no 
use in frail older people (mean age=86 years), and an even higher reduction (80%) in 
those only after hip fracture, although the number of BP users was very low (n=17).24,25 
However, BPs are not always found in literature to be beneficial on mortality risk 
reduction. Steinbuch et al reported no significant risk reduction in all-cause mortality for 
risedronate in patients with a history of vertebral or hip fracture or with low bone mass, 
although there were some benefits in case of stroke and cardiovascular events 
reduction.14 In “primary prevention arm” of the HORIZON trial, Black et al reported a 
small but not statistically significant increase in death numbers by using zoledronic acid 
and raised risk of serious atrial fibrillation adverse events.16 This might be comparable 
with our findings regarding the 7% higher mortality risk with current BP use in non-hip 
MOF patients. Although similar results regarding atrial fibrillation events have been 
reported from the Fracture Intervention Trial by using alendronate, this unconfirmed 
association has no apparent biologic plausibility, and we do not expect this happening to 
our patients.26  
There is some evidence from the literature regarding the anti-atherosclerotic effects of 
BPs, such as lowering low-density lipoprotein (LDL) cholesterol levels, decreasing arterial 
wall calcification, enhancing endothelial nitric oxide production, and reducing monocytes 
and platelets interactions with epithelial cells.12,13,27-30 If cardiovascular effects of BPs 
would be comparable to those of statins, there should be (indirect) evidence of 
comparability of the timing and size of the effect. Large RCTs showed that the statin-
induced reductions of mortality occurred after 11‒24 months of use, which suggests that 
the mortality reduction starting after 16 months of BP use in the HORIZON trial may be 
plausible.31-34 If we assume this timing to be true, part of our observations, such as the 
lower mortality among hip fracture patients (with 2.7 years of BP use) might be in line 
with the explained anti-atherosclerotic hypothesis of BPs. However, even among hip 
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not support this hypothesis as the proper timing has not been met. Also, the expected 
effect size is not comparable: large meta-analyses of RCTs comparing statin use with 
placebo reported an overall 13% reduction of all-cause mortality, or 9% mortality reduction 
per 1.0 mmol/L reduction of LDL cholesterol.35,36 BPs have been shown to lower LDL in a 
range from no effect up to a reduction of approximately 0.34 mmol/L, after 6‒12 months 
of use.12,37,38 In the best-case scenario, this would then translate into a 3% lower risk of all-
cause mortality,36 which is around 9 times lower than the observed 28% reduction in the 
HORIZON trial and results of our study in the hip fracture patients.15 Nevertheless, BPs 
could have other anti-atherosclerotic effects. A meta-analysis showed BPs have 
decreased aortic calcification by 11.2% compared with untreated individuals,13 and 
coronary artery calcification is a well-known risk factor for all-cause mortality.39,40  
Although some causal effect of BPs on all-cause mortality cannot be excluded, it is more 
likely that unmeasured distortion explains the largest proportion of the observed risk 
reductions in the HORIZON trial and our study. The HORIZON trial was later criticised 
because of some inconsistencies regarding the interpretation of data, early termination 
of the trial, and the high number of withdrawal or loss to follow-up.17 Observational 
studies may have been confounded by selective prescribing of BPs to patients at lower 
risk of mortality.41 Physicians rarely prescribe oral BPs to very ill and hospitalised patients. 
This can culminate in a spurious survival benefit for exposure drug as the very ill patients 
are unlikely to receive preventative medication. Moreover, healthy user and healthy 
adherer bias could also play a role.42,43 Previous studies have suggested that patients who 
start a preventative medication or who are more adherent are generally healthier than 
patients who are not, and therefore may be at lower risk of mortality.44 These bias 
scenarios, in addition to the high mortality rates in the early days after a fracture, could 
best explain the lowest HRs with 1-year analysis and the observed decreasing trend of 
HRs with shorter durations of follow-up. Moreover, assuming these bias scenarios, the 
generally lower HRs among the hip fracture patients, compared with the non-hip MOF 
patients, could be partly explained by longer hospitalisation and higher mortality rates 
after a hip fracture compared with other MOFs.45 Hip fracture patients are generally 
sicker with higher chance of mortality and, hence, are less likely to receive BPs. 
Our study had several strengths. First, we used the CPRD for data collection, which is one 
of the world’s largest primary care databases. Second, as our study period was relatively 
long (i.e., 19 years [2000-2018]), we could include more than 163,000 patients in the study 
cohort, which is by far the largest study sample among observational studies in this topic. 
Also, we considered not only hip but all MOFs, making this the first study to our 
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knowledge to evaluate the mortality after non-hip MOF with BP use. Furthermore, the 
statistical analysis was performed time-dependently, which means it incorporated all 
person time, avoiding immortal time bias.46 Moreover, we used different approaches to 
test the underlying hypothesis of a causal effect,47 such as assessing the same research 
question in two cohorts with different fracture sites and testing the underlying 
pharmacologic hypothesis with analyses that evaluated the onset and ending of the 
effect, which the other observational studies did not do.14,22-25 
This study had also some limitations. One objective was to differentiate between n-BP or 
non-n-BP respecting their effect on mortality reduction, which was not feasible due to 
low numbers of non-n-BP use in the UK. As mentioned above, we could not exclude those 
dying shortly after having a fracture, and this could result in distortion (i.e., higher 
estimates of drug effect than what it should be, especially with shorter durations of 
follow-up). Moreover, we could not measure or adjust for healthy user or healthy adherer 
effect, and we had no information about the cause of death, socioeconomic status of 
patients, or other similar indicators from CPRD. Nonetheless, we tried to overcome this 
by running multiple analyses that tested the same hypothesis indirectly in different ways, 
taking into account the hypothesised pharmacologic effect. 
In conclusion, although we found a higher risk of all-cause mortality with current BP 
exposure after non-hip MOF, a protective effect was observed with 1 and 5 years of 
follow-up. After a hip fracture, current BP exposure was associated with lower mortality 
risk in all analyses. Compared to statin studies and the effect of BPs on LDL reduction or 
arterial calcification, both the timing and the effect size of such an association is not 
supported by our results. Rather, the substantially lower mortality risk in the 1-year 
analysis and the decreasing trend of HRs with shorter durations of follow-up suggest that 
the vast majority of the observed association between BP use and mortality risk after 
fracture is explained by unknown distortion or unknown pleiotropic properties of BPs. 
We recommend that future studies focus on evaluation of these hypotheses to elucidate 
alternative mechanisms of potential pleiotropic effects of BPs, and on explaining 








 54  
f. References 
1. Nazrun AS, Tzar MN, Mokhtar SA, et al. A 
systematic review of the outcomes of 
osteoporotic fracture patients after hospital 
discharge: morbidity, subsequent fractures, 
and mortality. Ther Clin Risk Manag. 2014 
Nov;10:937-48. 
2. van der Velde RY, Wyers CE, Geusens PPMM, 
et al. Incidence of subsequent fractures in the 
UK between 1990 and 2012 among individuals 
50 years or older. Osteoporos Int. 2018 
Nov;29(11):2469-75.  
3. Gibson-Smith D, Klop C, Elders PJ, et al. The 
risk of major and any (non-hip) fragility 
fracture after hip fracture in the United 
Kingdom: 2000-2010. Osteoporos Int. 2014 
Nov;25(11):2555-63. 
4. Bliuc D, Nguyen ND, Milch VE, et al. Mortality 
risk associated with low-trauma osteoporotic 
fracture and subsequent fracture in men and 
women. JAMA. 2009 Feb;301(5):513-21. 
5. Brauer CA, Coca-Perraillon M, Cutler DM, et al. 
Incidence and mortality of hip fractures in the 
United States. JAMA. 2009 Oct;302(14):1573-9. 
6. Bliuc D, Nguyen ND, Nguyen TV, et al. 
Compound risk of high mortality following 
osteoporotic fracture and refracture in elderly 
women and men. J Bone Miner Res. 2013 
Nov;28(11):2317-24. 
7. Klop C, Welsing PM, Cooper C, et al. Mortality 
in British hip fracture patients, 2000-2010: a 
population-based retrospective cohort study. 
Bone. 2014 Sep;66:171-7. 
8. Wells G, Cranney A, Peterson J, et al. 
Risedronate for the primary and secondary 
prevention of osteoporotic fractures in 
postmenopausal women. Cochrane Database 
Syst Rev. 2008 Jan;(1):CD004523. 
9. Lee SY, Jung SH, Lee SU, et al. Can 
bisphosphonates prevent recurrent fragility 
fractures? a systematic review and meta-
analysis of randomized controlled trials. J Am 
Med Dir Assoc. 2018 May;19(5):384-90.e1. 
10. Colón-Emeric CS, Mesenbrink P, Lyles KW, et 
al. Potential mediators of the mortality 
reduction with Zoledronic acid after hip 
fracture. J Bone Miner Res. 2010 Jan;25(1):91-7. 
11. Ugur Ural A, Avcu F, Ozturk K. 
Bisphosphonates may retrieve endothelial 
function in vascular diseases similar to statins' 
effects. Eur J Haematol. 2008 Jul;81(1):77-8. 
12. Guney E, Kisakol G, Ozgen AG, et al. Effects of 
bisphosphonates on lipid metabolism. Neuro 
Endocrinol Lett. 2008 Apr;29(2):252-5. 
13. Kranenburg G, Bartstra JW, Weijmans M, et 
al. Bisphosphonates for cardiovascular risk 
reduction: A systematic review and meta-
analysis. Atherosclerosis. 2016 Sep;252:106-15. 
14. Steinbuch M, D'Agostino RB, Mandel JS, et al. 
Assessment of mortality in patients enrolled 
in a risedronate clinical trial program: a 
retrospective cohort study. Regul Toxicol 
Pharmacol. 2002 Jun;35(3):320-6.  
15. Lyles KW, Colón-Emeric CS, Magaziner JS, et 
al. Zoledronic acid and clinical fractures and 
mortality after hip fracture. N Engl J Med. 2007 
Nov;357(18):1799-809. 
16. Black DM, Delmas PD, Eastell R, et al. Once-
yearly zoledronic acid for treatment of 
postmenopausal osteoporosis. N Engl J Med. 
2007 May;356(18):1809-22. 
17. Järvinen TL, Michaëlsson K, Jokihaara J, et al. 
Overdiagnosis of bone fragility in the quest to 
prevent hip fracture. BMJ. 2015 
May;350:h2088/rr-22; 
www.bmj.com/content/350/bmj.h2088/rr-22 
18. Herrett E, Gallagher AM, Bhaskaran K, et al. 
Data resource profile: Clinical Practice 
Research Datalink (CPRD). Int J Epidemiol. 
2015 Jun;44(3):827-36. 
19. Van Staa TP, Abenhaim L, Cooper C, et al. The 
use of a large pharmacoepidemiological 
database to study exposure to oral 
corticosteroids and risk of fractures: 
validation of study population and results. 
Pharmacoepidemiol Drug Saf. 2000 
Sep;9(5):359-66. 
20. Bolland MJ, Grey AB, Gamble GD, et al. Effect 
of osteoporosis treatment on mortality: a 
meta-analysis. J Clin Endocrinol Metab. 2010 
Mar;95(3):1174-81. 
21. Cummings SR, Lui LY, Eastell R, et al. 
Association   between   drug   treatments    for 
3 
 
The association of oral bisphosphonate use with mortality risk following a major osteoporotic fracture 
 55 
patients with osteoporosis and overall 
mortality rates: a meta-analysis. JAMA Intern 
Med. 2019 Nov;179(11):1491-500.  
22. van Geel TACM, Bliuc D, Geusens PPM, et al. 
Reduced mortality and subsequent fracture 
risk associated with oral bisphosphonate 
recommendation in a fracture liaison service 
setting: A prospective cohort study. PLoS One. 
2018 Jun;13(6):e0198006. 
23. Bondo L, Eiken P, Abrahamsen B. Analysis of 
the association between bisphosphonate 
treatment survival in Danish hip fracture 
patients-a nationwide register-based open 
cohort study. Osteoporos Int. 2013 
Jan;24(1):245-52. 
24. Sambrook PN, Cameron ID, Chen JS, et al. 
Oral bisphosphonates are associated with 
reduced mortality in frail older people: a 
prospective five-year study. Osteoporos Int. 
2011 Sep;22(9):2551-6. 
25. Cameron ID, Chen JS, March LM, et al. Hip 
fracture causes excess mortality owing to 
cardiovascular and infectious disease in 
institutionalized older people: a prospective 
5-year study. J Bone Miner Res. 2010 
Apr;25(4):866-72. 
26. Cummings SR, Schwartz AV, Black DM. 
Alendronate and atrial fibrillation. N Engl J 
Med. 2007 May;356(18):1895-6. 
27. Sing CW, Wong AY, Kiel DP, et al. Association 
of alendronate and risk of cardiovascular 
events in patients with hip fracture. J Bone 
Miner Res. 2018 Aug;33(8):1422-34.  
28. Cutini PH, Rauschemberger MB, Sandoval MJ, 
et al. Vascular action of bisphosphonates: In 
vitro effect of alendronate on the regulation 
of cellular events involved in vessel 
pathogenesis. J Mol Cell Cardiol. 2016 
Nov;100:83-92. 
29. Okamoto M, Yamanaka S, Yoshimoto W, et al. 
Alendronate as an effective treatment for 
bone loss and vascular calcification in kidney 
transplant recipients. J Transplant. 2014 
Feb;2014:269613. 
30. Elmariah S, Delaney JA, O'Brien KD, et al. 
Bisphosphonate use and prevalence of 
valvular and vascular calcification in women 
MESA        (The       Multi-Ethnic       Study        of 
Atherosclerosis). J Am Coll Cardiol. 2010 
Nov;56(21):1752-9. 
31. Scandinavian Simvastatin Survival Study 
Group. Randomised trial of cholesterol 
lowering in 4444 patients with coronary heart 
disease: the Scandinavian Simvastatin Survival 
Study (4S). Lancet. 1994 Nov;344(8934):1383-
9. 
32. Heart Protection Study Collaborative Group. 
MRC/BHF Heart Protection Study of 
cholesterol lowering with simvastatin in 
20,536 high-risk individuals: a randomised 
placebo-controlled trial. Lancet. 2002 
Jul;360(9326):7-22. 
33. Shepherd J, Cobbe SM, Ford I, et al. 
Prevention of coronary heart disease with 
pravastatin in men with 
hypercholesterolemia. West of Scotland 
Coronary Prevention Study Group. N Engl J 
Med. 1995 Nov;333(20):1301-7. 
34. Nakamura H, Arakawa K, Itakura H, et al. 
Primary prevention of cardiovascular disease 
with pravastatin in Japan (MEGA Study): a 
prospective randomised controlled trial. 
Lancet. 2006 Sep;368(9542):1155-63. 
35. Naci H, Brugts JJ, Fleurence R, et al. 
Comparative benefits of statins in the primary 
and secondary prevention of major coronary 
events and all-cause mortality: a network 
meta-analysis of placebo-controlled and 
active-comparator trials. Eur J Prev Cardiol. 
2013 Aug;20(4):641-57. 
36. Cholesterol Treatment Trialists' (CTT) 
Collaborators, Mihaylova B, Emberson J, et al. 
The effects of lowering LDL cholesterol with 
statin therapy in people at low risk of vascular 
disease: meta-analysis of individual data from 
27 randomised trials. Lancet. 2012 
Aug;380(9841):581-90. 
37. Gonnelli S, Caffarelli C, Tanzilli L, et al. Effects 
of intravenous zoledronate and ibandronate 
on carotid intima-media thickness, lipids and 
FGF-23 in postmenopausal osteoporotic 
women. Bone. 2014 Apr;61:27-32. 
38. Celiloglu M, Aydin Y, Balci P, et al. The effect 
of alendronate sodium on carotid artery 
intima-media thickness and lipid profile in 




 56  
Menopause. 2009 Jul-Aug;16(4):689-93. 
39. Alexopoulos N, Raggi P. Calcification in 
atherosclerosis. Nat Rev Cardiol. 2009 
Nov;6(11):681-8.  
40. Taylor AJ, Burke AP, O'Malley PG, et al. A 
comparison of the Framingham risk index, 
coronary artery calcification, and culprit 
plaque morphology in sudden cardiac death. 
Circulation. 2000 Mar;101(11):1243-8.  
41. Shrank WH, Patrick AR, Brookhart MA. 
Healthy user and related biases in 
observational studies of preventive 
interventions: a primer for physicians. J Gen 
Intern Med. 2011 May;26(5):546-50. 
42. Brookhart MA, Stürmer T, Glynn RJ, et al. 
Confounding control in healthcare database 
research: challenges and potential 
approaches. Med Care. 2010 Jun;48(6 
Suppl):S114-20. 
43. Devold HM, Furu K, Skurtveit S, et al. 
Influence of socioeconomic factors on the 
adherence of alendronate treatment in 
incident users in Norway. Pharmacoepidemiol 
Drug Saf. 2012 Mar;21(3):297-304. 
44. Curtis JR, Delzell E, Chen L, et al. The 
relationship between bisphosphonate 
adherence and fracture: is it the behavior or 
the medication? Results from the placebo arm 
of the fracture intervention trial. J Bone Miner 
Res. 2011 Apr;26(4):683-8. 
45. Center JR, Nguyen TV, Schneider D, et al. 
Mortality after all major types of osteoporotic 
fracture in men and women: an observational 
study. Lancet. 1999 Mar;353(9156):878-82. 
46. Suissa S. Immortal time bias in pharmaco-
epidemiology. Am J Epidemiol. 2008 
Feb;167(4):492-9.  
47. Savitz DA, Wellenius GA. Interpreting 
Epidemiologic Evidence: Connecting Research 
to Applications. 2nd ed. Oxford University 
Press; 2016. Chapter 4, Strategy for drawing 


















Impact of cumulative exposure to high-dose 
oral glucocorticoids on fracture risk in 
Denmark: a population-based case-control 
study 
 
M Amine Amiche 
Shahab Abtahi 
Johanna H M Driessen 
Peter Vestergaard 
Frank de Vries 
Suzanne M Cadarette 








 60  
a. Abstract 
Background 
The effect of cumulative exposure to high daily doses of oral glucocorticoids on fracture 
risk remains debated. We therefore aimed to examine the hip fracture risk associated 
with short courses and heavy use of high-dosed oral glucocorticoids. 
 
Methods 
We conducted a population-based case-control study using the Danish National Health 
Service data, 1996–2011. Cases were those aged ≥18 years who sustained a hip (primary 
outcome) fracture (n=81,342). Vertebral and forearm fractures were considered in 
secondary analyses. Controls (matched 1:1) were those without a fracture. Average daily 
dose (DD) and total cumulative dose (CD) were calculated among current oral 
glucocorticoid users. Among patients with a high daily dose (DD ≥15 mg), we identified 
short-course users as those with a CD <1 g and heavy users as those with a CD ≥1 g. We 
estimated adjusted odds ratio (adj. OR) of fracture with current glucocorticoid use 
compared to never-use, using conditional logistic regression. 
 
Results 
A high DD (≥15 mg) and high CD (≥1 g) were independently associated with an increased 
hip fracture risk (adj. OR 2.5; 95% CI 2.2–2.9; adj. OR 1.6; 95% CI 1.5–1.8, respectively). 
However, the risk was substantially increased among heavy users (DD ≥15 mg and CD ≥1 g: 
adj. OR 2.9; 95%CI 2.5–3.4) as compared to short-course users (DD ≥15 mg and CD <1 g: adj. 
OR 1.4; 95%CI 1.1–1.9). Associations were stronger for vertebral fractures, yet little 
association was identified for forearm fractures. 
 
Conclusions 
Among patients receiving a high DD (≥15 mg), heavy users (≥1 g CD) showed the most 
substantial increase in hip fracture risk. Among those receiving high DD, a threshold of 1 g 






Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark 
 61 
b. Introduction 
Oral glucocorticoids (GCs) are widely prescribed drugs with established clinical benefits 
for patients with chronic inflammatory and autoimmune diseases, such as chronic 
respiratory disease, inflammatory arthritis, and dermatologic disease.1–3 It is estimated 
that the prevalence of oral GC use among adults ranges between 1.5 and 3% worldwide.4 
Unfortunately, oral GC use is limited by significant side effects that usually appear after an 
extended period of exposure.5–7 GC-induced musculoskeletal disorders, such as 
osteoporosis, are a major problem and a well-documented side effect.8–13 Indeed, it is 
estimated that oral GCs are associated with a 30 to 120% increased risk of hip fracture and 
2- to 3-fold increase in vertebral fracture risk compared with non-use.14–16 For 
inflammatory conditions, short courses of high doses with tapering regimens are often 
required for symptom management. While it is well-known that oral GC-induced bone 
loss and fracture risk is dose-dependent,15,17 the relationship with the cumulative 
exposure is less well established.15,17 
To minimise fracture risk, clinical practice guidelines recommend that osteoporosis 
pharmacotherapy should be given to patients that are expected to receive a daily dose of 
5 to 7.5 mg of prednisone equivalent for 3–6 months.10,18–20 However, in a real-world 
setting, patients with inflammatory conditions often receive intermittent short courses 
(7–14 days) of high doses (40–60 mg per day), or a continuous low dose (5–10 mg per 
day) for longer periods until remission of the underlying disease.21–23 In both cases, this 
may result in a similar cumulative exposure; however, the impact on bone and fracture 
may differ due to the daily dose.  
To date, data related to the risk of bone fracture associated with these different patterns 
of exposure are limited, and it is often difficult to examine different cumulative and daily 
dose exposure patterns in database research. Thus, in this study using population-level 
data from Denmark, we sought to examine the association between the daily dose and 
cumulative exposure to oral GCs and the risk of fracture. Hip fracture is the most 
burdensome osteoporotic (OP) fracture, and its identification using hospital and 
physician diagnosis codes is accurate compared to other common OP fractures.24,25 In 
particular, we focus on the effect of “short courses” or “heavy use” of high daily doses of 
oral GCs and hip fracture risk. Additionally, as the association of oral GC exposure with 
other fractures (forearm and vertebra) is not yet clear, we further examined other 
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c. Methods  
Data Source 
We utilised data from the Danish National Health Service Register that covers all contacts 
with the health sector for over five million individuals in Denmark.26 The National Health 
Service Register captures all contacts with general practitioners. The National Hospital 
Discharge Register includes information on hospital admissions since 1977 and all 
outpatient and emergency department visits since 1995.27 All diagnoses are coded using 
the International Classification of Diseases and Related Health Problems (ICD) system, 
with high precision for diagnoses, particularly for fractures.28 The vital status for the 
entire Danish population is identified from the Civil Registration System. The Danish 
Medicines Agency Register of Medicinal Product Statistics is a nationwide prescription 
database that uses the Anatomical Therapeutic Chemical Classification (ATC) system and 
includes information on the type, amount, and prescription date. All registers can be 




We completed a population-based case-control study. Cases were all patients aged 18 
years or older, who sustained the first ever hip, vertebral, or forearm fracture between 1 
January 1996, and 31 December 2011. The primary fracture of interest was hip fracture 
(ICD-10 codes: S72.0–S72.2). We further identified patients with clinical symptomatic 
vertebral fractures (ICD-10 codes: S12, S22.0, S22.1, S32.0, T08) and forearm fractures: 
radius or ulna (ICD-10 code: S52).  
We randomly selected a control for each case, matched on age and year of birth, using 
incidence density sampling. Controls had no fracture during the study period. The date of 
the first fracture was used as the index date for the cases, and controls were assigned the 
index date of their matched case. 
 
Exposure 
We defined oral GC exposure based on most recent GC prescription prior to the index 
date: current (within 91 days), recent (92–182 days), past (183–364 days), and distant past 
(≥365 days). Patients with no GC prescriptions prior to the index date were classified as 
never users and were the reference category in all analyses.  
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Average daily dose (DD) and the cumulative dose (CD) of oral GCs were calculated among 
current users and expressed as prednisone equivalents. The average DD was calculated 
by dividing CD by the treatment time (days between the first GC prescription to the index 
date) and categorised into three groups: low (<7.5 mg), moderate (7.5–14.9 mg), and high 
(≥15 mg). CD was calculated by summing defined daily doses of GC prescriptions prior to 
the index date, according to the World Health Organisation. The primary exposure 
categories of interest were defined as follows: CD was categorised as low (<1 g CD) or 
high (≥1 g CD) (Figure 4.1). In a secondary analysis, we defined high CD as ≥5 or ≥10 g, with 
relevant sub-groups of CD (1.0–4.9 g, and 5.0–9.9 g), where appropriate. 
To examine fracture risk associated with different patterns of GC exposure, we further 
stratified exposure by both DD and CD to capture short-course and heavy users of high 
DD (≥15 mg) oral GCs. Among these patients with a high DD, we defined “short-course 
users” as those with <1 g CD, while “heavy users” were those with a CD ≥1 g. These 
definitions were used as a heavy user would be a patient receiving 2–3 months of 15 mg 
daily, or more than a 30-day exposure to 40–60 mg daily. 
 
Covariates 
A history of the following comorbidities were identified if they occurred any time before a 
patient’s index date: secondary osteoporosis (type 1 diabetes mellitus, hypogonadism, or 
premature menopause), fracture (prior to 1996), rheumatoid arthritis, gout, inflammatory 
bowel disease, chronic obstructive pulmonary disease, alcoholism, cerebrovascular 
disease, congestive heart failure, pneumonia, type 2 diabetes mellitus, hyperthyroidism, 
hypothyroidism, malignancies (excluding non-melanoma skin cancer), dementia, and 
retinopathy. All potential confounders were identified using ICD-8 or ICD-10 codes. In the 
6 months before the index date, we identified the following prescriptions as potential 
confounders: bone-sparing drugs (bisphosphonates, vitamin D, calcium, calcitonin, 
denosumab, raloxifene, and strontium ranelate), hormone replacement therapy, 
parathyroid hormone, antidepressants, antipsychotics, hypnotics/ anxiolytics, 
anticonvulsants, anti-Parkinson drugs, inhaled bronchodilators, inhaled corticosteroids, 
xanthine derivatives, antihypertensive drugs, and proton pump inhibitors. 
 
Statistical Analysis 
Conditional logistic regression was used to estimate the association between the use of 
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corresponding 95% confidence intervals (95% CIs). Analyses were stratified by DD, CD, and 
the DD stratified by CD (i.e., short-course vs. heavy use). Final regression models were 
determined using stepwise backward elimination using a significance level of 0.05. We 
completed an additional analysis that adjusted the final model for osteoporosis 
medications in addition to identified significant covariates. Separate models were run for 
hip (primary outcome), clinical symptomatic vertebral, and forearm fracture. Analyses 







Figure 4.1. Study design diagram.  
*DD: average daily dose in milligrams of prednisone equivalent measured among current users. CD: cumulative 
exposure in grams of prednisone equivalent measured among current users. Notes: index date defined as the first 
fracture occurring between 1996 and 2011. Oral glucocorticoid exposure based on most recent glucocorticoid 
prescription prior to the index date: current (within 91 days), recent (92–182 days), past (183–364 days), and distant 
past (>364 days). Comorbidities: any diagnoses code prior to the index date. Drug use: any drug prescription within 6 




Primary fracture site: hip fracture 
We identified 81,342 cases of hip fracture who were well matched to controls on age 
(mean 78.6 years, standard deviation 12 years) and sex (women 68.6%) (Table 4.1). 
Compared with controls, a higher proportion of cases had comorbidities, such as the 
history of fracture (27 cases vs. 11% controls), chronic obstructive pulmonary disease (10 
cases vs. 7% controls), and secondary osteoporosis (8 cases vs. 5% controls). Drug use in 
the 6 months prior to the index date was higher among the fracture cases, as compared 
to controls: bisphosphonates (3.5 vs. 2.4%), antipsychotics (9.3 vs. 4.3%), anticonvulsants 
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Table 4.1. Baseline characteristics of cases of hip fracture and controls.  
 Cases (n=81,342) Controls (n=81,342)  
 N %  N %  P value 
Women 55,776 68.6 55,776 68.6 1 
Mean age in years (SD) 78.6 (12.0) 78.6 (12.0) 0.99 
Age group      
18–49 years 2237 2.8 2240 2.8 0.99 
50–59 years 3791 4.7 3794 4.7 0.99 
60–69 years 8565 10.5 8578 10.6 0.91 
70–79 years 21,513 26.5 21,545 26.5 0.86 
80+ years 45,236 55.6 45,185 55.6 0.8 
History of comorbidities*      
COPD 7986 9.8 5293 6.5 <0.001 
Fracture (prior to 1996) 21,653 26.6 8672 10.7 <0.001 
Rheumatoid arthritis 2318 2.9 1452 1.8 <0.001 
Inflammatory bowel disease 1998 2.5 1405 1.7 <0.001 
Secondary osteoporosis† 6189 7.6 3951 4.9 <0.001 
Drug use 6 months before index 
date 
     
Bisphosphonates 2868 3.5 1917 2.4 <0.001 
Vitamin D 156 0.2 122 0.2 <0.05 
Calcium 1718 2.1 1109 1.4 <0.001 
Raloxifene 104 0.1 62 0.1 <0.01 
Strontium ranelate 37 0.1 19 0.0 0.01 
Denosumab 8 0.0 – – – 
Parathyroid hormone 30 0.0 20 0.0 0.16 
Hormone replacement therapy 4306 5.3 5875 7.2 <0.001 
Inhaled corticosteroids 2948 3.6 2625 3.2 <0.001 
Inhaled bronchodilators 7020 8.6 5436 6.7 <0.001 
Antipsychotics 7552 9.3 3496 4.3 <0.001 
Antidepressants 18,138 22.3 8783 10.8 <0.001 
Hypnotics/ Anxiolytics 13,053 16.1 8734 10.7 <0.001 
Anticonvulsants 3660 4.5 1539 1.9 <0.001 
Anti-Parkinson drugs 2124 2.6 841 1.0 <0.001 
COPD: Chronic obstructive pulmonary disease, SD: Standard deviation. Cells <6 are not reported. 
* Comorbidities: any diagnoses code (ICD-8 or ICD-10) recorded prior to the index date. 
† Secondary osteoporosis defined as a diagnosis of type 1 diabetes mellitus, hypogonadism, or premature 
menopause. 
 
A total of 16,606 patients with hip fracture (20.4%) and 13,763 controls (16.9%) had used 
oral GCs prior to the index fracture (Supplementary Table S4.1). Current use of oral GCs 
was associated with an increased risk of hip fracture (adjusted [adj.] OR 1.56, 95% CI [1.48–
1.65]), as compared to never users of oral GCs (Figure 4.2). Among current users, a dose-
response relationship was observed with increasing DD: <7.5 mg (adj. OR 1.37 [95% CI 
1.28–1.47]), 7.5–14.9 mg (adj. OR 1.53 [95% CI 1.39–1.68]), and ≥15 mg (adj. OR 2.5 [95% CI 
2.19–2.85]) (Supplementary Table S4.1). Likewise, a higher CD was associated with an 
increased hip fracture risk. A CD <1 g was associated with a 1.3-fold increased hip fracture 
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g (adj. OR 1.64 [95% CI 1.54–1.74]), CD ≥5 g (adj. OR 1.61 [95% CI 1.50–1.74]), and CD ≥10 g 
(adj. OR 1.57 [95% CI 1.42–1.73]). 
To examine the association between “heavy” and “short-course” users of high-dosed 
oral GCs, the DD was further stratified by the CD (Figure 4.2). Among short-course users 
(DD ≥15 mg and CD <1 g), a 42% increase in hip fracture risk was observed (adj. OR 1.42 
[95% CI 1.08–1.86]). In contrast, “heavy” use of high doses (DD ≥15 mg and CD ≥1 g) 
resulted in a tripled risk of hip fracture (adj. OR 2.94 [95% CI 2.52–3.42]). When CD 
exceeded 5 or 10 g, among those with a high DD, the hip fracture risk was similar (CD ≥5 

















Figure 4.2. Odds ratio of hip fracture by glucocorticoid use (vs. never).  
CD: cumulative dose, DD: average daily dose, GC: glucocorticoid. 
Oral GC exposure based on most recent GC prescription prior to the index date: current (within 91 days), recent (92–182 
days), past (183–364 days), and distant past (>364 days). DD and CD were calculated among current users. Adjusted for 
history of chronic obstructive pulmonary disease, fracture (prior to 1996), rheumatoid arthritis, inflammatory bowel 
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Secondary fracture sites: vertebral and forearm fractures 
Figure 4.3 and Supplementary Table S4.2 present the ORs of clinical symptomatic 
vertebral fracture by GC exposure. Current use of oral GCs was associated with doubled 
risk of clinical vertebral fracture (adj. OR 2.36 [95% CI 2.15–2.60]). A high DD (≥15 mg/day) 
was associated with a 3.8-fold increased clinical vertebral fracture risk (adj. OR 3.76 [95% 
CI 2.97–4.77]), and a CD ≥1 g was associated with a 2.6-fold increased risk (adj. OR 2.57 
[95% CI 2.30–2.87]). Among the high DD users, short-course use was associated with a 
doubled risk of clinical symptomatic vertebral fracture risk (adj. OR 2.13, 95% CI 1.30–3.49), 
while “heavy” use was associated with a more than 4-fold increased risk (adj. OR 4.36, 


























Figure 4.3. Odds ratio of vertebral fracture by glucocorticoid dose (vs. never). 
CD: cumulative dose, DD: average daily dose, GC: glucocorticoid. 
Oral GC exposure based on most recent GC prescription prior to the index date: current (within 91 days), recent (92–182 
days), past (183–364 days), and distant past (>364 days). DD and CD were calculated among current users. Adjusted for 
history of chronic obstructive pulmonary disease, fracture (prior to 1996), rheumatoid arthritis, inflammatory bowel 
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Among patients with forearm fractures, the analysis showed minimal to no association 
with oral GC exposure (Figure 4.4). No dose-response of forearm fracture risk was 






















Figure 4.4. Odds ratio of forearm fracture by glucocorticoid dose (vs. never). 
CD: cumulative dose, DD: average daily dose, GC: glucocorticoid. 
Oral GC exposure based on most recent GC prescription prior to the index date: current (within 91 days), recent (92–182 
days), past (183–364 days), and distant past (>364 days). DD and CD were calculated among current users. Adjusted for 
history of chronic obstructive pulmonary disease, fracture (prior to 1996), rheumatoid arthritis, inflammatory bowel 
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e. Discussion 
In this population-based case-control study, we identified that heavy use (high DD and 
high CD) of oral GCs was associated with a 3-fold increased hip fracture risk, which was 
substantially higher as compared to short-course users. While both the DD and CD were 
independently associated with hip fracture risk, our results suggest that hip fracture risk 
was modified by the CD among patients receiving a high DD of oral GCs. This association 
was not observed among patients with a low to moderate DD, thereby suggesting that 
heavy users of high DD oral GCs are a distinct patient group with substantially elevated 
fracture risk. 
Interestingly, in our study, we did not observe an incremental increase in hip fracture risk 
among patients receiving CD exceeding 1 g of prednisone equivalent (≥5 or ≥10 g). This 
result may indicate a threshold effect for the CD, which may be used to guide clinical 
decision making to determine patients in need of fracture/osteoporosis management. 
Our study further showed that the odds of sustaining fractures among GC users were 
stronger for clinical symptomatic vertebral fracture than hip fracture, while forearm 
fracture risk was minimal to non-significant among current users and across dose 
categories. 
Systemic GCs cause considerable inhibition of bone formation and bone resorption, but 
particularly when given at higher doses and longer durations. Additionally, systemic GCs 
impair renal and intestinal calcium absorption, reduce sexual hormone secretion, and 
cause muscle atrophy and gait impairment, which in turn increase bone loss and fracture 
risk.5 These pleiotropic effects significantly increase fracture risk, and we speculate that it 
is the high daily and cumulative doses which can explain the effect modification that we 
observed. Our finding is also in line with a previous cohort study in the UK.15 
In clinical practice, treatment with bisphosphonates for osteoporosis management is 
often suboptimal among patients receiving oral GCs, particularly those receiving short 
courses as they do not reach the guideline recommendation of 7.5 mg per day for a 
duration of 3 months. As a result, these patients remain at high risk for potentially 
devastating hip fractures. Since the cycle of bone remodelling takes on average 3 
months, 30 multiple short courses are likely to hinder bone metabolism by preventing the 
skeleton to completely regenerate. Indeed, data have shown that fracture risk can persist 
up to 1 year after oral GC cessation.15,17 However, the association between a more 
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effect of a CD of oral GCs, particularly in relation to the DD, on fracture risk remains 
debated. 
While it is well established that a DD exceeding 15 mg is associated with a significant 
increase in fracture risk, our study highlighted that the magnitude of fracture risk 
associated with a high DD differed depending on the CD thresholds. We observed that 
patients receiving short courses (<1 g CD) of high DD had an elevated hip and clinical 
symptomatic vertebral fracture risk, yet heavy users (≥1 g CD) of high DD had a tripled risk 
of hip fracture, and a 4.5-fold increase in clinical symptomatic vertebral fracture risk. 
Interestingly, we observed that fracture risk reached a plateau starting at a CD ≥1 g. Prior 
studies have shown that GC daily dose is a stronger predictor than the cumulative 
dose.12,15,16 However, our results suggest that high DD with low CD does not confer higher 
risk of fractures, and therefore, we assume that there is a threshold duration of exposure 
or a minimum number of high daily doses that are causing the highest risk of fracture. 
Our results support that a clinical threshold of 1 g prednisone equivalent may be useful to 
guide therapeutic interventions to prevent OP fracture. Indeed, clinical practice 
guidelines use various oral GC exposure thresholds to consider anti-fracture treatment, 
yet no agreement between guidelines is established.10,18–20 
When placing our results in the context of the literature, we note that the most 
comparable study to ours is a large cohort study conducted by de Vries et al., using the 
UK primary care data (Clinical Practice Research Datalink) to examine fracture risk among 
GC users covering the period between 1987 and 1997.15 In their study, de Vries et al. 
examined similar GC DD and CD exposure to our study, and showed a 49% increase in 
relative risk of hip and femur fracture, and more than 3-fold risk increase of vertebral 
fracture. The authors showed similar dose-response patterns for the average DD and CD 
and OP fracture overall. However, contrary to our study, de Vries et al. assessed fracture 
risk by disease at baseline, limiting the direct comparison with our study. Additionally, the 
comparator group in the study by de Vries et al. were those with past use of GCs, while 
never users were compared in our study. Thus, a larger overall effect of current use in our 
study would be expected. 
Additionally, a case-control study in the Netherlands investigated inhaled and oral GC 
users from 1991 to 2002, identifying cases of 366 hip or femur fracture among current oral 
GC users.31 This study examined daily dose-response and showed lower overall risk than 
identified in our study. However, this study did not consider the total CD of GCs, which is 
an important factor to estimate differential fracture risk. Consequently, we are unable to 
make a direct comparison regarding the effect of heavy or short-term use on fracture 
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risk. Finally, Vestergaard et al. showed that the highest increase in hip fracture risk by 
cumulative dose was among patients receiving ≥1500 mg prednisone equivalent in the 
year preceding the fracture (OR 4.2, 95% CI 1.96–9.00 vs. OR 1.89, 95% CI 1.62–2.21 for 
patients receiving 500–1499 mg prednisone equivalent).32 However, this analysis was not 
stratified by GC daily dose.  
Other observational studies have examined the association of short courses of GC 
exposure and support our findings of a moderately increased fracture risk. A cohort study 
using administrative healthcare databases reported a similar increase in hip fracture risk 
(60%) among all GC users, and RR of hip fracture equal to 1.26 (95% CI 0.87–1.83) among 
patients with short courses of oral GCs (<90 days). A lack of statistical power is likely to 
cause the non-significant results for short courses. Another cohort study reported 
increased risk of hip fracture among oral GC users (RR 1.87, 95% CI 1.19–2.94).16 In addition, 
increases in daily dose and duration were significantly associated with hip and clinical 
symptomatic vertebral fracture risk. This study showed that short duration of oral GC 
exposure also increased fracture risk.  
In interpreting our data, we are mindful of some limitations. By design, the case-control 
study is not able to provide an absolute risk. We used a density sampling technique which 
allowed us to interpret the odds ratio as risk ratio since controls were selected based on 
the person-time duration corresponding to each case.33 There remains debate of the 
thresholds of GC exposure resulting in fracture risk. Consequently, our definition of dose 
and duration thresholds may be debatable. Many guidelines recommend treatment 
among patients receiving a planned systemic GC dose ≥7.5 mg prednisone equivalent 
daily and a duration of 3 months.19,34 However, the patterns of GC exposure are often 
complex, requiring multiple courses and may therefore not meet guidelines for 
treatment, leaving many patients at risk. While the definition of high GC daily doses is 
debated, doses <7.5 mg/day prednisone equivalent are often considered as low doses in 
clinical trials of oral GCs.35,36 While our study did not identify significant differentiation 
between those receiving <7.5 mg daily and those receiving 7.5–14.9 mg daily, there was a 
significant increased hip and vertebral fracture risk among those receiving ≥15 mg daily. 
Additionally, there may be limitations regarding our definition of short-course and heavy 
users of high DD oral GCs. In this study, we assumed patients with a DD ≥15 mg and CD <1 
g may have received intermittent use (short-courses) of oral GC therapy, as this would 
suggest that a patient received two or fewer 30-day courses of 15 mg per day. Conversely, 
the heavy users with ≥1 g CD were more likely to have received more prolonged exposure 
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may not be the most optimal choice. In many clinical cases, dosing schedule of oral GCs 
consists of a high DD and a short duration. In this study, we assumed that less than 1 g of 
prednisone equivalent before the fracture event is indicative of short-course or 
intermittent use for acute symptom management. This would correspond to one or two 
30-day courses of 15 mg per day. However, it is possible that intermittent users may 
accumulate more than 1 g of exposure if a DD exceeded 30 mg. Nonetheless, we expect 
that this is likely to happen in very few cases only. 
Additionally, while we adjusted for common GC indications, we did not stratify our results 
by the specific disease indications. Similarly, while we adjusted comorbidities and drug 
use, residual confounding remains a limitation. We recognise that other risk factors have 
not been captured in our data and therefore not adjusted for. These include patient body 
mass index, smoking status, and bone mineral density values. However, we note that de 
Vries et al. reported similar results using UK data, which adjusted for these variables, and 
there is evidence showing that the fracture risk could be partly independent from the 
diminished bone density in patients who take oral GCs.37  
Another limitation was the possibility of misclassification bias in the Danish database. 
Vertebral fractures can be asymptomatic and likely have a low predictive value when 
defined using claims data.38 This may have resulted in an underestimated effect in our 
vertebral fracture results. However, we believe there is little chance of differential 
misclassification and commonly used codes for OP fracture were identified. Additionally, 
misclassification of exposure is possible with GCs as information was derived from 
pharmacy claims, and we cannot be assured that the pills were taken as prescribed. 
Indeed, GCs may be prescribed on a “take as needed” basis, and therefore may have 
been collected at the pharmacy and not taken. In this study, the average daily dose was 
used, yet we acknowledge that this method has limitations with oral GCs, particularly 
when the GC regimen requires adjustment and gradual tapering for long exposure 
periods.39 This may result in underestimating the DD. However, the CD may partially 
adjust for this by estimating the overall exposure.  
There are several strengths to our current study. We used the Danish nationwide 
population register, which is a large population-based register that permitted the 
examination of a large number of cases and controls. In Denmark, all residents receive 
universal medical and prescription services. Thus, the data are complete and collected 
longitudinally. This data also permitted the inclusion of many important confounders. 
Additionally, the prescription data in Denmark are claims-based and collected 
longitudinally, permitting us to calculate a reliable cumulative and average daily dose. 
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The literature is consistent with respect to increases in fracture risk related to oral GC 
exposure, yet the independent and combined effects of DD and CD on fracture risk 
remains controversial. According to the underlying condition, patients are faced with 
various instructions regarding GC exposure - including tapering over time, alternate day 
use, and “take as needed” instructions. Thus, defining an exposure threshold to initiate 
osteoporosis treatment is ambiguous, and difficult to assess in research using population-
based data. In general, the literature shows suboptimal osteoporosis management 
among oral GC users, where up to 70% of eligible users have no bone protection 
treatment.3,41 Many oral GC users may not fall under clinical guidelines’ eligibility criteria 
to receive osteoporosis management. 
The results of this study, therefore, provide additional evidence that a high DD (≥15 
mg/day) and a CD exceeding 1 g is likely to cause the greatest risk of hip and clinical 
symptomatic vertebral fracture. Thus, while patients receiving short courses of high DD 
should continue to be monitored, focused attention for fracture management and 
osteoporosis pharmacotherapy should be given to patients with heavy use. These results 
may help clinical guidance to elaborate an evidence-based strategy for bone protection 
among oral GC users. 
 
Conclusion 
In conclusion, heavy use of high-dosed oral GCs is associated with a substantial 3-fold 
increase in hip fracture risk. Therefore, while short courses or more intermittent use of 
high-dosed oral GCs do increase fracture risk, primary attention should be paid to patients 
with heavy use - defined as those receiving multiple short or prolonged courses of high 
GC doses that result in a cumulative exposure exceeding 1 g prednisone equivalent. 
Knowing a patients’ prescription history to identify the cumulative exposure to high daily 
doses of oral GCs may help clinicians to identify patients that are at high risk of fractures. 
These patients should then be targeted for osteoporosis management strategies to 
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Clinical trials have shown that low-dose glucocorticoid therapy in patients with 
rheumatoid arthritis (RA) reduces bone loss in hands or hip, but the effect on 
osteoporotic fractures is not yet clear. Therefore, we investigated the use of low-dose 
oral glucocorticoids and risk of osteoporotic fractures among patients with RA. 
 
Methods 
This was a cohort study including patients with RA aged 50+ years from the Clinical 
Practice Research Datalink between 1997 and 2017. Exposure to oral glucocorticoids was 
stratified by the most recent prescription in current (<6 months), recent (7-12 months), 
and past (>1 year) use, and average daily and cumulative doses. Risk of incident 
osteoporotic fractures (including hip, vertebrae, humerus, forearm, pelvis, and ribs) was 
estimated by time-dependent Cox proportional-hazards models, adjusted for life-style 
parameters, comorbidities, and comedications. Secondary analyses assessed 




Among 15,123 patients with RA (mean age 68.8 years, 68% females), 1640 osteoporotic 
fractures occurred. Current low-dose oral glucocorticoid therapy (≤7.5 mg prednisolone 
equivalent/day) in patients with RA was not associated with overall risk of osteoporotic 
fractures (adjusted hazard ratio 1.14, 95% CI 0.98-1.33) compared with past glucocorticoid 
use, but was associated with an increased risk of clinical vertebral fracture (adjusted 
hazard ratio 1.59, 95% CI 1.11-2.29). Results remained unchanged regardless of a short-term 
or a long-term use of oral glucocorticoids. 
 
Conclusions 
Clinicians should be aware that even in RA patients who receive low daily glucocorticoid 
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b. Introduction 
Osteoporotic (OP) fractures are a major complication among patients with rheumatoid 
arthritis (RA).1-3 The reason for this increased susceptibility of OP fractures in RA is the 
underlying chronic inflammation of the disease, and the pharmacotherapy that patients 
with RA receive, most importantly oral glucocorticoids (GCs). Short-term GC therapy is 
part of the European Alliance of Associations for Rheumatology (EULAR) 
recommendations 2019 update for RA management, and around a quarter of RA patients 
are treated with GCs in the UK.1,4 GC therapy leads to decreased bone mineral density 
(BMD) and increased fracture risk from early in the treatment course, by mediating a 
reduction in bone formation and an increase in bone resorption.5-8 
Low-dose GC therapy, especially in chronic inflammatory diseases, could also have 
positive effects on bone loss, where it suppresses the underlying deleterious 
inflammation and improves the functional status of patient.9-14 The randomised 
controlled trial (RCT) by Haugeberg et al reported a statistically significant reduced bone 
loss in hands after 1- and 2-years in RA patients who were taking 7.5 mg prednisolone 
once daily compared to placebo.9 However, extrapolation of this local beneficial effect in 
hands to the generalised bone loss in RA and the resulting risk of OP fracture is 
questionable. On the other hand, observational studies have reported higher fracture 
rates with low-dose oral GC use (i.e., ≤7.5 mg prednisolone equivalent dose [PED] per 
day) in RA compared to non-use,13,15,16 although these findings may be confounded by 
indication or disease severity. Additionally, the results of a review by an EULAR task force 
regarding the risk of harm (including osteoporosis and OP fractures) of long-term GC 
therapy in RA was inconclusive for dosages between 5-10 mg PED/day.17 These conflicting 
findings and the uncertainty over any possible beneficial effect of low daily doses of oral 
GCs on fracture risk in RA justifies a more detailed examination of this association using 
real-world data. Thus, the objective of this study was to investigate the use of low-dose 
oral GCs and risk of OP fractures among patients with RA. 
 
c. Methods  
Database 
This is a retrospective cohort study using data from the Clinical Practice Research 
Datalink, GOLD (CPRD; www.cprd.com). CPRD is one of the world’s largest primary care 





representing 4.4 million active patients that equalled to 6.9% of the total population.18 It 
includes data on patient demographics, life-style parameters, clinical diagnoses, 
prescription details, laboratory test results, specialist referrals, and major outcomes since 
1987, with continuing data collection. The CPRD has been well validated for a wide range 
of diseases, including hip and vertebral fractures.19,20 
 
Study Population 
The study population comprised all adults aged 50+ years diagnosed with RA in the CPRD 
between 01 January 1997 and 31 December 2017. We used a validated algorithm that 
detected 86% of the true RA cases among people with an RA Read code in the CPRD 
(Supplementary Table S5.1).21,22 The date of the first RA diagnosis during the period of 
valid data collection (considering up to standard time of the CPRD practice) defined the 
index date (i.e., start of follow-up). Each patient was then followed from the index date 
until the occurrence of the intended outcome, the end of study period, moving out of the 
practice area, death, or last data collection date of the CPRD practice, whichever came 
first. Follow-up time was broken down into 30-day periods. Patients with a history of oral 
GC use during the 1 year before the index date, and those with an OP fracture prior to the 
index date were excluded. 
 
Exposure and Outcome 
The exposure of interest was the use of oral GCs, which was assessed time-dependently 
in 30-day periods. At the start of each 30-day period, we identified prescribing of oral GCs 
in a retrospective manner. A period was defined as current, recent, or past use when the 
most recent prescription of oral GCs was issued within 6 months before, 7-12 months 
before, and >12 months before, respectively.6,23 Non-use was defined as all other follow-
up time without a history of oral GC exposure.  
Current GC use was further broken down into subcategories based on average daily and 
cumulative dose. All oral GC prescriptions were retrieved, and the prescribed quantity 
was extracted and converted into PED, using the World Health Organisation Anatomical 
Therapeutic Chemical classification system of defined daily doses (ATC/DDD).24 Values for 
missing data on prescribed quantity were assigned the median value of all prescriptions. 
The cumulative amount of the drug prescribed in each follow-up period was estimated by 
summing all consecutive prescriptions since the index date. The average daily dose in 
each follow-up period was calculated by dividing the cumulative amount prescribed by 
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the treatment time (i.e., the time between the first oral GC prescription and the start date 
of a period of current use). The composite outcome in this study was the occurrence of a 
first OP fracture in patients with RA after the index date, including the hip, clinically 




Sex, body mass index (BMI), smoking status and alcohol use were assessed at the index 
date. During follow-up, we determined age, and a history of asthma, chronic obstructive 
pulmonary disease, ischaemic heart disease (including myocardial infarction), 
cerebrovascular disease, congestive heart failure, anaemia, peripheral arterial disease, 
gastroesophageal reflux disease, peptic ulcer disease, inflammatory bowel disease 
(Crohn disease and ulcerative colitis), Coeliac disease, hyperthyroidism, hypothyroidism, 
type 1 and 2 diabetes mellitus, osteomalacia, hypopituitarism, Cushing’s disease, bilateral 
orchidectomy or oophorectomy, chronic renal failure, ankylosing spondylitis, muscular 
dystrophy, dementia, Parkinson’s disease, spinal cord injury, anorexia nervosa, major 
infections (i.e., sepsis, meningitis, upper and lower respiratory tract infections), 
malignant neoplasms (excluding non-melanoma skin cancers), and organ 
transplantation.27 Falls were determined in 7-12 months before each period. The use of 
comedications in six months prior was determined and included antihypertensives, 
anticoagulants, proton pump inhibitors, calcium/vitamin D, bisphosphonates, hormone 
replacement therapy, anticonvulsants, hypnotics/anxiolytics, antidepressants and 
antipsychotics. The following medications were measured at the same time-windows and 
were considered as indicators of the underlying severity of RA: non-selective non-
steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 selective inhibitors, 
paracetamol, tramadol, opioids (stronger than tramadol), and conventional synthetic 
disease-modifying antirheumatic drugs (csDMARDs). 
 
Statistical Analysis 
Time-dependent Cox proportional-hazards models estimated the risk of OP fracture in RA 
patients with current use of low-dose oral GCs (average daily dose ≤7.5 mg PED/day 
[based on EULAR definitions]4) versus past use. We selected past use as the reference 
category - instead of non-use, to have the most comparable control group and to reduce 





mg PED/day and ≥15.0 mg PED/day, respectively) were compared with past use. All these 
exposure subcategories under current GC use were statistically compared with a Wald 
test. Additionally, separate analyses were conducted for various OP fracture sites. Any of 
the potential confounders were incorporated in the model if they changed the beta 
coefficient of the association >5% or based on literature following authors’ assessment. 
Collinearity between potential confounders was assessed. 
In secondary analyses, cumulative use of oral GCs and its combination with average daily 
doses of oral GCs in RA patients were compared with past use. Furthermore, four 
sensitivity analyses were conducted. First, OP fracture risk in RA was assessed in various 
other cut-offs for low GC use (i.e., ≤5.0 mg PED/day and ≤2.5 mg PED/day). Second, we 
repeated a Cox model to estimate the risk of OP fracture with low-dose oral GC use by 
removing csDMARDs as confounder, since we thought csDMARDs, as a measure of RA 
disease severity, might lie in the causal pathway of this association.4,28 In the third 
sensitivity analysis, we repeated the main model, only after excluding those patients with 
a prior OP fracture in 1 year before the index date. Fourthly, we ran a Cox model by 
comparing current use of low-dose oral GCs to non-use of GCs. Finally, a post hoc analysis 
was performed to evaluate the association between a GC daily dose of 5.1-7.5 mg PED/day 
and OP fractures in patients with RA. Data were analysed using SAS version 9.4 (SAS 
Institute Inc. Cary, NC, USA). This study was approved by the Independent Scientific 
Advisory Committee for Medicines and Healthcare products Regulatory Agency database 
research (protocol 19_201). 
 
d. Results 
The study population consisted of 15,123 RA patients aged 50+ years (Figure 5.1). Table 5.1 
shows a mean follow-up time of 8.1 years for GC users (N=7039), and 6.2 years for non-
users (N=8084). The average duration of GC use was 3.7 years. The mean age of GC users 
at the index date was 68.4 years and of non-users was 69.1 years. Females constituted 
67% of GC users and 70% of non-users. Around one third of both exposure groups had a 
normal-range BMI (25-30 kg/m2). While 23% of GC users were current smokers, only 19% of 
non-users were smokers at the index date. The most frequent comorbidities among GC 
users were major infections and asthma, and major infections and anaemia among non-
users. Around 30% of GC users and >35% of non-users were concomitantly taking 



















Figure 5.1. Flowchart on establishment of patient population.  
CPRD: Clinical Practice Research Datalink, GC: glucocorticoid, OP: osteoporotic, RA: rheumatoid arthritis, TOD: transfer out 
of database date (i.e., date the patient transferred out of the practice), UTS: Up to standard time (i.e., date at which the 
practice data is deemed to be of research quality). 
* The numbers for specific exclusion criteria would not add up to the total excluded number as there was some overlap 
between the exclusion categories.                                                                                                                                                                                                                                                                                                           
 
Table 5.1. Baseline characteristics of patients with rheumatoid arthritis, stratified by oral   
glucocorticoid therapy status during follow-up (N=15,123).  




 N % - SD N % - SD 
Mean duration of follow-up (years, SD)  8.1  4.9  6.2  4.7 
Age(years)†     
Mean (SD) 68.4 8.6 69.1 8.7 
50-59 1150 16.3 1211 15.0 
60-69 2842 40.4 3052 37.8 
70-79 2312 32.8 2817 34.8 
80+ 735 10.4 1004 12.4 
Number of Females 4687 66.6 5654 69.9 
BMI (kg/m2)†     
Mean (SD) 26.5 5.2 26.3 5.2 
<20.0 481 6.8 568 7.0 
20.0-24.9 2279 32.4 2642 32.7 
25.0-29.9 2432 34.6 2687 33.2 
30.0-34.9 1003 14.2 1039 12.9 
≥35.0 394 5.6 435 5.4 
Exclusion due to a recorded date of 
death before the start of study or 
UTS, or a recorded date of death or 
TOD before or on index date  
n= 3907 
• Exclusion based on Thomas 
algorithm,21 without a definite RA 
diagnosis (n= 5557) 
• Exclusion due to a history of OP 
fractures (n= 2770) 
• Exclusion due to GC use in the 1 
year before index date (n= 8338) 
n= 14,339* 
Total RA patients aged over 50 
from CPRD between 1997-2017 
n= 33,369 
RA patients with index date 








Table 5.1. (continued)     
Missing 450 6.4 713 8.8 
Smoking status†     
Non 2488 35.3 3132 38.7 
Current 1609 22.9 1557 19.3 
Past 2856 40.6 3183 39.4 
Missing 86 1.2 212 2.6 
Alcohol use†     
No  2058 29.2 2205 27.3 
Yes 4464 63.4 5125 63.4 
Missing 517 7.3 754 9.3 
History of comorbidities†     
Asthma 942 13.4 536 6.6 
COPD 544 7.7 263 3.3 
Ischaemic heart disease (including 
myocardial infarction) 
940 13.4 987 12.2 
Cerebrovascular disease 399 5.7 470 5.8 
Congestive heart failure 192 2.7 254 3.1 
Anaemia 923 13.1 1126 13.9 
Peripheral arterial disease 364 5.2 416 5.1 
Gastroesophageal reflux disease 585 8.3 596 7.4 
Peptic ulcer disease 66 0.9 64 0.8 
Coeliac disease 22 0.3 26 0.3 
Inflammatory bowel disease 75 1.1 66 0.8 
Hyperthyroidism 48 0.7 46 0.6 
Hypothyroidism 558 7.9 619 7.7 
Diabetes mellitus type 1 51 0.7 54 0.7 
Diabetes mellitus type 2 425 6.0 560 6.9 
Chronic renal failure 363 5.2 394 4.9 
Ankylosing spondylitis 9 0.1 18 0.2 
Dementia 34 0.5 65 0.8 
Parkinson’s disease 14 0.2 47 0.6 
Major infections‡ 1437 20.4 1414 17.5 
Malignant neoplasms (excluding 
non-melanoma skin cancers) 
651 9.2 747 9.2 
Falls (7-12 months before) 47 0.7 71 0.9 
Comedications use (6 months before)†     
Antihypertensives 2597 36.9 3141 38.9 
Anticoagulants 218 3.1 237 2.9 
Proton pump inhibitors 1756 24.9 2006 24.8 
Calcium/vitamin D 380 5.4 574 7.1 
Bisphosphonates 280 4.0 385 4.8 
Hormone replacement therapy  233 3.3 231 2.9 
Anticonvulsants 118 1.7 159 2.0 
Hypnotics/ Anxiolytics 647 9.2 589 7.3 
Antidepressants 916 13.0 967 12.0 
Antipsychotics 67 1.0 77 1.0 
Disease severity indicators     
Non-selective NSAIDs 4057 57.6 4344 53.7 
COX-2 selective inhibitors 711 10.1 669 8.3 
Paracetamol 3603 51.2 3811 47.1 
Tramadol 541 7.7 513 6.3 
Opioids (stronger than tramadol) 430 6.1 392 4.8 
csDMARDs 2104 29.9 2849 35.2 
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Table 5.1. (continued) 
BMI: body mass index, COPD: chronic obstructive pulmonary disease, COX-2: cyclooxygenase-2, csDMARDs: 
conventional synthetic disease-modifying antirheumatic drugs, NSAIDs: non-steroidal anti-inflammatory 
drugs, SD: standard deviation. 
Data on a history of osteomalacia, hypopituitarism, Cushing’s disease, bilateral orchidectomy/  
oophorectomy, muscular dystrophy, spinal cord injury, anorexia nervosa, and organ transplantation 
are not shown due to a small number of patients in both cohorts. 
* Oral glucocorticoid users are patients who had at least 1 prescription of an oral glucocorticoid 
during follow-up. 
† At the index date (and start of follow-up). 
‡ Major infections included sepsis, meningitis, upper and lower respiratory tract infections. 
 
 
Current use of low-dose oral GCs (≤7.5 mg PED/day) was not associated with overall risk 
of OP fractures among patients with RA compared with past GC use (adjusted hazard 
ratio [adj. HR] 1.14, 95% CI 0.98-1.33), (Table 5.2). However, current use of higher daily 
dosages of oral GCs incurred a 38% increased (adj. HR of 1.38, 95% CI 1.11-1.73 for 7.6-14.9 
mg PED/day) or an 84% increased risk (adj. HR of 1.84, 95% CI 1.23-2.74 for ≥15.0 mg 
PED/day) of OP fractures. The increased fracture risk with high-dose oral GCs was 
statistically different from low-dose oral GC use (Wald test, P <0.05). Sensitivity analyses 
showed that current use of lower dosages of oral GCs shifted the association further 
towards null, yielding an adj. HR of 1.07 (95% CI 0.89-1.29) for an average daily dose ≤5.0 
mg PED/day, and an adj. HR of 1.00 (95% CI 0.77-1.31) for an average daily dose ≤2.5 mg 
PED/day for OP fracture risk (Supplementary Table S5.2). 
Table 5.3 shows that treatment with low daily doses of oral GCs in patients with RA was 
associated with a 59% increased risk of clinical vertebral fracture, compared with past GC 
use (adj. HR 1.59, 95% CI 1.11-2.29). Nonetheless, the risk of other individual OP fracture 
sites, i.e., hip, humerus, forearm, pelvic and rib fractures, was not associated with low-
dose oral GC use versus past use. 
Patients with RA who were current users of low-dose oral GCs had no increased risk of OP 
fracture, regardless of a short-term (≤1.0 g PED) or a long-term (>1.0 g PED) use (Table 
5.4). In contrast, high-dose (≥7.5 mg PED/day) long-term oral GC users had a 1.5-fold 
increased risk of OP fracture compared to patients who had stopped taking oral GCs for 
>1 year, yielding an adj. HR of 1.52 (95% CI 1.22-1.89). 
When csDMARDs were removed from the Cox model as confounder, we observed similar 
estimates of OP fracture risk with the various daily doses of oral GCs (Supplementary 
Table S5.3). However, exclusion of patients with a prior fracture only in 1 year before the 





(Supplementary Table S5.4). Finally, a comparison of current use of oral GCs to non-use, 
instead of past GC use, resulted in a statistically significant 21% increased risk of OP 
fracture with low-dose oral GC use (ad. HR of 1.21, 95% CI 1.05-1.39) (data not shown). 
Finally, 136 OP fractures occurred among those RA patients who used a GC daily dose of 
5.1-7.5 mg PED/day, with an incidence rate (IR) of 23.2 per 1000 person years (PYs). 
Current use of oral GCs with a dose of 5.1-7.5 mg PED/day in RA incurred a 24% increased 
risk of OP fractures (adj. HR 1.24, 95% CI 1.02-1.51), compared to past GC use. 
 
 
Table 5.2. Use of oral glucocorticoids and risk of osteoporotic fracture in patients with rheumatoid 
arthritis, by average daily dose.  
Oral Glucocorticoid Use  
   By recency of use 










Current use‡ 428 21.3 1.36 (1.18-1.56) 1.22 (1.06-1.40) 
Mean daily dose ≤7.5 mg 
PED/day 
301 20.3 1.26 (1.08-1.46) 1.14 (0.98-1.33) 
Mean daily dose 7.6-14.9 mg 
PED/day 
101 23.3 1.60 (1.29-2.00) 1.38 (1.11-1.73) 
Mean daily dose ≥15.0 mg 
PED/day 
26 27.9 2.09 (1.40-3.11) 1.84 (1.23-2.74)§ 
Recent use‡ 36 11.1 0.76 (0.54-1.06) 0.71 (0.51-1.00) 
Past use‡ 375 15.7 Reference Reference 
Non-use  801 12.6 0.90 (0.80-1.02) 0.94 (0.83-1.07) 
CI: confidence interval, IR: incidence rate, OP: Osteoporotic, PED: prednisolone equivalent dose, PYs: person years.  
Statistically significant hazard ratios are shown in bold. 
* 1640 OP fracture events among all included patients. 
† Adjusted at baseline for sex, body mass index, smoking status and alcohol use, and during follow-up for age, a 
history of ankylosing spondylitis, chronic obstructive pulmonary disease, dementia, falls (in the past 7-12 months), 
inflammatory bowel disease, and the use in the past 6-months of antidepressants, antihypertensives, proton 
pump inhibitors, paracetamol, non-selective non-steroidal anti-inflammatory drugs, cyclooxygenase-2 selective 
inhibitors, tramadol, opioids stronger than tramadol and conventional synthetic disease-modifying antirheumatic 
drugs. 
‡ Current, recent and past use refer to the last prescription within 6 months, 7-12 months, and >12 months before a 
period, respectively. 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Oral Glucocorticoid Use  













Current use** 2.0 1.78 (1.08-2.94)  1.2 1.07 (0.62-1.86) 
Mean daily dose ≤7.5 mg PED/day 1.8 1.59 (0.93-2.73)  1.1 1.08 (0.59-1.98) 
Mean daily dose 7.6-14.9 mg PED/day 2.3 2.22 (1.08-4.55)  1.7 1.50 (0.67-3.34) †† 
Mean daily dose ≥15.0 mg PED/day 3.1 3.57 (1.07-11.89)  - N/A 
Recent use** 1.4 1.53 (0.58-3.99)  0.6 0.59 (0.14-2.48) 
Past use** 1.0 Reference  1.0 Reference 
Non-use  0.9 1.29 (0.81-2.07)  0.6 0.61 (0.37-1.01) 
§ Adjusted at baseline for sex, and during follow-up for age, and use in the past 6-months of ADs, antihypertensives, 
PPIs, paracetamol, tramadol, OPI, csDMARDs. 
¶ Adjusted at baseline for sex, and during follow-up for age, and use in the past 6-months of PPIs and paracetamol.  
†† Due to no rib fracture in the high daily GC use (≥15.0 mg PED/day) group, this group was lumped together with 
users of medium oral GCs, together representing a mean daily dose >7.5 mg/day. 
 
 
Table 5.4. Use of oral glucocorticoids and risk of osteoporotic fracture in patients with rheumatoid 
arthritis, by cumulative and average daily dose.  
Oral Glucocorticoid Use  













Current use‡ 428 21.3 1.36 (1.18-1.56) 1.22 (1.06-1.40) 
❶Cumulative use ≤1.0 g PED 70 17.4 1.20 (0.93-1.55) 1.11 (0.86-1.44) 
-Mean daily dose ≤7.5 mg PED/day 53 17.2 1.18 (0.88-1.57) 1.10 (0.83-1.47) 
-Mean daily dose >7.5 mg PED/day 17 18.0 1.27 (0.78-2.06) 1.15 (0.71-1.87) 
❷Cumulative use >1.0 g PED 358 22.3 1.39 (1.21-1.61) 1.24 (1.07-1.44) 
-Mean daily dose ≤7.5 mg PED/day 248 21.2 1.27 (1.09-1.50) 1.15 (0.98-1.35) 
-Mean daily dose >7.5 mg PED/day 110 25.5 1.77 (1.43-2.20) 1.52 (1.22-1.89)§ 
Past use‡ 375 15.7 Reference Reference 
Non-use  801 12.6 0.90 (0.80-1.02) 0.94 (0.83-1.07) 
CI: confidence interval, IR: incidence rate, OP: Osteoporotic, PED: prednisolone equivalent dose, PYs: person years.  
Statistically significant hazard ratios are shown in bold.  
* 1640 OP fracture events among all included patients. 
† Adjusted at baseline for sex, body mass index, smoking status and alcohol use, and during follow-up for age, a 
history of ankylosing spondylitis, chronic obstructive pulmonary disease, dementia, falls (in the past 7-12 months), 
inflammatory bowel disease, and use in the past 6-months of antidepressants, antihypertensives, proton pump 
inhibitors, paracetamol, non-selective non-steroidal anti-inflammatory drugs, cyclooxygenase-2 selective inhibitors, 
tramadol, opioids stronger than tramadol, conventional synthetic disease-modifying antirheumatic drugs, and 
recent use of oral glucocorticoids.  
‡ Current, recent and past use refer to the last prescription within 6 months, 7-12 months, and >12 months before a 
period, respectively. 
§ Statistically different from low daily GC use (≤7.5 mg PED/day) within the same stratum of cumulative use, Wald 




We found that current low-dose oral GC use (≤7.5 mg PED/day) in patient with RA was not 
associated with an increased risk of OP fractures compared to past GC use. Similar 
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findings were revealed for lower daily doses, i.e., ≤5.0 mg PED/day and ≤2.5 mg PED/day. 
Nevertheless, low-dose oral GC therapy was associated with an increased risk of clinical 
vertebral fracture, while the risk of other individual OP fracture sites was not increased. 
Additionally, the main results remained unchanged regardless of a short-term or a long-
term use. 
There is evidence from RCTs reporting that GC therapy in RA especially in low-doses 
might have local protective effects on bone health, probably by suppressing the 
inflammatory process of the disease.9,10 Apart from the reduced hand bone loss in RA by 
once daily 7.5 mg prednisolone reported by Haugeberg et al.,9 another RCT from the 
Better Anti-Rheumatic FarmacOTherapy (BARFOT) study group showed conservation of 
BMD at the hip, but not in the spine, by taking 7.5 mg prednisolone daily for two years in 
patients with active RA compared to no prednisolone treatment.10 However, there was 
no statistically significant difference in BMD changes at the hip or lumbar spine between 
the treatment groups in the latter study.10 Our findings of no higher risk of non-vertebral 
OP fractures with an average daily dose of ≤7.5 mg/day was to some extent comparable 
to the findings of these RCTs. The only fracture in our study with an observed increased 
risk with low daily GC use was the clinical vertebral (adj. HR 1.59). We know that vertebral 
fracture risk is markedly increased in RA,1,29 and it is well-known that GC therapy in 
particular affects trabecular bone, which is abundantly present in lumbar vertebrae.5 
Therefore, we can hypothesise that the beneficial effect of low-dose GC therapy on 
suppressing the background inflammation of RA could probably be enough to offset its 
negative effect on bone synthesis in most fracture sites but not in vertebrae. 
When comparing our findings to those of RCTs several points need further clarification. 
First, BMD changes associated with GC therapy cannot be directly translated into changes 
in fracture risk. A meta-analysis of observational studies showed that the increase in hip 
and vertebral fractures after GC use is higher than the rate estimated based on BMD 
decrease alone.5 This may be due to GC-induced micro-architectural changes at specific 
active sites in bone, which were not reflected by the lowered BMD.8 Second, the choice 
of past users as the comparator in our study might not fully mimic the placebo group in 
the RCTs,9,10 as past users could have already reduced levels of disease activity, hence an 
improved bone health and a reduced fracture risk. Moreover, as any possible beneficial 
effect of GCs on bone is thought to be through reduction of RA’s background 
inflammation, adjusting for csDMARDs in analyses (which was intended to minimise 
confounding) might have annihilated this beneficial effect through overadjustment.4,28 





the main model (Supplementary Table S5.3). This shows that csDMARD use was not 
perhaps a strong indicator of the disease severity and the background inflammation. 
Conflicting results have been reported from observational studies. Our findings were 
partly in line with those from a recently conducted study that used the same data source, 
but with a different study design and underlying hypothesis.16 Robinson and colleagues 
found no increased OP fracture risk in RA patients taking an average daily dose up to 5.0 
mg PED/day, but increased risks with daily doses ≥5.0 mg PED/day compared to non-
users.16 Our post hoc analysis showed conformity with these findings, as we observed an 
increased risk of OP fractures with a GC dose of 5.1-7.5 mg PED/day, and comparable IRs 
of OP fracture between this daily dose group (23.2 per 1000 PYs) and that of the next 
stratum, i.e., 7.6-14.9 mg PED/ day (23.3 per 1000 PYs). While we both studied cohorts of 
RA patients in CPRD, the age limit of included patients (50+ in our study vs. 18+ in 
Robinson et al.16) and the comparator group (past use vs. non-use) were different. 
Higher fracture rates with low-dose GC therapy (<7.5 mg/day) were also found in two 
other studies that compared current GC users to non-users. These included US patients 
who had a mix of autoimmune diseases including RA and Danish patients from the 
general population.15,30 The choice of non-users as the comparator group without 
adjustment for additional indicators of RA severity in these studies could have possibly 
introduced confounding by indication. This might have led to an overestimation of the 
associations between GC use and OP fractures in these studies and the observed 
discrepancy to our main findings in Table 5.2. The statistically significant association 
between low daily GC use and OP fracture risk only against non-use in our study and not 
against past GC use supports such hypothesis. We observed no increased OP fracture risk 
with cumulative GC use ≤1.0 g PED, even for doses >7.5 mg PED/day. This is in line with the 
results from a paper that used older data from the same data source (1987-1997) and 
reported no increased OP fracture rates in patients with arthropathy with a cumulative 
GC use ≤1.0 g and an average daily dose ≥15.0 mg/day compared to past use.23 This 
suggests that short-term intermittent high-dose GC therapy had no considerable effect 
on fracture risk.  
Our study had several strengths. We used data from CPRD, which is one of the world’s 
largest primary care databases. Validated definitions of RA were used in this study by 
means of a previously verified algorithm.21,22 Moreover, an on-treatment study design was 
utilised, allowing for relatively fair and flexible assessment of changes in onset and offset 
of oral GC exposure, which also helped to avoid time-related biases. Also, by complying 
with the new-user design, we could tackle biases that would arise from inclusion of 
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prevalent users.31 Furthermore, we statistically adjusted for a wide range of potential 
confounders including well-established risk factors of fractures.  
This study had also limitations. Disease-severity indicators of RA, such as the Disease 
Activity Score in 28 joints (DAS28),32 and the use of biological drugs were not available 
from the CPRD. This may have resulted in confounding by disease severity. Patients with a 
more severe RA have higher odds of receiving GCs and are at higher risk of having an OP 
fracture.1,16 Also, the 1.9-year difference in follow-up time between GC users and non-
users could be due to inclusion of more patients with a shorter follow-up and less severe 
RA. However, we incorporated five analgesics and csDMARDs into the Cox model to also 
consider the effect of RA disease severity on the observed association. Another limitation 
was a potential misclassification of exposure with oral GCs, as we had only prescribing 
information from CPRD, which is roughly two steps behind actual drug use by patients.33 
Non-adherence with medication and an “as needed” order for oral GCs might lead to 
overestimation of drug use by patients and underestimation of the association between 
oral GCs and fracture risk in our study. However, an average duration of GC use of 3.7 
years was an indication of actual use. On the other hand, as our primary care data was not 
linked to Hospital Episodes Statistics, covering outpatient and admitted patient care by 
specialist teams at hospitals, we might have missed information on some short episodes 
of GC therapy during hospitalisations. Furthermore, detection bias might explain at least 
part of the finding of an increased risk of clinical vertebral fracture in our study.33 In 
contrast to other fracture types, about two thirds of all vertebral fractures remain 
undetected in clinical practice as asymptomatic fractures, and hence their IRs would be 
underestimated when using large databases.34-36 Patients who have more frequent visits 
to medical doctors, e.g. because of complaints that require prescriptions of oral GCs may 
discuss complaints of back pain more often and may have higher odds to be referred for 
further diagnosis. 
In conclusion, we found an increased risk of clinical vertebral fracture with low-dose GC 
therapy in RA patients compared with past GC use, while the risk of non-vertebral OP 
fractures was not increased. Our results are partly in line with findings from RCTs 
reporting a local beneficial effect of low-dose GC therapy on BMD in various anatomical 
sites. Clinicians should be aware that even in RA patients who receive low daily GC doses, 
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g. Supplementary material 
Table S5.1. Criteria from Thomas et al. algorithm to detect true cases of rheumatoid arthritis in the 
General Practice Research Database, also used in the updated version by Muller et al.21,22 
 
 
Table S5.2. Sensitivity analysis 1, evaluating use of oral glucocorticoids and risk of osteoporotic 
fracture in patients with rheumatoid arthritis, by different definitions of average daily dose. 
Oral Glucocorticoid Use  













Current use‡     
Mean daily dose ≤2.5 mg PED/day 63 16.8 1.09 (0.84-1.42) 1.00 (0.77-1.31) 
Mean daily dose >2.5 mg PED/day 365 22.4 1.42 (1.23-1.64) 1.27 (1.09-1.47) 
     
Mean daily dose ≤5.0 mg PED/day 165 18.5 1.16 (0.97-1.40) 1.07 (0.89-1.29) 
Mean daily dose >5.0 mg PED/day 263 23.6 1.52 (1.30-1.78) 1.34 (1.14-1.57)§ 
Past use‡ 375 15.7 Reference Reference 
Non-use  801 12.6 0.90 (0.80-1.02) 0.94 (0.83-1.07) 
CI: confidence interval, IR: incidence rate, OP: Osteoporotic, PED: prednisolone equivalent dose, PYs: person years.  
Statistically significant hazard ratios are shown in bold.  
* 1640 OP fracture events among all included RA patients. 
† Adjusted at baseline for sex, body mass index, smoking status and alcohol use, and during follow-up for age, a 
history of ankylosing spondylitis, chronic obstructive pulmonary disease, dementia, falls (in the past 7-12 months), 
inflammatory bowel disease, and use in the past 6-months of antidepressants, antihypertensives, proton pump 
inhibitors, paracetamol, non-selective non-steroidal anti-inflammatory drugs, cyclooxygenase -2 selective 
inhibitors, tramadol, opioids stronger than tramadol, conventional synthetic disease-modifying antirheumatic 
drugs, and recent use of oral glucocorticoids. 
‡ Current, recent, and past use refer to the last prescription within 6 months, 7-12 months, and >12 months before a 
period, respectively. 





Criterion 1 At least one diagnostic Read code for RA and at least one appropriate prescription of a 
DMARD with no alternative indication for the DMARD; 
OR 
Criterion 2 all three of the following: 
a) two or more diagnostic Read codes for RA (on different dates). 
b) no alternative diagnosis after the final RA code. 
c) RA code in group 1 (seropositive or erosive RA) or group 2 (‘rheumatoid arthritis’ 
codes e.g., RA of knee), opposed to only group 3 (systemic manifestations of RA) or 
group 4 (seronegative RA or other weak evidence of RA). 
DMARD: disease-modifying antirheumatic drugs, RA: rheumatoid arthritis. 
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Table S5.3. Sensitivity analysis 2, use of oral glucocorticoids and risk of osteoporotic fracture in 
patients with rheumatoid arthritis, by average daily dose, after removing conventional synthetic 
disease-modifying antirheumatic drugs as confounder from the Cox model. 
Oral Glucocorticoid Use  













Current use‡ 428 21.3 1.36 (1.18-1.56) 1.22 (1.06-1.40) 
Mean daily dose ≤7.5 mg PED/day 301 20.3 1.26 (1.08-1.46) 1.14 (0.98-1.33) 
Mean daily dose 7.6-14.9 mg PED/day 101 23.3 1.60 (1.29-2.00) 1.38 (1.11-1.73) 
Mean daily dose ≥15.0 mg PED/day 26 27.9 2.09 (1.40-3.11) 1.83 (1.23-2.74)§ 
Recent use‡ 36 11.1 0.76 (0.54-1.06) 0.71 (0.51-1.00) 
Past use‡ 375 15.7 Reference Reference 
Non-use  801 12.6 0.90 (0.80-1.02) 0.94 (0.83-1.07) 
CI: confidence interval, IR: incidence rate, OP: Osteoporotic, PED: prednisolone equivalent dose, PYs: person years. 
Statistically significant hazard ratios are shown in bold. 
* 1640 OP fracture events among all included patients. 
† Adjusted at baseline for sex, body mass index, smoking status and alcohol use, and during follow-up for age, a 
history of ankylosing spondylitis, chronic obstructive pulmonary disease, dementia, falls (in the past 7-12 months), 
inflammatory bowel disease, and the use in the past 6-months of antidepressants, antihypertensives, proton 
pump inhibitors, paracetamol, non-selective non-steroidal anti-inflammatory drugs, cyclooxygenase-2 selective 
inhibitors, tramadol and opioids stronger than tramadol. 
‡ Current, recent and past use refer to the last prescription within 6 months, 7-12 months, and >12 months before a 
period, respectively. 
§ Statistically different from low daily GC use (≤7.5 mg PED/day), Wald test P <0.05. 
 
 
Table S5.4. Sensitivity analysis 3, use of oral glucocorticoids and risk of osteoporotic fracture in 
patients with rheumatoid arthritis, by average daily dose, only by excluding those patients with a   
prior fracture in 1 year before the index date (N=16,450). 
Oral Glucocorticoid Use  













Current use‡ 491 22.8 1.38 (1.21-1.57) 1.24 (1.09-1.42) 
Mean daily dose ≤7.5 mg PED/day 342 21.6 1.27 (1.10-1.46) 1.16 (1.00-1.33) 
Mean daily dose 7.6-14.9 mg PED/day 122 26.3 1.71 (1.40-2.09) 1.49 (1.21-1.82)§ 
Mean daily dose ≥15.0 mg PED/day 27 27.0 1.90 (1.29-2.80) 1.66 (1.13-2.46) 
Recent use‡ 40 11.4 0.74 (0.53-1.02) 0.70 (0.50-0.96) 
Past use‡ 424 16.5 Reference Reference 
Non-use  928 13.7 0.93 (0.83-1.04) 0.98 (0.87-1.10) 
CI: confidence interval, IR: incidence rate, OP: Osteoporotic, PED: prednisolone equivalent dose, PYs: person years. 
Statistically significant hazard ratios are shown in bold. 
* 1883 OP fracture events among all included patients. 
† Adjusted at baseline for sex, body mass index, smoking status and alcohol use, and during follow-up for age, a 
history of ankylosing spondylitis, chronic obstructive pulmonary disease, dementia, falls (in the past 7-12 months), 
inflammatory bowel disease, and the use in the past 6-months of antidepressants, antihypertensives, proton 
pump inhibitors, paracetamol, non-selective non-steroidal anti-inflammatory drugs, cyclooxygenase-2 selective 
inhibitors, tramadol, opioids stronger than tramadol and conventional synthetic disease-modifying antirheumatic 
drugs. 
‡ Current, recent and past use refer to the last prescription within 6 months, 7-12 months, and >12 months before a 
period, respectively. 
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Patients with rheumatoid arthritis (RA)  commonly use oral glucocorticoids (GCs) and 
proton  pump inhibitors (PPIs), both associated with osteoporotic  fractures. We 
investigated the association between concomitant use of oral GCs and PPIs and the risk 
of osteoporotic fractures among patients with RA. 
 
Methods 
This was a cohort study including patients  with RA aged 50+ years from the Clinical 
Practice  Research Datalink between 1997 and 2017. Exposure  to oral GCs and PPIs was 
stratified by the most recent  prescription as current use (<6 months), recent use  (7–12 
months) and past use (>1 year); average daily and cumulative dose; and duration of use. 
The risk of incident  osteoporotic fractures (including hip, vertebrae, humerus,  forearm, 
pelvis, and ribs) was estimated by time-dependent  Cox proportional-hazards  models, 
statistically adjusted for lifestyle parameters, comorbidities and comedications. 
 
Results 
Among 12,351 patients with RA (mean age of 68 years, 69% women), 1411 osteoporotic 
fractures occurred. Concomitant current use of oral GCs and PPIs was associated with a 
1.6-fold increased risk of osteoporotic fractures compared with non-use (adjusted HR: 
1.60, 95% CI: 1.35 to 1.89). This was statistically different from a 1.2-fold increased 
osteoporotic fracture risk associated with oral GC or PPI use alone. Most individual 
fracture sites were significantly associated with concomitant use of oral GCs and PPIs. 
Among concomitant users, fracture risk did not increase with higher daily dose or 
duration of PPI use. 
 
Conclusions 
There was an interaction in the risk of osteoporotic fractures with concomitant use of 
oral GCs and PPIs. Fracture risk assessment could be considered when a patient with RA is 
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b. Introduction 
Rheumatoid arthritis (RA) is a common chronic musculoskeletal inflammatory disease 
with many complications, including an elevated risk of osteoporotic (OP) fractures.1,2,3 
The contributors to increased fracture risk include the inflammatory process of RA and 
the pharmacologic treatment of the disease, most importantly oral glucocorticoids (GCs). 
About one-quarter of RA patients in the UK are current users of oral GCs.1 Patients with 
RA taking oral GCs have reduced bone mineral density (BMD) at the hip and vertebrae 
and up to a 35% increased 5-year fracture risk.1,4 This higher fracture risk with GCs is 
independent of the disease process and by known mechanisms, such as decreased bone 
formation, elevated bone resorption, and ultimately reduced bone density.5-9  
Apart from GCs, patients with RA frequently use other medications that could also be 
associated with fragility fractures. Non-steroidal anti-inflammatory drugs (NSAIDs) are 
routinely prescribed for patients with RA as analgesics, and proton pump inhibitors (PPIs) 
may be co-prescribed to reduce the gastrointestinal side effects. A randomised, double-
blind, crossover trial showed that fractional 45calcium absorption was significantly 
decreased among elderly women using omeprazole (3.5%) versus placebo (9.1%), possibly 
because of hypochlorhydria.10 Observational studies have reported conflicting results. 
Some reported an increased risk of hip and vertebral fractures with PPI use suggesting a 
causal effect,11-15 whereas others could not match the shape of the hazard function of PPI-
induced fracture risk to calcium absorption hypothesis.16,17 Other mechanisms such as an 
increased fall risk due to hypomagnesemia, or explanations such as unmeasured 
confounding were also proposed to explain this association.16-20  
A population-based study reported a 2.4-fold increased risk of hip fracture among 
concomitant users of both PPIs and high-dose oral GCs (≥15 mg prednisolone equivalent 
dose [PED]).16 But, to our knowledge, no studies have evaluated the effects of 
simultaneous use of both drugs on fracture risk in patients with RA, particularly in elderly 
patients who are regular users of PPIs.21,22 Thus, we sought to investigate the association 
between concomitant use of oral GCs and PPIs and the risk of OP fractures among 









c. Methods  
Data Source 
This was a retrospective cohort study based on the Clinical Practice Research Datalink 
(CPRD) GOLD database (http://www.cprd.com). The CPRD is one of the largest databases 
of primary care data in the world, which contained medical records of 674 practices in the 
UK in 2013, representing 4.4 million active patients, which equalled 6.9% of the total 
population.23 It includes data on patient demographics, clinical diagnoses, prescription 
details, laboratory test results, specialist referrals and major outcomes since 1987, with 
continuing data collection. The CPRD has been well validated for a wide range of 
diseases, including hip and vertebral fractures.24,25 
 
Study Population 
The study cohort included adults aged 50+ years and diagnosed with RA between 1 
January 1997 and 31 December 2017. We used a validated algorithm to identify definite RA 
cases in the CPRD, which can detect 86% of the true RA cases (Supplementary Table 
S6.1).26,27 The date of the first RA diagnosis during valid data collection defined the index 
date. Patients were followed until the occurrence of the outcome, the end of the study 
period, a patient’s transfer out of practice, death, or the end of data collection, 
whichever came first. Following a new-user design, patients with a history of GC/PPI use 
during the 1 year before the index date and those with an OP fracture prior to the index 
date were excluded. 
 
Exposure and Outcome 
Oral GCs and PPIs were the exposures of interest. From the RA index date, follow-up was 
divided into consecutive 30-day periods and exposure status was assessed time-
dependently at the start of each period. A period was defined as current, recent, or past 
use when the most recent prescription of oral GCs/PPIs was issued within 6 months, 7–12 
months and >12 months before a period, respectively.7,11,12,16,28 Follow-up time was defined 
as non-use if no oral GC/PPI had ever been prescribed. Patients were allowed to move 
between exposure states during follow-up. Once a non-user had taken oral GCs/PPIs, he 
could never become a non-user again. 
To evaluate a dose–response relationship and to replicate previous similar studies,11,17,28 
current use of both drugs was further stratified in average daily and cumulative dose, and 
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duration of treatment. All oral GC and PPI prescriptions were retrieved, and the 
prescribed quantity was extracted and converted into PED for GCs and omeprazole 
equivalent dose (OED) for PPIs using the WHO Anatomical Therapeutic Chemical 
classification system.29 Values for missing data on prescribed quantity were assigned the 
median value of all prescriptions. The cumulative amount of the drug prescribed in each 
follow-up period was estimated by summing all consecutive prescriptions since the index 
date. The average daily dose in each follow-up period was calculated by dividing the 
cumulative amount prescribed by the treatment time (i.e., the time between the first oral 
GC/PPI prescription and the start date of a period of current use). Continuous duration of 
PPI use was determined at each period of current use using the prescribed quantity and 
written dosage information, allowing a gap of 30 days after the expected end date of a 
prescription.30 The outcome in this study was a first OP fracture after the RA index date, 




Body mass index (BMI), smoking status and alcohol use were determined at the index 
date. Age and history of comorbidities and comedications were determined time-
dependently. Comorbidities included asthma, chronic obstructive pulmonary disease, 
ischaemic heart disease (including myocardial infarction), cerebrovascular disease, 
congestive heart failure, anaemia, peripheral vascular disease, gastro-oesophageal reflux 
disease, peptic ulcer disease, inflammatory bowel diseases (Crohn’s disease and 
ulcerative colitis), coeliac disease, hyperthyroidism, hypothyroidism, type 1 and 2 diabetes 
mellitus, chronic renal failure, ankylosing spondylitis, dementia, Parkinson’s disease, 
major infections (i.e., sepsis, meningitis, and upper and lower respiratory tract infections) 
and malignant neoplasms (excluding non-melanoma skin cancers).33 Falls were measured 
in the 7–12 months prior to a period. Use of comedications in the 6 months prior included 
antihypertensives, anticoagulants, calcium/vitamin D, bisphosphonates, hormone 
replacement therapy, anticonvulsants, hypnotics/anxiolytics, antidepressants and 
antipsychotics. The following proxy indicators of RA severity were included: use of non-
selective NSAIDs, cyclo-oxygenase-2 selective inhibitors, paracetamol, tramadol, opioids 
(stronger than tramadol) or conventional synthetic disease-modifying antirheumatic 







Time-dependent Cox proportional-hazards models estimated the risk of OP fracture in 
patients with RA with concomitant current use of oral GCs and PPIs versus non-use. Also, 
the use of oral GCs alone and PPIs alone, and the recent and past use of oral GCs and PPIs 
(regardless of the use of the other drug) were compared with non-use. Individual 
exposure categories were statistically compared with a Wald test to detect between-
group significance. Stratified analyses were conducted for various OP fracture sites. 
Potential confounders were incorporated into the model if the beta coefficient of the 
association changed by >5% or based on expert opinion. 
Secondary analyses focused on average daily and cumulative dose of current GC use in 
relation to average daily dose and continuous duration of PPI use. Furthermore, three 
sensitivity analyses were performed. First, calcium/vitamin D and bisphosphonates were 
added to the model as confounders. They were not considered in the main analysis 
because of the accompaniment of their prescriptions with those of oral GCs and as we 
expected them to lie in the causal pathway of the intended association as mediators.34-36 
Second, the main association was re-evaluated by including the prevalent users of GCs 
and PPIs. Finally, the association between PPI use and OP fractures was assessed among 
the primary cohort of patients with RA, by excluding only those with PPI use during the 1 
year before the index date. Data were analysed using SAS V.9.4 (SAS Institute).  
This study was reviewed and approved by the Independent Scientific Advisory Committee 
of the Clinical Practice Research Datalink (reference 19_018R), which is responsible for 
reviewing protocols for scientific quality. 
 
d. Results 
The study population included 12,351 patients with RA (Figure 6.1). The mean age of 
concomitant users of oral GCs and PPIs at the index date was 67.5 years, 1.5 years 
younger than non-users (Table 6.1). The mean duration of follow-up was 9.1 years for 
concomitant users and 5.1 years for non-users. About two-thirds of patients with RA were 
women (concomitant users: 67%; non-users: 70%). More than one-third of concomitant 
users were overweight, whereas 34% of non-users had a normal BMI. In the 6 months 
before the index date, 54% of concomitant users and 48% of non-users had taken non-
selective NSAIDs. The average duration of drug use was 3.3 years for concomitant and 
single GC users, and 4.1 years for single PPI users. 
6 
 
















Figure 6.1. Flowchart on establishment of patient population. 
CPRD: Clinical Practice Research Datalink, GC: glucocorticoid, OP: osteoporotic, PPI: proton pump inhibitor, RA: rheumatoid 
arthritis, TOD: transfer out of database date (i.e., date the patient transferred out of the practice), UTS: Up to standard 
time (i.e., date at which the practice data is deemed to be of research quality). 
 
Table 6.1. Baseline characteristics of study population at index date, stratified by oral GC and PPI therapy 
status during follow-up (N=12,351).  
 Concomitant 
users of oral GCs 
and PPIs* 
(N=4254) 












 N % N % N % N % 
Mean duration of follow-up 
(years, SD) 
9.1 5.0 7.5 4.9 8.4 5.0 5.1 4.3 
Age(years)§         
Mean (SD) 67.5  8.4  68.3 8.8 67.5  8.5  69.0 9.2 
50-59 802  18.9  390 18.3 540  19.1  550 17.5 
60-69 1763  41.4  813 38.1 1190  42.2  1102 35.1 
70-79 1328  31.2  699 32.7 842  29.8  1055 33.6 
80+ 361  8.5  234 11.0 251  8.9  431 13.7 
Number of Females 2837  66.7  1443 67.6 2003  71.0  2190 69.8 
BMI (kg/m2)§         
Mean (SD) 26.4  5.1  26.2 5.0 26.2  5.1  25.9 5.1 
<20.0 304  7.1  146 6.8 200  7.1  222 7.1 
20.0-24.9 1384  32.5  735 34.4 937  33.2  1079 34.4 
25.0-29.9 1482  34.8  698 32.7 981  34.8  965 30.8 
Exclusion due to death before start of study 
or UTS, or death or TOD before or on index 
date 
n= 3907 
• Exclusion based on Thomas algorithm,27 
without a definite RA diagnosis 
• Exclusion due to a history of OP fractures 
or GC and/or PPI use in the 1-year look-back 
period 
n= 17,111 
(n= 7812 were excluded in sensitivity 
analysis 2, for the prevalent user cohort) 
(n= 14,860 were excluded in sensitivity 
analysis 3, for the PPI use-fracture risk 
association) 
Patients aged 50+ with a RA diagnosis 
from CPRD between 1997-2017 
n= 33,369 
 





(For sensitivity analysis 2, n= 21,650 
[see Table S6.4]) 
(For sensitivity analysis 3, n= 14,602 





Table 6.1. (continued)         
30.0-34.9 586  13.8  279 13.1 377  13.4  328 10.5 
≥35.0 234  5.5  109 5.1 142  5.0  151 4.8 
Missing 264  6.2  169 7.9 186  6.6  393 12.5 
Smoking status§         
Non 1560  36.7  805 37.7 1158  41.0  1252 39.9 
Current 988  23.2  522 24.4 571  20.2  646 20.6 
Past 1670  39.3  770 36.0 1058  37.5  1104 35.2 
Missing 36  0.8  39 1.8 36  1.3  136 4.3 
Alcohol use§         
No  1249  29.4  559 26.2 780  27.6  795 25.3 
Yes 2720  63.9  1380 64.6 1819  64.4  1969 62.7 
Missing 285  6.7  197 9.2 224  7.9  374 11.9 
History of comorbidities         
Asthma 573  13.5  277 13.0 170  6.0  207 6.6 
COPD 321  7.5  161 7.5 65  2.3  102 3.3 
Ischaemic heart disease 
(including myocardial 
infarction) 
503  11.8  234 11.0 278  9.8  323 10.3 
Cerebrovascular disease 234  5.5  109 5.1 139  4.9  152 4.8 
Congestive heart failure 98  2.3  70 3.3 61  2.2  115 3.7 
Anaemia 520  12.2  262 12.3 338  12.0  399 12.7 
Peripheral arterial 
disease 
200  4.7  103 4.8 132  4.7  139 4.4 
Gastroesophageal reflux 
disease 
198  4.7  94 4.4 130  4.6  110 3.5 
Peptic ulcer disease 38  0.9  15 0.7 21  0.7  15 0.5 
Coeliac disease 10  0.2  5 0.2 9  0.3  6 0.2 
Inflammatory bowel 
disease 
45  1.1  19 0.9 28  1.0  19 0.6 
Hyperthyroidism 24  0.6  13 0.6 16  0.6  15 0.5 
Hypothyroidism 289  6.8  149 7.0 206  7.3  213 6.8 
Diabetes mellitus type 1 25  0.6  17 0.8 17  0.6  15 0.5 
Diabetes mellitus type 2 230  5.4  101 4.7 164  5.8  172 5.5 
Chronic renal failure 144  3.4  68 3.2 81  2.9  110 3.5 
Ankylosing spondylitis 6  0.1  <5 <0.3 5  0.2  7 0.2 
Dementia 17  0.4  11 0.5 19  0.7  28 0.9 
Parkinson’s disease 10  0.2  4 0.2 9  0.3  20 0.6 
Malignant neoplasms 
(excl. non-melanoma skin 
cancers) 
371  8.7  173 8.1 248  8.8  244 7.8 
Major infections¶ 812  19.1  397 18.6 468  16.6  452 14.4 
Falls (7-12 months 
before) 
38  0.9  10 0.5 16  0.6  21 0.7 
Comedications use (6 
months before) 
        
Antihypertensives 1383  32.5  718 33.6 905  32.1  1117 35.6 
Anticoagulants 118  2.8  70 3.3 45  1.6  104 3.3 
Calcium/vitamin D 290 6.8 105 4.9 133 4.7 190 6.1 
Bisphosphonates 260 6.1 87 4.1 108 3.8 119 3.8 
Hormone replacement 
therapy  
184  4.3  65 3.0 107  3.8  81 2.6 
Anticonvulsants 51  1.2  29 1.4 37  1.3  46 1.5 
Hypnotics/ Anxiolytics 356  8.4  168 7.9 184  6.5  189 6.0 
Antidepressants 498  11.7  237 11.1 275  9.7  290 9.2 
6 
 
 Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures 
 113 
Table 6.1. (continued)         
Antipsychotics 36  0.8  19 0.9 17  0.6  40 1.3 
Disease severity indicators         
Non-selective NSAIDs 2309  54.3  1202 56.3 1514  53.6  1518 48.4 
COX-2 selective 
inhibitors 
409  9.6  205 9.6 255  9.0  191 6.1 
Paracetamol 2117  49.8  987 46.2 1147  40.6  1328 42.3 
Tramadol 263  6.2  113 5.3 148  5.2  138 4.4 
Opioids (stronger than 
tramadol) 
241  5.7  105 4.9 114  4.0  118 3.8 
csDMARDs 1323  31.1  637 29.8 915  32.4  1091 34.8 
BMI: body mass index, COPD: chronic obstructive pulmonary disease, COX-2: cyclooxygenase-2, csDMARDs: conventional 
synthetic disease-modifying antirheumatic drugs, GC: glucocorticoid, NSAIDs: non-steroidal anti-inflammatory drugs, PPI: 
proton pump inhibitor, SD: standard deviation. 
* Concomitant users of oral GCs and PPIs are patients who had at least one co-prescription of an oral GC and PPI during 
follow-up. 
† Users of oral GCs alone are patients who had at least one prescription of an oral GC during follow-up without having 
prescribed PPI and excluding concomitant users. 
‡ Users of PPIs alone are patients who had at least one prescription of a PPI during follow-up without having prescribed 
oral GCs and excluding concomitant users and users of oral GCs alone. 
§ At the index date. 
¶ Major infections included sepsis, meningitis, and upper and lower respiratory tract infections. 
 
 
Concomitant current use of oral GCs and PPIs in patients with RA was associated with a 
1.6-fold increased risk of OP fractures compared with non-use of both drugs (adjusted HR 
(adj. HR): 1.60, 95% CI: 1.35 to 1.89; Table 6.2). Both oral GC and PPI use alone had a 1.2-fold 
increased risk of OP fracture (adj. HR: 1.23, 95% CI: 1.03 to 1.47 (oral GC use alone); adj. HR: 
1.22, 95% CI: 1.05 to 1.42 (PPI use alone)). The OP fracture risk associated with the current 
use of oral GCs or PPIs alone was statistically different from concomitant use. There was 
no significant increase in OP fracture risk in those patients who had stopped taking oral 
GCs or PPIs for more than 6 months (recent and past users) versus non-use. Considering 
calcium/vitamin D and bisphosphonates as confounders reduced the association to a 1.4-
fold increased fracture risk for concomitant users and to a statistically non-significant risk 
for oral GC use alone versus non-use (Supplementary Table S6.3). 
Table 6.3 shows that among patients with RA, most OP fracture sites were statistically 
significantly associated with concomitant current use of oral GCs and PPIs versus non-use. 
With concomitant current use of oral GCs and PPIs, we observed a 1.5-fold increased risk 
of hip fracture, a 2.8-fold increased risk of clinical vertebral fracture, a 2.5-fold increased 
risk of pelvic fracture and a 4-fold increased risk of rib fracture. Risks of fracture of the 





Table 6.4 shows the stratification of concomitant oral GC and PPI use by average daily 
doses of GCs and then substratification by average daily doses and continuous duration 
of PPI use. There was no increased fracture risk with increasing PPI daily doses. Under all 
strata of GC use, short-term PPI use (≤1 year) was associated with higher fracture risk, but 
there was no association between long-term PPI use (>1 year) and OP fractures. When 
concomitant use of GCs and PPIs was stratified by cumulative GC use and then 
substratified by PPI use, similar associations were observed (Supplementary Table S6.2). 
The second sensitivity analysis including prevalent users of GCs and PPIs (N=21,650) 
resulted in similar estimates to the main analyses (Supplementary Table S6.4). In the third 
sensitivity analysis (N=14,602), current PPI use was associated with a 1.3-fold increased 
risk of OP fractures (adj. HR: 1.30, 95% CI: 1.15 to 1.47) versus non-use (Supplementary 
Table S6.5). 
 
Table 6.2. OP fracture risk by concomitant use of oral GCs and PPIs in patients with rheumatoid 
arthritis.  











Non-use of GCs and PPIs 325 10.5 Reference Reference 
Current use‡     
GCs and PPIs concomitantly 264 24.4 1.93 (1.65-2.27) 1.60 (1.35-1.89) 
GCs alone 178 15.5 1.34 (1.12-1.59) 1.23 (1.03-1.47)§ 
PPIs alone 324 16.7 1.32 (1.14-1.54) 1.22 (1.05-1.42)§ 
Recent GC use‡ ¶ 34 11.0 0.87 (0.62-1.23) 0.82 (0.58-1.16) 
Recent PPI use‡ ¶ 49 16.0 1.21 (0.90-1.62) 1.17 (0.87-1.57) 
Past GC use‡ ¶ 339 15.6 1.16 (1.01-1.33) 1.13 (0.98-1.29) 
Past PPI use‡ ¶ 219 13.5 0.96 (0.82-1.13) 0.94 (0.80-1.10) 
CI: confidence interval, GCs: glucocorticoids, IR: incidence rate, OP: osteoporotic, PPIs: proton pump inhibitors, PYs: 
person years. Statistically significant hazard ratios are shown in bold. 
* 1411 OP fracture events among all included patients with RA. The number of events in exposure groups do not 
sum to this total due to the overlap between recent and past use of GCs and PPIs. 
† Adjusted at baseline for sex, body mass index, smoking status, and alcohol use; during follow-up for age, a 
history of ankylosing spondylitis, chronic obstructive pulmonary disease, dementia, falls (in the past 7–12 months) 
and inflammatory bowel disease; and use in the past 6 months of antidepressants, paracetamol, non-selective 
non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2 selective inhibitors, tramadol, opioids, and conventional 
synthetic disease-modifying antirheumatic drugs. 
‡ Current, recent and past use refer to the last prescription within 6 months, 7–12 months and >12 months before a 
period, respectively. 
§ Statistically different from concomitant GC and PPI use, Wald test P <0.05. 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Non-use of GCs and PPIs 0.6 Reference  0.6 Reference 
Current use††        
GCs and PPIs concomitantly 2.9 2.47 (1.41-4.34)  1.7 4.03 (2.13-7.63) 
GCs alone 0.9 1.07 (0.54-2.14)‡‡  1.2 2.28 (1.17-4.46) 
PPIs alone 1.6 1.93 (1.11-3.34)  0.8 1.24 (0.66-2.34)‡‡ 
Recent GC use†† §§ 1.2 0.97 (0.35-2.72)  0.6 1.21 (0.29-5.14) 
Recent PPI use†† §§ 0.9 1.16 (0.35-3.87)  1.5 2.17 (0.83-5.62) 
Past GC use†† §§ 0.8 0.64 (0.37-1.11)  1.2 2.43 (1.39-4.22) 
Past PPI use†† §§ 0.9 1.17 (0.62-2.20)  0.6 0.86 (0.43-1.75) 
¶ Adjusted at baseline for sex, during follow-up for age and use in the past 6 months of AD, paracetamol and OPI. 
** Adjusted at baseline for sex and during follow-up for age. 
†† Current, recent and past use refer to the last prescription within 6 months, 7–12 months and >12 months before a 
period, respectively. 
‡‡ Statistically different from concomitant GC and PPI use within the same fracture type, Wald test P <0.05. 




Concomitant use of oral GCs and PPIs was associated with an increased risk of OP 
fractures compared with non-use in patients with RA. This was significantly higher when 
compared with the single use of oral GCs or PPIs. Increased fracture risk associated with 
concomitant GC and PPI use was observed for fractures of the hip, clinical vertebrae, 
pelvis and ribs, but not for those of the humerus or forearm. Among concomitant users, 
there was no increased OP fracture risk with higher daily dose or longer duration of PPI 
use. 
This is the first study, to our knowledge, that looked into the association between 
concomitant use of GCs and PPIs and the risk of OP fracture in patients with RA. A Dutch 
population-based study found a 1.3-fold to 2.4-fold increased risk of hip/femur fracture 
with concomitant use of PPIs and various daily doses of oral GCs.16 This is in line with our 
finding for the concomitant current use of GCs and PPIs (adj. HR: 1.60) and most of the 
strata of concomitant use in Table 6.4. However, their reference group was different and 
limited to never PPI users. Moreover, they focused on 18+ general population, whereas 
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Table 6.4. OP fracture risk by average daily dose of oral GC use in rheumatoid arthritis patients, 
stratified by average daily dose and continuous duration of PPI use.  












Non-use of GCs and PPIs 325 10.5 Reference Reference 
Current use of GCs and PPIs concomitantly‡ 264 24.4 1.93 (1.65-2.27) 1.60 (1.35-1.89) 
❶Low GC use (DD ≤7.5 mg PED/day) 
+ Low-dose PPI use (DD <20 mg OED/day) 142 23.2 1.75 (1.44-2.13) 1.42 (1.16-1.74) 
+ Medium-dose PPI use (DD 20–35 mg 
OED/day) 
39 24.9 1.93 (1.39-2.69) 1.54 (1.10-2.16) 
+ High-dose PPI use (DD >35 mg OED/day) 8 34.2 2.72 (1.35-5.47) 2.10 (1.04-4.24) 
+ Short-term continuous PPI use (≤1 year) 89 25.7 2.00 (1.59-2.52) 1.60 (1.26-2.04) 
+ Long-term continuous PPI use (>1 year) 71 20.3 1.49 (1.15-1.93) 1.18 (0.91-1.53) 
+ No continuous duration of PPI§ 29 30.4 2.36 (1.62-3.45) 2.00 (1.36-2.93)¶ 
❷Medium GC use (DD 7.6–14.9 mg PED/day)     
+ Low-dose PPI use (DD <20 mg OED/day) 43 25.0 2.22 (1.62-3.04) 1.76 (1.27-2.43) 
+ Medium-dose PPI use (DD 20–35 mg 
OED/day) 19 27.7 2.41 (1.52-3.82) 1.92 (1.20-3.05) 
+ High-dose PPI use (DD >35 mg OED/day) <5 17.2 1.46 (0.36-5.86) 1.26 (0.31-5.07) 
+ Short-term continuous PPI use (≤1 year) 36 30.2 2.70 (1.92-3.80) 2.20 (1.55-3.11) 
+ Long-term continuous PPI use (>1 year) 23 20.9 1.78 (1.17-2.72) 1.37 (0.89-2.10) 
+ No continuous duration of PPI§ 5 22.3 2.00 (0.83-4.84) 1.67 (0.69-4.03) 
❸High GC use (DD ≥15.0 mg PED/day)     
+ Low-dose PPI use (DD <20 mg OED/day) 5 21.1 1.92 (0.79-4.64) 1.58 (0.65-3.81) 
+ Medium-dose PPI use (DD 20–35 mg 
OED/day) 
<5 38.8 3.77 (1.41-10.09) 3.05 (1.13-8.18) 
+ High-dose PPI use (DD >35 mg OED/day) <5 41.1 3.83 (0.95-15.37) 3.30 (0.82-13.26) 
+ Short-term continuous PPI use (≤1 year) 9 34.1 3.21 (1.66-6.21) 2.72 (1.40-5.27) 
+ Long-term continuous PPI use (>1 year) <5 11.3 0.99 (0.14-7.08) 0.72 (0.10-5.15) 
+ No continuous duration of PPI§ <5 27.1 2.65 (0.37-18.90) 2.38 (0.33-16.97) 
CI: confidence interval, DD: average daily dose, GCs: glucocorticoids, IR: incidence rate, OED: omeprazole equivalent dose, OP: 
osteoporotic, PED: prednisolone equivalent dose, PPIs: proton pump inhibitors, PYs: person years. Statistically significant 
hazard ratios are shown in bold.  
* 1411 OP fracture events among all included patients with RA. The number of fractures in exposure groups do not sum to 
this total due to not reporting the current only use and recent and past use of GCs and PPIs. 
† Adjusted at baseline for sex, body mass index, smoking status, and alcohol use; during follow-up for age, a history of 
anaemia, ankylosing spondylitis, chronic obstructive pulmonary disease, dementia, falls (in the past 7–12 months) and 
inflammatory bowel disease; use in the past 6 months of antidepressants, paracetamol, non-selective non-steroidal 
anti-inflammatory drugs, cyclo-oxygenase-2 selective inhibitors, tramadol, opioids and conventional synthetic disease-
modifying antirheumatic drugs; and current only use and recent and past use of oral GCs and PPIs. 
‡ Concomitant current use refers to the most recent prescription of both oral GCs and PPIs in the 6 months before the 
start of a period. 
§ This represents fracture events that happened during a current period of PPI use but not eligible for a continuous 
duration of use calculation (i.e., up to 6 months after the last PPI prescription, but after 1-month threshold gap of our 
definition for the continuous duration of PPI use). 
¶ Statistically different from long-term continuous PPI use within the same category, Wald test P <0.05. 
 
Our results regarding the higher fracture risk with PPI use are partly in line with several 
previous observational studies.11,12,15-17 A meta-analysis of observational studies in non-RA 
patients reported increased risk of hip and spine fracture with PPI use (relative risks of 





and OP fractures in our study. However, a recent study in patients with RA did not reveal 
a higher risk of OP fractures with PPI use, which was attributed to higher use of 
bisphosphonates among PPI users.22 Previous studies found stronger associations with 
higher daily doses of PPIs,11 or with 7 years of PPI use and fracture risk,12 whereas another 
older study that used the same data source but a different reference group did not report 
any dose–response or duration–response relationships at all.17 Our findings (i.e., no 
specific trend with longer duration or higher daily doses of PPI use) are comparable to 
the latter study.  
Our findings in the single GC use group were generally consistent with the literature. 
Previous observational studies have reported increased OP fracture risks in patients with 
RA with current GC use between 43% and 70%, higher than the 23% increased risk that we 
found.1,31 We used a different reference group (non-users of both GCs and PPIs), which 
may also explain the unexpected lack of statistical significance for a higher risk of clinical 
vertebral fracture with current GC use alone.  
The magnitude of the association between concomitant GC and PPI use and the risk of OP 
fracture may indicate an additive effect of the individual drugs rather than a synergistic 
effect. This was suggested by a significantly higher fracture risk with concomitant GC and 
PPI use compared with monotherapy with either drug and as the observed HRs seem to 
be additive. This may be related to different biological mechanisms of GCs and PPIs acting 
on osteoporosis or falling. The effect of GCs on bone is mostly via decreased bone 
formation and interference with active bone remodelling sites.1,6,8,9 But additionally, GCs 
might increase the fracture risk by inducing muscle atrophy or cataract especially with 
higher doses and in long-term use.37-39 Previous studies have shown that the onset and 
offset of the effects of GCs on fracture risk are rather rapid, which is supported by our 
results.7,31,40 Similar to GCs, the positive association of fracture risk with PPI use quickly 
subsided when the patient discontinued the treatment (after 6 months). But for PPIs, 
underlying pharmacological effects on fracture are not well understood.41,42 The US Food 
and Drug Administration published a drug safety communication for a possible increased 
fracture risk with PPI use in 2011, which remained unchanged to date and was based on 
evidence from observational studies.43 This was later criticised for not being supported by 
a clear biological mechanism.44 
Various pharmacological mechanisms have been proposed to explain the PPI use and 
fracture risk association. Reduced intestinal absorption of calcium was previously 
suggested due to induced hypochlorhydria by PPI therapy and the effect on bone 
quality.10 However, a more recent trial found no BMD changes after 52 weeks and non-
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significant changes in bone turnover markers after 26 weeks with dexlansoprazole or 
esomeprazole use.45 An alternative mechanism is an increased falling risk due to muscle 
weakness and drowsiness, caused by malabsorption of magnesium or vitamin B12.18-20,46,47 
Long-term PPI therapy (≥1 year) in elderly women was shown to significantly reduce 
serum vitamin B12 levels and double the 5-year risk of injurious falling-related and 
fracture-related hospitalisation.46 But the design of this study did not consider proper 
timing of the exposure and outcome, which limits its interpretation. A third mechanism is 
effects on osteoclasts to increase bone resorption by PPIs.48 Finally, methodological 
explanations for the observed associations include selection bias and/or unknown 
confounding.16,17,44 Significant association only with short-term PPI use and no specific 
trend with increasing daily doses do not fit into any of the proposed mechanisms 
mentioned above. As we used different strategies in design and analysis to avoid 
potential sources of bias and to adjust for confounding, and when the GC findings are 
supported by previous literature with well-known biological mechanisms, the mere 
explanation of the PPI results by unmeasured confounding would be difficult. Hence, 
more research is recommended to elaborate on the exact biological mechanism of PPIs 
on bone. 
This study had several strengths. We used data from the CPRD, which is one of the 
world’s largest primary care databases. Our study had a substantial mean duration of 
follow-up (9.1 years for concomitant users). To bring more insight into the observed 
association, we stratified GC and PPI use by recency of use, average daily and cumulative 
dose, and duration of treatment. Furthermore, all analyses were performed time-
dependently, incorporating all follow-up times, to avoid time-related biases. There were 
also several limitations. Biological therapies, especially during hospitalisation, and some 
RA severity indices (e.g., the disease activity score in 28 joints [DAS-28]) were not 
adequately captured in the CPRD as a general practice database, which might have 
introduced confounding by indication or disease severity. Patients with higher disease 
activity may have an elevated risk of fracture and be more prone to receive oral GCs/PPIs. 
Also, an improved clinical status might have led to both discontinuation of drug(s) and 
lower fracture rates. To partly overcome this, we statistically adjusted our analyses for six 
indicators of RA severity, including analgesics and csDMARDs. We cannot confirm the 
actual use of medications as we only had prescribing information, and GCs and PPIs are 
often prescribed on an “as needed” basis. The over-the-counter use of PPIs was also not 
captured. However, with an average duration of use of >3 years, repeated prescriptions 





underestimated, as some of them might not immediately come into clinical attention.49,50 
This might virtually increase the HRs for vertebral fractures due to detection bias.35  
In conclusion, there was an interaction in the risk of OP fracture with concomitant use of 
oral GCs and PPIs. This increased risk seems to emerge from separate mechanisms of 
action of GCs and PPIs on bone or falling risk. Considering the increasing life expectancies 
and high consumption of PPIs among elderly patients, fracture risk assessment could be 
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g. Supplementary material 
Table S6.1. Criteria from Thomas et al. algorithm to detect true cases of rheumatoid arthritis in the 
General Practice Research Database, also used in the updated version by Muller et al.26,27 
 
 
Table S6.2. OP fracture risk by cumulative use of oral GCs in rheumatoid arthritis patients, stratified by 
average daily dose and duration of use of PPIs.  












Non-use of GCs and PPIs 325 10.5 Reference Reference 
Current use of GCs and PPIs concomitantly‡ 264 24.4 1.93 (1.65-2.27) 1.60 (1.35-1.89) 
❶Low GC use (CD ≤1.0 g PED) 
+ Low-dose PPI use (DD <20 mg OED/day) 21 25.4 2.10 (1.36-3.27) 1.79 (1.15-2.79) 
+ Medium-dose PPI use (DD 20–35 mg 
OED/day) <5 15.3 1.33 (0.50-3.56) 1.10 (0.41-2.96) 
+ High-dose PPI use (DD >35 mg OED/day) <5 22.7 1.86 (0.46-7.46) 1.61 (0.40-6.47) 
+ Short-term continuous PPI use (≤1 year) 18 26.4 2.22 (1.38-3.56) 1.89 (1.17-3.03) 
+ Long-term continuous PPI use (>1 year) <5 7.7 0.62 (0.15-2.47) 0.50 (0.12-2.01) 
+ No continuous duration of PPI§ 7 29.9 2.54 (1.20-5.37) 2.25 (1.06-4.75) 
❷Medium GC use (CD 1.1-4.9 g PED)     
+ Low-dose PPI use (DD <20 mg OED/day) 61 29.5 2.34 (1.79-3.07) 1.95 (1.48-2.57) 
+ Medium-dose PPI use (DD 20–35 mg 
OED/day) 
19 27.0 2.22 (1.40-3.52) 1.82 (1.15-2.90) 
+ High-dose PPI use (DD >35 mg OED/day) <5 28.5 2.32 (0.87-6.22) 1.85 (0.69-4.97) 
+ Short-term continuous PPI use (≤1 year) 50 30.8 2.53 (1.89-3.40) 2.11 (1.57-2.84) 
+ Long-term continuous PPI use (>1 year) 21 23.2 1.75 (1.12-2.71) 1.41 (0.91-2.20) 
+ No continuous duration of PPI§ 13 34.1 2.78 (1.60-4.84) 2.40 (1.38-4.17) 
❸High GC use (CD ≥5.0 g PED)     
+ Low-dose PPI use (DD <20 mg OED/day) 108 20.8 1.61 (1.30-2.00) 1.26 (1.01-1.58) 
+ Medium-dose PPI use (DD 20–35 mg 
OED/day) 39 28.0 2.22 (1.59-3.09) 1.72 (1.23-2.41) 
+ High-dose PPI use (DD >35 mg OED/day) 6 35.1 2.94 (1.31-6.59) 2.28 (1.01-5.12) 
+ Short-term continuous PPI use (≤1 year) 66 25.3 2.01 (1.54-2.62) 1.56 (1.19-2.05) 
+ Long-term continuous PPI use (>1 year) 72 20.4 1.55 (1.20-2.01) 1.20 (0.92-1.56) 
+ No continuous duration of PPI§ 15 25.0 1.93 (1.15-3.24) 1.59 (0.95-2.67) 
Criterion 1 At least one diagnostic Read code for RA and at least one appropriate prescription of a 
DMARD with no alternative indication for the DMARD; 
OR 
Criterion 2 all three of the following: 
a) two or more diagnostic Read codes for RA (on different dates). 
b) no alternative diagnosis after the final RA code. 
c) RA code in group 1 (seropositive or erosive RA) or group 2 (‘rheumatoid arthritis’ 
codes e.g., RA of knee), opposed to only group 3 (systemic manifestations of RA) or 
group 4 (seronegative RA or other weak evidence of RA). 
DMARD: disease-modifying antirheumatic drugs, RA: rheumatoid arthritis. 
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Table S6.2. (Continued) 
CI: confidence interval, CD: cumulative dose, DD: average daily dose, GCs: glucocorticoids, IR: incidence rate, OED: omeprazole 
equivalent dose, OP: osteoporotic, PED: prednisolone equivalent dose, PPIs: proton pump inhibitors, PYs: person years. 
Statistically significant hazard ratios are shown in bold. None of the Wald tests comparing exposure states within the 
same category were statistically significant. 
* 1411 OP fracture events among all included RA patients. The number of fractures in exposure groups do not sum to this 
total due to not reporting the current only use and recent and past use of GCs and PPIs. 
† Adjusted at baseline for sex, body mass index, smoking status and alcohol use, and during follow-up for age, a history of 
anaemia, ankylosing spondylitis, chronic obstructive pulmonary disease, dementia, falls (in the past 7-12 months), 
inflammatory bowel disease, and the use in the past 6-months of antidepressants, paracetamol, non-selective non-
steroidal anti-inflammatory drugs, cyclooxygenase-2 selective inhibitors, tramadol, opioids, conventional synthetic 
disease modifying antirheumatic drugs, and current only use and recent and past use of oral glucocorticoids and proton 
pump inhibitors. 
‡ Concomitant current use refers to the most recent prescription of both oral GCs and PPIs within the 6 months before 
the start of a period. 
§ This represents fracture events that happened during a current period of PPI use but not eligible for a continuous 
duration of use calculation (i.e., up to 6 months after the last PPI prescription, but after 1-month threshold gap of our 
definition for the continuous duration of PPI use). 
 
 
Table S6.3. Sensitivity analysis 1, the association between concomitant use of oral GCs and PPIs and OP 
fracture risk after adding calcium/vitamin D and bisphosphonates as confounders to the Cox model.  











Non-use of GCs and PPIs 325 10.5 Reference Reference 
Current use‡     
GCs and PPIs concomitantly 264 24.4 1.93 (1.65-2.27) 1.39 (1.16-1.66) 
GCs alone 178 15.5 1.34 (1.12-1.59) 1.11 (0.92-1.33)§ 
PPIs alone 324 16.7 1.32 (1.14-1.54) 1.20 (1.03-1.40)§ 
Recent GC use‡ ¶ 34 11.0 0.87 (0.62-1.23) 0.79 (0.56-1.12) 
Recent PPI use‡ ¶ 49 16.0 1.21 (0.90-1.62) 1.16 (0.86-1.56) 
Past GC use‡ ¶ 339 15.6 1.16 (1.01-1.33) 1.10 (0.96-1.27) 
Past PPI use‡ ¶ 219 13.5 0.96 (0.82-1.13) 0.93 (0.79-1.10) 
CI: confidence interval, GCs: glucocorticoids, IR: incidence rate, OP: osteoporotic, PPIs: proton pump inhibitors, PYs: 
person years. Statistically significant hazard ratios are shown in bold. 
* 1411 OP fracture events among all included patients with RA. The number of events in exposure groups do not 
sum to this total due to the overlap between recent and past use of GCs and PPIs. 
† Adjusted at baseline for sex, body mass index, smoking status, and alcohol use, and during follow-up for age, a 
history of ankylosing spondylitis, chronic obstructive pulmonary disease, dementia, falls (in the past 7-12 months), 
inflammatory bowel disease, and the use in the past 6-months of calcium/vitamin D supplements, 
bisphosphonates, antidepressants, paracetamol, non-selective non-steroidal anti-inflammatory drugs, 
cyclooxygenase-2 selective inhibitors, tramadol, opioids, conventional synthetic disease modifying antirheumatic 
drugs. 
‡ Current, recent and past use refer to the last prescription within 6 months, 7–12 months and >12 months before a 
period, respectively. 
§ Statistically different from concomitant GC and PPI use, Wald test P <0.05. 







Table S6.4. Sensitivity analysis 2, evaluating a prevalent user cohort instead of a new-user cohort 
(Table 6.2). OP fracture risk by concomitant use of oral GCs and PPIs in patients with rheumatoid 
arthritis (N=21,650).  











Non-use of GCs and PPIs 325 10.5 Reference Reference 
Current use‡     
GCs and PPIs concomitantly 613 25.0 2.00 (1.76-2.26) 1.63 (1.43-1.85) 
GCs alone 363 16.8 1.33 (1.17-1.52) 1.21 (1.06-1.38)§ 
PPIs alone 622 16.5 1.34 (1.19-1.51) 1.21 (1.07-1.37)§ 
Recent GC use‡ ¶ 66 11.7 0.85 (0.66-1.10) 0.81 (0.63-1.05) 
Recent PPI use‡ ¶ 93 17.3 1.30 (1.04-1.62) 1.24 (1.00-1.55) 
Past GC use‡ ¶ 541 15.3 1.07 (0.96-1.20) 1.05 (0.94-1.17) 
Past PPI use‡ ¶ 376 14.4 1.04 (0.91-1.18) 1.00 (0.88-1.14) 
CI: confidence interval, GCs: glucocorticoids, IR: incidence rate, OP: osteoporotic, PPIs: proton pump inhibitors, PYs: 
person years. Statistically significant hazard ratios are shown in bold. 
* 2384 OP fracture events among all included RA patients. The number of events in exposure groups do not sum to 
this total due to overlap between recent and past use of GCs and PPIs.  
† Adjusted at baseline for sex, body mass index, smoking status, and alcohol use, and during follow-up for age, a 
history of ankylosing spondylitis, chronic obstructive pulmonary disease, dementia, falls (in the past 7-12 months), 
inflammatory bowel disease, and the use in the past 6-months of antidepressants, paracetamol, non-selective non-
steroidal anti-inflammatory drugs, cyclooxygenase-2 selective inhibitors, tramadol, opioids, conventional synthetic 
disease modifying antirheumatic drugs. 
‡ Current, recent and past use refer to the last prescription within 6 months, 7–12 months and >12 months before a 
period, respectively. 
§ Statistically different from concomitant GC and PPI use, Wald test P <0.05. 
¶ Regardless of the use of the other drug. 
 
 
Table S6.5. Sensitivity analysis 3, OP fracture risk by use of PPIs in patients with rheumatoid arthritis 
(N=14,602). 











Non-use of PPIs 680 11.9 Reference Reference 
Current PPI use‡ 626 19.8 1.52 (1.35-1.70) 1.30 (1.15-1.47) 
Recent PPI use‡ 58 17.0 1.31 (1.00-1.72) 1.23 (0.94-1.61) 
Past PPI use‡ 265 14.1 1.04 (0.90-1.21) 1.00 (0.86-1.16) 
CI: confidence interval, IR: incidence rate, OP: osteoporotic, PPIs: proton pump inhibitors, PYs: person years. 
Statistically significant hazard ratios are shown in bold. 
* 1629 osteoporotic fracture events among all included RA patients. 
† Adjusted at baseline for sex, body mass index, smoking status and alcohol use, and during follow-up for age, a 
history of ankylosing spondylitis, chronic obstructive pulmonary disease, dementia, falls (in the past 7-12 months), 
inflammatory bowel disease, and the use in the past 6-months of oral glucocorticoids, antidepressants, 
paracetamol, non-selective non-steroidal anti-inflammatory drugs, cyclooxygenase-2 selective inhibitors, tramadol, 
opioids, conventional synthetic disease modifying antirheumatic drugs. 
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In this final chapter, first a summary of the main findings of each study will be provided, in 
the light of the existing knowledge gaps and the objective and sub-objectives of this 
thesis. The overall objective of this thesis was to study the osteoporotic (OP) fractures 
and their relation to mortality, medication use and rheumatoid arthritis (RA). The first 
sub-objective aimed to investigate various attributes of OP fractures in the general 
population, including a recent secular trend, the mortality after fracture in association 
with oral bisphosphonate (BP) use, and the association between various exposure 
patterns of oral glucocorticoids (GCs) and OP fracture risk. The second sub-objective was 
to evaluate the role of medications, including low-dose oral GCs, concomitant use of oral 
GCs and proton pump inhibitors (PPIs), and biological disease-modifying antirheumatic 
drugs (bDMARDs), in the risk of OP fractures among patients with RA. Following the 
summary, findings will be compared to those of the key published studies addressing the 
same research area/ topic. Then, a methodological evaluation of the studies in this thesis 
will be provided by introducing the major limitations of pharmacoepidemiological 
research, their examples in our studies, and the strategies that we adopted to avoid 
them. Finally, the clinical impact of our findings and some potential future ideas for 
research will be presented. 
 
a. Main findings 
The aim of Section 1 was to evaluate various attributes of OP fractures in the general 
population. This included an investigation of recent secular trends in incidence rates (IRs) 
of OP fractures in the general population of Denmark in Chapter 2. In a series of 
contiguous cross-sectional analyses, we found a general decline in IRs of major OP 
fractures (MOF) for 50+ adults in Denmark between 1995 and 2010. The overall IR 
dropped from 169.8 per 10,000 person years (PYs) in 1995 to 148.0 per 10,000 PYs in 2010. 
The remarkable finding was the declining hip fracture rate among both men (from 36.5 in 
1995 to 29.6 in 2010 per 10,000 PYs) and women (from 87.2 to 59.9 per 10,000 PYs). All 
other fracture sites (i.e., clinical vertebral, humerus, and forearm) were also declining in 
women. But in contrast, and with the exception of a gradual decrease in forearm 
fractures, increasing rates for clinical vertebral and steady rates for humerus fracture 
were observed in men. Another study using Danish data showed that the overall IR of hip 
and MOF in Denmark in 2011 was 43.8 and 142.0 per 10,000 PYs, respectively.1 This 
obviously shows a continuous decreasing trend in hip and MOFs in Denmark from 1995 
until 2011. Our findings were also in line with other studies from Denmark (from 1997 to 
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2006),2 Canada (from 1985 to 2005),3 US (from 1986 to 2005),4 Minnesota, US (between 
1989–1991 and 2009–2011),5 and Manitoba, Canada (from 1986 to 2006),6 respecting a 
generally declining trend in hip fracture rates in both sexes and an increasing trend in 
vertebral fractures especially among men. 
The association between oral BP use and mortality risk following a MOF was evaluated in 
Chapter 3. Based on the evidence from the Health Outcomes and Reduced Incidence with 
Zoledronic Acid Once Yearly (HORIZON) trial reporting a 28% mortality reduction with 
zoledronic acid use after hip fracture,7 and some reported anti-atherosclerotic effects of 
BPs,8,9 we hypothesised a reduced mortality rate with oral BP use after MOF in our study. 
To investigate this, we included all patients with a MOF in the UK Clinical Practice 
Research Datalink (CPRD) between 2000 and 2018. We observed a 7% increased risk of all-
cause mortality after non-hip MOF, and a 28% reduced risk after hip fracture with current 
oral BP use versus never use. With the total follow-up time of BP use being 7.6 years in 
the non-hip MOF and 5.7 years in hip fracture group, censoring the follow-up time at 1- 
and 5-years shifted the association towards a stronger protective effect of BPs on 
mortality risk. In other words, the shorter the follow-up time, the greater the protective 
effect. This argues against anti-atherosclerotic properties of BPs, as both timing and 
effect size of the association revealed in our study do not support this hypothesis. 
Alternatively, unknown distortion due to healthy-user bias and selective prescribing, or 
unknown pleiotropic properties of BPs might be an explanation. Although, our finding of 
a 28% lower mortality with oral BP use after hip fracture was in line with a 28% mortality 
reduction observed in the HORIZON trial, the design, conduct and analysis of this trial was 
later criticised.7,10 Furthermore, two meta-analyses of randomised controlled trials (RCTs), 
both including the HORIZON trial, did not find any association between all-cause mortality 
and BP use versus placebo.11,12 
In Chapter 4, we explored the role of daily dose and cumulative exposure to oral GCs on 
OP fracture risk in the general population of Denmark. For doing this, we designed a case-
control study using the Danish National Health Service data, which permitted us to 
include almost all patients with an OP fracture in Denmark between 1996 and 2011. Heavy 
users of oral GCs, defined as those taking oral GCs in high daily doses (≥15.0 mg 
prednisolone equivalent dose [PED] per day) and with a cumulative dose ≥1.0 g PED had a 
distinctive 2.9-fold increased risk of hip fracture and a 4.4-fold increased risk of clinical 
vertebral fracture, compared to non-use. This was in clear contrast to short-course users 
(taking oral GCs ≥15.0 mg PED/day but with a cumulative dose <1.0 g PED), who 





vertebral fracture versus non-use. However, risk of forearm fracture was non-significant 
to slightly increased among current users of oral GCs in various dosages. Our findings 
were in line with an older study that showed a similar effect modification of the 
combination of daily and cumulative doses of oral GCs on hip/femur and vertebral 
fracture risk.13 Presumably, the threshold for a marked increased fracture risk in high daily 
oral GC users is the cumulative use ≥1.0 g PED, which is a hallmark of long-term GC 
therapy. 
The aim of Section 2 was to investigate the risk of OP fracture with various medication 
use among patients with RA. The association between low-dose oral GC use (≤7.5 mg 
PED/day) and OP fracture risk in patients with RA was evaluated in Chapter 5. There is 
evidence from previous RCTs that 7.5 mg prednisolone once daily in early active RA could 
have a beneficial effect on bone loss in hands or hip.14,15 Also, a review by the European 
Alliance of Associations for Rheumatology (EULAR) task force on the hazards of long-
term GC therapy in RA was not decisive for risk of OP fracture with dosages between 5.0-
10.0 mg PED, and concluded that the effect of low dose GC on bone was mostly 
dependent on patient-specific parameters.16 We investigated this association in a 
retrospective cohort study using data from the UK CPRD between 1997 and 2017. Current 
use of low-dose oral GCs (≤7.5 mg PED/day) was not associated with overall risk of OP 
fractures (adjusted hazard ratio [adj. HR]: 1.14, 95% confidence interval [CI] 0.98-1.33) 
compared with past GC use. This lack of association between low-dose oral GC use and 
OP fracture risk was notwithstanding with an observed 22% increased risk with current 
oral GC therapy in our study and 49% to 70% increased risks reported by the previous 
literature.13,17 There was no association between low-dose oral GC therapy and non-
vertebral OP fracture sites versus past GC use; however, it incurred a 59% increased risk of 
clinical vertebral fracture. Within the limits of comparability, the elevated risk of clinical 
vertebral fracture with low-dose oral GC use in our study might be in line with lack of 
bone mineral density (BMD) conservation in the spine noticed in the RCT by Engvall et 
al.15 It could be thought that any positive impact of low-dose GC on suppressing the 
chronic inflammation of RA is enough to offset its negative effect on bone resorption in 
most fracture sites but not in vertebrae.  
The association between concomitant use of oral GCs and PPIs and OP fracture risk in 
patients with RA was studied in Chapter 6. Both drugs are commonly prescribed in RA, 
and both are associated with an increased fracture risk, albeit the biological mechanism is 
known for oral GCs but not yet for PPIs.18-20 For conducting this study, we again used a 
cohort of RA patients from the UK CPRD between 1997 and 2017. We observed a 1.6-fold 
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increased risk of OP fractures with concomitant current use of oral GCs and PPIs in RA 
patients compared to non-use of both drugs. This was statistically different from a 1.2-fold 
increased fracture risk associated with single use of oral GCs or PPIs. Although, an 
interaction was suggested between oral GCs and PPIs in concomitant users on the risk of 
OP fracture, the interaction term, relative excess risk due to interaction (RERI), was not 
statistically significant.21 Hence, there seems to be an additive effect of GCs and PPIs on 
bone and/or falling rather than a synergistic effect. We did not observe an increasing 
trend in fracture risk with higher daily doses or longer durations of PPI use, which is in 
contrast to older observational studies.22,23 The timing and magnitude of our GC results 
were fairly in line with the previous literature,17,24,25 explained by known effects of GCs on 
bone or falling, e.g. reduced bone formation, microarchitectural changes, and muscle 
atrophy.18 In contrast, our PPI findings could not be mechanistically justified based on the 
few proposed biological mechanisms, such as hypochlorhydria and calcium 
malabsorption or an increased falling risk due to hypomagnesemia or malabsorption of 
vitamin B12.26-28  
The last project in this thesis evaluated the association between use of bDMARDs and OP 
fracture risk in patients with RA compared with no biological treatment in Chapter 7. 
There is evidence from clinical trials reporting beneficial effects of bDMARDs on bone 
health in RA,29-32 but the few observational studies have found no reduced fracture risk 
with biological drugs.33-35 In order to investigate this, we conducted a retrospective 
cohort study using nationwide registries in Denmark with the possibility to include almost 
all RA patients under rheumatological care between 2006 and 2016.36 This study has 
benefited from the novel prevalent new-user design, introduced by Suissa and colleagues 
in 2017,37 which enabled us to match bDMARD users to bDMARD naïve patients by time-
conditional propensity scores (PSs) in a pool of both incident and prevalent users of 
csDMARDs, as the first-line treatment in RA. We found no reduced risk of OP fractures 
with bDMARD use in patients with RA (HR 0.97, 95% CI 0.78-1.20), compared with no 
treatment with biologicals. The only known mechanism of action of bDMARDs on bone 
health is through the inflammatory cycle.38 By using real-world data from a specialty 
clinical register, we can expect that the disease activity in bDMARD naïve patients has 
been also controlled during follow-up with a “treat-to-target” strategy of RA 
management by clinicians. Control of disease activity in both comparison groups could 
result in comparable beneficial effects on bone health and no observed reduction in 







b. Methodological evaluation 
The studies in this thesis were observational in design and used secondary healthcare 
data. Therefore, they are essentially prone to some inherent limitations of observational 
studies. A brief overview of the major limitations in observational research in general, and 
pharmacoepidemiological studies in particular, will be described in this part. Each 
limitation will be introduced and presented by examples that could have been occurred in 
the studies of this thesis. Then, the strategies that we adopted to avoid or minimise these 
limitations and their possible impact on the final results will be mentioned. 
As previously mentioned in Chapter 1, pharmacoepidemiological studies complement 
RCTs by providing information on longer term or rarer adverse (or beneficial) effects of 
medications using real-world data. But both in theory and in practice, it is impossible to 
exactly reproduce the randomisation of an RCT in observational studies, in order to have 
two precisely identical comparing groups (beside the role of chance, and apart from the 
exposure and outcome of interest), and additionally to have internal and external validity 
generalisable to the source population.39,40 This will be the source of two main types of 
methodological limitations in observational research including pharmacoepidemiological 
studies: confounding and bias. Confounding refers to the distortion of an estimated 
association between the exposure and outcome due to another determinant, which is 
associated with both the exposure and outcome but lies not in the causal pathway.39,41 A 
bias signifies any systematic error in making an epidemiologic estimation (rather than a 
random error), which renders the findings of such study less valid.40,41 Such a bias can 
occur in various stages of a scientific research such as in study design, data collection, 
analysis, reporting of the results, publication, or review of data.42 It can result in 
differential (moving in either direction, away or towards the null) or non-differential 
(moving towards the null) distortion of the risk estimate. While we treat these two 
entities as separate methodological limitations in this thesis as per definition, there is a 
degree of overlap when classifying confounding and bias according to some authors.43 
Figure 8.1 shows a graphical depiction of different sorts of confounding and bias 
elaborated on in this chapter. A review of observational clinical studies based on large 
healthcare databases between 2000 and 2018 has shown that misclassification bias 
(under measurement [information] bias), confounding by indication (under 





















Figure 8.1. Major limitations in observational research.  
* Misclassification bias is a broader term compared with other biases in this category and is usually considered to be 
equivalent to the information bias itself. 
† If the misclassified time was excluded from the analyses, immortal time bias can be regarded as a kind of selection bias 




Confounding by indication or disease severity is one of the most challenging pitfalls in 
pharmacoepidemiological studies. It occurs when some patients in the study population, 
who have a more severe disease with a poor prognosis, are also more likely to receive the 
exposure drug.39,41 The result would be a higher risk estimate for the association between 
the exposure drug and the adverse outcome, compared to the true effect of the drug 
itself. This type of confounding might have existed in the studies in Chapters 4, 5, 6, and 7 
where patients who received oral GCs, PPIs, or bDMARDs may have a more severe 
background medical condition (such as RA) that would also result in a higher risk of 
fractures. Figure 8.2 depicts such a possible confounding effect from the RA’s severity (or 
indication) on the association between oral GC use and OP fracture risk with a directed 




































acyclic graph. We tried to overcome this issue by better choices of the comparator group, 
such as selecting past users of oral GCs (who are more likely to also have a more severe 
disease course) instead of non-users in Chapter 5. Furthermore, we adjusted the analyses 
with some covariates as proxies of the disease severity, such as considering five 
analgesics and conventional synthetic DMARDs (csDMARDs) in the Cox regression model 
in Chapters 5 and 6, by adopting a PS matching model that included disease severity 
indicators (such as disease duration, Disease Activity Score in 28 joints, C-reactive protein, 
etc.) in Chapter 7, and by adjusting the analyses with a history of multiple comorbidities 
and various drug use as proxies of GC indications in Chapter 4. Nevertheless, we cannot 
exactly measure this type of confounding and its impact on our results, but comparability 












Figure 8.2. Confounding by disease severity (or indication) depicted by a directed acyclic graph in the 
association between oral GCs and OP fracture risk in patients with RA. A true confounder must be 
associated with both the exposure and the outcome but does not lie in the causal pathway of this 
association. In this example, a severe disease state might predispose to an imminent OP fracture, and 
at the same time requires higher use of anti-inflammatory medications, such as oral GCs. Thus, it can 
confound the true association between the drug and the outcome, if not considered and adjusted for 
in the analyses. 
GCs: glucocorticoids, OP: osteoporotic, RA: rheumatoid arthritis. 
 
Unmeasured or residual confounding is an ever-existing problem in observational research. 
This type of confounding is usually a problem of the data that we collect from a 
secondary healthcare data source, not necessarily collected for research purposes, for 
example in case of administrative or claims databases. Additionally, some covariates are 
usually not recorded (and perhaps are never measured) in electronic healthcare 
databases (EHDs) such as those we used as our data source, for instance exercise level, 
nutritional status, genetic factors, etc. In general, to minimise the confounding effect of 
Oral GCs OP fractures 
Disease severity of RA 
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various covariates, we can take advantage of few strategies in design and analyses, 
including matching, stratification, and multivariable adjustment in analyses. We 
considered a long list of covariates including well-established risk factors of fracture in 
Chapters 4, 5, 6 and 7, where we studied the association between various drug use and 
OP fracture risk. In Chapters 4, 5, and 6 multivariable adjustment was performed, and a 
PS matching model was designed for Chapter 7. Similarly, we used multivariable 
adjustment in Chapter 3, where we included important risk factors of all-cause mortality. 
In Chapter 2, we stratified fracture IRs by the fracture type and sex, and also stratified the 
analyses by calendar year including only a population of 50+ years. We expect that any 
remaining impact from the residual (unmeasured) confounding in our studies would be 
minimal. Nonetheless, we acknowledge that the produced risk estimates in our studies 
can never be free from such an impact. 
 
Selection bias 
Selection bias is a systematic divergence of study results due to inclusion of an 
unrepresentative group of patients due to a different pattern of exposure and/or 
outcome of interest in comparison with the source population.39,41 It could be more of a 
concern with prospective study designs, such as in field studies, where voluntary referrals 
by clinicians or self-selection by subjects could lead to an unrepresentative study 
population.45 However, this can also happen in retrospective studies using data from the 
EHDs, as highlighted by the following examples. 
Prevalent user bias occurs when patients are entered into the study regardless of their 
starting date of the exposure drug, so many of them were actually prevalent users of the 
exposure drug when they were started to follow up (Figure 8.3).39,46,47 When the hazard 
function of the exposure-outcome is varying over time, this could possibly distort the risk 
estimates, as the included prevalent users are probably the survivors of the early phase of 
the pharmacotherapy. This usually results in a protective/ beneficial effect of the 
exposure drug on the adverse outcome. This effect - especially with acute outcomes, has 
also been called depletion of susceptibles, such as in case of non-steroidal anti-
inflammatory drug use and upper gastrointestinal bleeding.48,49 The solution to this type 
of bias would be an incident new-user design.46,47 With this design, one only includes 
patients with an incident (new) use of the exposure drug, so it would be possible to 
capture the whole period of hazard function for the exposed group, in order to have a 





Study start date time=0, Initiation 
of drug utilisation 
prescriptions, medical diagnoses, and other covariates with their exact start (and stop) 
date has made such a design easier in practice. We used an incident new-user design in 
the cohort studies in Chapters 3, 5, and 6, by excluding the exposure drug users before 
the index date. Furthermore, the case-control study in Chapter 4 had a non-nested design 
that took into account all oral GC use times as current, recent, past, distant past or never 
use irrespective of the case accrual period, and also selected never users as the 
comparator.46 Thus, we do not expect a prevalent user bias occurred in any of these 
studies. 
 













Figure 8.3. Prevalent user bias in pharmacoepidemiological studies. Hazard function of an adverse 
outcome for a given exposure drug is depicted in a hypothetical patient population. Susceptible 
patients who develop the adverse outcome after drug use are shown in red, while those who do not 
are shown in green. As drug utilisation starts at time=0, most of the adverse outcomes happen in the 
early phase of the pharmacotherapy. A study design that would include prevalent users of the 
exposure drug would intersect this hazard function at the middle, thus would only include survivors of 
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In Chapter 7, we profited from a novel study design called prevalent new-user design, in 
order to compare new use of bDMARDs in RA patients with no biological use respecting 
the effect on fracture risk among incident and prevalent users of csDMARDs.37 This 
design would be beneficial in head-to-head comparison of two drugs that are normally 
prescribed in different stages of the same disease. The users of the study (newer) drug 
are allowed to be prevalent users of the comparator (older) drug, where the likelihood of 
receiving the study (new) drug would be estimated by means of time-conditional PSs 
allowing for appropriate matching with controls in the same stage of the disease 
course.37 This design would also allow to tackle the issues related to the prevalent user 
bias, as the new (incident) use of the study drug (as either initiation or switch from the 
older dug) will be assessed, where the prevalent use of the older drug has been 
adequately matched and balanced among comparing groups. 
Healthy-user bias can be deemed as a specific form of prevalent user bias under the 
category selection bias. It arises when healthier patients are more routinely treated with 
(especially preventative) medications, and due to their healthy behaviour, they would 
also have lower odds to have the outcome of interest.50 If the point of divergence 
addresses the adherence with the medication, a similar bias would be ensued, called 
healthy-adherer bias.50,51 Both these biases would result in an exaggeration of a beneficial 
effect of the (preventative) medication on the outcome of interest. A classic example 
was the apparently protective effect of hormone replacement therapy (HRT) against 
cardiovascular risk in postmenopausal women in observational studies, which later was 
found to be due to healthier HRT users in those studies.52 We may suffer from healthy-use 
(and -adherer) bias in Chapter 3, where oral BP users could have been healthier patients 
who had taken this preventative medication more frequently (and more adherently) after 
having a MOF compared with the more fragile and sick patients who never took these 
medications. This could result in a spurious beneficial effect for oral BPs on all-cause 
mortality, especially with shorter durations of follow-up, as the biased effects are 
expected to be stronger in a shorter period. This can partly explain the mortality lowering 
effects that we observed with oral BPs in fracture patients in Chapter 3.  
Time-lag bias is one of the time-related biases that lies under the selection bias. It can 
occur when patients in two different stages of the same disease are compared with each 
other because of using drugs that are specified as different lines of treatment for that 
disease (Figure 8.4).53 The problem usually arises when the outcome of interest has a 





in the case of fracture risk in RA. We know from previous literature that the risk of an 
imminent OP fracture increases when the RA advances.17 This could be of concern in 
Chapters 5, 6, and 7, where the fracture risk was evaluated in cohorts of patients with RA, 
especially where we included both incident and prevalent cases of RA. In Chapter 5, 
current oral GC use was compared with past GC use in a time-dependent Cox regression 
model. This could be a fairer and more reasonable comparator group than non-users and 
thereby reducing the possibility of time-lag bias, considering an incident new-user design 
and as the person time from past GC use have been derived from the follow-up time of 
the same patients (i.e., those who stopped taking oral GCs for >1 year). If there was an 
impact from time-lag bias, we would expect higher fracture rates among our exposed 
patients and an artificially increased fracture risk with low-dose oral GC use. One 
sensitivity analysis in Chapter 5 confirmed this hypothesis, where a comparison to non-
use instead of past GC use shifted the associations away from the null. But in Chapter 6, 
the concomitant current use of oral GCs and PPIs has been compared to non-use of both 
drugs, and the mean follow-up time was around 4 years shorter for non-users (9.1 years, 
SD 5.0 years for concomitant users, and 5.1 years, SD 4.3 years for non-users). This might 
mean a less advanced disease and lower odds of fracture among non-users due to the 
inflammatory process of RA.17 Thus, it might be deemed that part of the observed 
association was due to the time-lag bias. However, as past use of oral GCs or PPIs did not 
show any significant risk change compared to non-use of both drugs, and as this person 
time came from the same patients who contributed person time for concomitant use, an 
effect from time-lag bias was probably negligible. In Chapter 7, we used a PS matching 
model that considered covariates such as disease duration, and other disease severity 
indicators and medications. However, there was a 0.7-year difference in follow-up time 
between bDMARD users (4.4 years) and bDMARD naïve patients (3.7 years) after 
matching. This longer follow-up time could mean a more advanced RA disease course for 
bDMARD users and hence more fracture rates due to the inflammatory process of the 
disease. This might have masked a beneficial effect from bDMARDs on reducing OP 
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Figure 8.4. Time-lag bias in pharmacoepidemiological studies. The follow-up times of two random 
patients from our cohort studies in Chapters 5 or 6 are depicted here, with the exposure of interest 
being oral GCs. Follow-up time starts at the first date of a diagnosis of RA in the database during the 
valid data collection and study period. Two different approaches in analyses are shown. With the 
approach “A”, a period of current use would be compared with a period of non-use, which might 
represent a very different stage of the disease, hence different odds for occurrence of an osteoporotic 
fracture due to advancement and inflammatory process of the disease. The other approach, “B”, 
takes advantage of a comparison between a period of current use and a period of past use, which 
could be in a more similar disease stage, therefore similar chances for occurrence of an osteoporotic 
fracture due to advancement of the disease course.   




Information bias occurs when there is a systematic divergence of the study results due to 
flawed measuring and the resulting erroneous data on various study variables.39,45 A 
synonymous term in literature is misclassification bias, which applies to any erroneous 
measurement and classification of the exposure drug, outcome, covariates, or disease 
diagnosis among the comparison groups in a pharmacoepidemiological study, which 
would lead to flawed study results.39,42,54 In this part, first we will explain important 
examples of misclassification of exposure and outcome in our studies, then we will 
continue to introduce other potentially important cases of information bias in this thesis.  
We expect some extent of misclassification of exposure in our studies, as we used data 
from the primary care, clinical, or specialty EHDs, such as the CPRD and Danish national 
registries. For instance, we had only information on drug prescriptions from the CPRD, 
Non-use Current use Past use 





which is roughly two steps behind the actual drug use by patient; first, we had no 
information on the dispensation of the prescribed drug, and second, we did not know 
whether the prescribed (and dispensed) drug had been actually consumed by patient 
(i.e., adherence to medication).39 Previous studies using data from the CPRD showed that 
above 20% of patients with diabetes mellitus and above 60% of patients with gout were 
not adherent to their therapies (i.e. glucagon-like peptide-1 receptor agonists and 
allopurinol, respectively).55,56 Apart from the issue with non-adherence, some of our 
studied drugs were also available as over-the-counter, such as PPIs, and some were also 
prescribed in an “as needed” basis, for example in case of oral GCs. Non-adherence with 
the prescribed medication and an “as needed” order could lead to an overestimation of 
actual drug use in our analyses, while an over-the-counter use could lead to an 
underestimation of actual drug use. This would result in a differential distortion of our 
risk estimates, which has possibly underestimated the association for oral BP use and all-
cause mortality in Chapter 3, the association of oral GC use and OP fracture risk in 
Chapter 4, and the association of low-dose oral GC use and OP fracture risk in Chapter 5. 
Following this rationale, the association between oral GC use alone and OP fracture risk in 
Chapter 6 might be underestimated, while PPI use alone-OP fracture risk association 
could be overestimated (if we assume PPI users in our study had also more over-the-
counter PPI use than the reference group). As the use of bDMARDs is principally 
parenteral, non-adherence would not be an issue for the exposure drug in Chapter 7. 
However, the same non-adherence issue with the mostly orally taken csDMARDs might 
have a differential impact on the final results, depending on the degree of non-adherence 
among the comparison groups, and the hypothetical effect of csDMARDs and bDMARDs 
on fracture risk. 
Misclassification of outcome would be less of an issue in our studies, as the outcome of 
interest was either an OP fracture (in Chapters 4, 5, 6, and 7) or all-cause mortality (in 
Chapter 3), where both are clinically definitive endpoints and quite well recorded in an 
EHD.57,58 However, one exception in our studies may be vertebral fracture, where two 
thirds of cases never come to clinical attention, and the only one third are normally found 
accidentally and due to other complaints.59 Thus, not only we certainly underestimated 
IRs of vertebral fractures in our studies, but also the ascertainment of clinically 
symptomatic vertebral fracture in our studies might have suffered from detection 
(surveillance) bias. This occurs when patients with a given exposure have higher odds of 
detection of the outcome of interest, due to an associated symptom which leads to more 
screening or testing for that outcome.39 In our studies, those patients who had received 
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oral GCs might have higher odds to be clinically examined or to undergo radiological 
imaging because of complaints such as a back pain or a stoop, which might end up in 
diagnosis of a vertebral fracture. For this reason, we expect a differential divergence, and 
an overestimation of risk estimates for the association between oral GC use and clinical 
vertebral fracture in Chapters 4, 5 and 6. This included increased vertebral fracture risks, 
such as an observed 4.4-fold with heavy GC use in Chapter 4, a 1.6-fold with low-dose oral 
GC use in Chapter 5, and a 2.8-fold with concomitant oral GC and PPI use in Chapter 6. So, 
it is not unlikely that at least part of these associations was due to detection bias.  
Other forms of time-related biases, i.e., immortal time bias or time-window bias fall under 
the information bias. Immortal time bias refers to an improper handling of the follow-up 
time, when patients should have an “immortal” event-free period before the exposure 
drug could start (Figure 8.5).49,53,60 It normally results in a beneficial (protective) effect for 
the exposure drug due to erroneous underestimation of the denominator in IRs of the 
unexposed (control) group. If the misclassified time was totally excluded from the 
analyses, immortal time bias can then be classified under selection bias. A typical example 
are the observational studies that found a protective role for metformin or statins in a 
wide range of outcome measures such as various cancers, or diabetes progression.53,61 
The solution is to implement a time-dependent design (instead of a time-fixed analysis) 
that carefully considers all the follow-up time of the included patients, for instance by 
considering the exact start dates of prescriptions. As we used time-dependent regression 
models by incorporating all person times in our analyses (Chapters 3, 4, 5, and 6), such a 
bias is not expected in these studies. The prevalent new-user design in Chapter 7 might 
be prone to such a bias, where the index date of the comparator group is defined as the 
cohort entry date. However, we will not “look-into-the-future” for selecting the patients, 
also with an intention-to-treat analysis and a balanced state of prevalent use of 
csDMARDs among both comparison groups, we do not expect immortal time bias here. 
Time-window bias occurs when there are different opportunities for having the outcome 
between the various exposure groups usually due to different follow-up times in a case-
control study.49,53,62 This often resulted in spurious protective effect of the medication 
(e.g. statins) on several adverse outcomes (such as various cancers), as the control group 
in those examples had a longer and different follow-up time and automatically higher 
odds to develop the outcome.62 The ideal solution is a risk-set (or incidence density) 
sampling to allow for equal observation time for cases and controls. In our case-control 
study in Chapter 4, we used the date of first fracture as the index date for cases and the 
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were matched by year of birth and gender using incidence density sampling. Also, as the 
nationwide Danish databases covered all inhabitants with all data from a certain time 
point onward, there is unlikely that the comparison groups had different exposure 
opportunities. Moreover, unlike cancer outcome in the examples above, our outcome of 
interest (i.e., OP fracture) had not a long latency period after GC use. Hence, we expect 
relatively similar opportunities for cases and controls to have the exposure, and time-










Figure 8.5. Immortal time bias in pharmacoepidemiological studies. The follow-up times of two 
random patients are depicted here in a hypothetical cohort study, which compares the risk of adverse 
outcome Y in patients who ever used drug X (such as Patient A) versus those who never used this drug 
(such as Patient B). The index date in such a design starts at the cohort entry date. As the exact start 
date of using drug X (e.g., the prescription dates) has not been taken into account, patients (such as 
Patient A) should survive enough without having the adverse outcome to be able to receive the 
exposure drug and counted as drug users, so there is an “immortal time” before the drug exposure in 
this group. The sole comparison of incidence rates of adverse outcome Y among ever users of drug X 
versus those of never users would usually result in a beneficial (protective) effect of the drug on the 
adverse outcome. This is because the time before start date of drug use among ever users (such as in 
Patient A, shown with pink patterned line) has been mistakenly considered as part of the denominator 
of the incidence rate of Y among the exposed group (drug users). This non-use time should be instead 
considered as part of the denominator of the incidence rates of the unexposed (control) group. 
 
No drug use Drug use 
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A period of 
hospitalisation 
Immeasurable time bias concerns some differential recording of the exposure of interest 
between the two comparing groups because of some periods during follow-up, in which 
the exposure could not be recorded, mainly due to hospitalisation episodes that are not 
registered in the database (Figure 8.6).49,63 It often happens when patients with a chronic 
debilitating disease are studied, where they need long periods of hospitalisation with no 
available information on any inpatient prescriptions. In Chapters 5 and 6, we focused on 
patients with RA, and we did not have information on any drug usage during 
hospitalisations from the CPRD. But it is unlikely that patients with RA need long periods 
of hospitalisation. Additionally, there is no indication that such hospitalisation periods 
and the resulting immeasurable time were different between the two comparing groups 
in each study. Moreover, our definitions for the classification of GC exposure in these 
studies, as current (<6 months before), recent (6-12 month before) and past (>1 year) use, 
would hamper a large effect from any hospitalisations. Thus, we do not expect an 








Figure 8.6. Immeasurable time bias in pharmacoepidemiological studies. The follow-up times of two 
random patients are shown in a hypothetical cohort study, where patients need long periods of 
hospitalisation (boxes with patterned lines) due to the background disease or its complications. This 
type of information bias might occur, when there is no information available from the data source for 
the hospitalisation periods on the exposure, outcome, death, or other study variables, which can end 










Recall bias is defined as differential remembrance of a past exposure among patients with 
different outcomes.39,42,64 For example, patients with thromboembolism have been 
reported to recall more the use of oral contraceptives than healthy controls in a classic 
study.65 We used data from the EHDs, such as the CPRD and Danish national registries, 
filled in by physicians and not from questionnaires, so in general it is unlikely that our data 
were affected by this bias. However, we used data from the DANBIO register in Chapter 
7, and some of the variables have been entered into the DANBIO via patients, called 
patient-reported outcome measures, such as educational level, smoking status, and 
physical activity.36 There is also a possibility that some few variables have been entered 
into the CPRD by physician or nurse but only after questioning the patient, such as 
previous falls, in Chapters 3, 5, and 6. In either case, the data have been collected 
prospectively and ideally before an outcome of interest. This reduces the risk and 
potential impact of recall bias on our findings.  
Protopathic bias occurs when early symptoms of an outcome would affect prescribing of 
the exposure drug, thus leading to an erroneous positive association between the 
exposure and outcome.39 With this bias, one normally observes a reverse causality, where 
it is actually the outcome that is causing the exposure of interest to befall. This type of 
bias might happen in the pharmacoepidemiological studies on cancer, as the outcome 
has a long latency period, for instance starting of antidiabetic drugs for treating diabetes 
mellitus that heralds an imminent pancreatic cancer.66 However, the outcomes of interest 
in our studies, i.e., OP fractures or all-cause mortality, do not seem to be good candidates 
for predisposing to such a bias. One exception could be vertebral fracture, where two 
thirds of cases remain to be undiagnosed,59 and a symptom or sign of the undetected 
fracture may induce the use of some medications such as analgesics. However, it sounds 
unlikely that even an undetected vertebral facture had caused prescribing of oral GCs, 
PPIs, or bDMARDs. So, we do not expect protopathic bias in this thesis. 
In addition to the established study designs and a range of strategies that were embraced 
to tackle different sorts of bias and confounding, we also took advantage of running 
several sensitivity analyses in each study. The goal of these analyses was to further test 
the robustness of the observed association. Additionally, by running multiple sensitivity 
analyses we could indirectly evaluate the findings and their alignment with the presumed 
underlying pharmacological hypothesis.67 An example was stratification of OP fracture 
sites as the outcome of interest in secondary analyses in Chapters 4, 5, 6, and 7, 
evaluating the association for the other cut-offs of low-dose oral GC use and fracture risk 
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in Chapter 5, or the impact of censoring the follow-up time after oral BP use on mortality 
reduction in Chapter 3. 
 
c. Clinical implications & suggestions for future research 
Before formulating the conclusions of this thesis, the relevance of the findings of our 
studies for patients, clinicians, and policymakers will be presented in this part. 
Furthermore, some novel ideas for future research in the studied topics will be 
introduced, which are inspired by the findings and limitations of our studies. 
The first part of this thesis aimed to investigate various attributes of OP fractures in the 
general population. When exploring this, we found an overall declining trend in IRs of 
MOF in Denmark between 1995 and 2010, no beneficial effect for oral BPs against 
mortality after a MOF, and a marked increased risk of OP fractures with a cumulative oral 
GC use ≥1.0 g PED among high daily GC users as the hallmark of long-term GC therapy in 
the general population.  
Aside from a generally declining trend in MOF rates, the important finding in Chapter 2 
was a lower rate of decrease of hip fractures among men compared with women, and an 
increasing trend in clinical vertebral fractures rates in men. Osteoporosis has been long 
considered a disease of postmenopausal women, and consistent with many other 
previous studies, we observed higher IRs of MOF among 50+ women (211.5 per 10,000 
PYs in 2010) compared with 50+ men (77.6 per 10,000 PYs). But this intersexual gap is 
rapidly shrinking especially in some OP fractures such as the clinical vertebral. Some 
aetiologic factors have been proposed to explain the trend changes in general (e.g. 
higher BMD or higher frequency of overweight/ obese people due to a birth cohort 
effect, or urbanisation rates), and the differential changes between men and women 
(e.g. more anti-osteoporotic therapy among post-menopausal women), but there is no 
definite answer.2,4,68,69 Our findings are important for clinicians and policymakers, as we 
recommend appropriate screening for OP fractures (by fracture risk assessment and BMD 
measurements),70 in addition to appropriate use of anti-osteoporotic treatments not only 
in postmenopausal women, but also in older men. We think there is an urgent need for 
future research to investigate into the underlying reasons for the changes in the secular 
trends in OP fractures, and specifically into the differential changes between men and 
women. We also recommend an updated investigation of the secular trends in IRs of 





comprehensive data from various countries with different levels of sun exposure, 
healthcare utilisation, and cultural and racial determinants. 
Any potential beneficial effect of BPs on mortality is highly controversial in the bone 
research field. At least part of our positive findings in Chapter 3, i.e., oral BPs’ effects on 
mortality reduction, could be explained by several bias scenarios, including the healthy-
user bias or confounding by selective prescribing. But the observation of a mortality 
reduction as soon as the first year after a fracture strongly argues against the anti-
atherosclerotic hypothesis of BPs. While there is some evidence supporting favourable 
effects of BPs on the cardiovascular outcomes or cancer incidence, a net benefit on the 
all-cause mortality has never been consolidated.11,12,71 On the other hand, there is 
substantial evidence that BPs would prevent a recurrent fracture.7,72,73 For this reason and 
aside from the still unknown beneficial effects on mortality, oral BP use is highly 
recommended as first-line treatment in patients with osteoporosis or those who already 
had an OP fracture, in order to avoid a future fracture.74,75 To solve this ongoing and 
relevant discussion, we recommend conducting in vitro and in vivo studies that would 
elaborate on the alternative biological mechanisms or pleiotropic properties of BPs, 
which confer a mortality benefit. 
Our findings in Chapter 4 could be important to guide clinicians and possibly to inform 
the future guidelines in how and when to treat patients receiving oral GCs, who need 
long-term treatment due to a chronic inflammatory disease. The key finding was a clear 
distinction between a cumulative oral GC use ≥1.0 g PED and <1.0 g PED in marking a 
substantially elevated risk of hip and clinical vertebral fractures in patients who were 
using an average daily dose ≥15.0 mg PED. This group of heavy GC users (those taking an 
average GC daily dose ≥15.0 mg PED and a cumulative dose ≥1.0 g PED) are probably the 
most fragile group respecting the risk of OP fractures. Therefore, avoiding unnecessary 
high doses of oral GCs, adequate fracture assessment and timely anti-osteoporotic 
therapy are all recommended in order to avoid the catastrophic consequences of an 
imminent fracture. One research area would be a continued effort to develop new anti-
inflammatory drugs, which can act more specifically at the inflammation site with less 
adverse impact on bone, such as those potential therapy targets found with the recent 
explorations in the new mechanisms of action of GCs.76 Such new therapies could be 
more suitable for the long course of treatment of a chronic inflammatory disease. 
The second part of this thesis aimed to address some knowledge gaps on the role of 
medications in the risk of OP fractures in patients with RA. We found an increased risk of 
clinical vertebral fracture with low-dose oral GC use in RA patients, but no association 
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with non-vertebral OP fractures. Furthermore, we found a significant increased risk of OP 
fractures with concomitant use of oral GCs and PPIs in patients with RA. Finally, we 
showed that bDMARD use was not associated with a reduced risk of OP fractures in RA. 
The significantly increased risk of clinical vertebral fracture with low-dose oral GC use 
(≤7.5 mg PED/day) in RA was an important finding in Chapter 5. We already know from 
the previous literature that vertebrae are one of the most susceptible sites to GC therapy, 
culminating in highest fracture risks, presumably because of high proportion of trabecular 
bone.77,78 We also acknowledge that a (small) part of this association in our study might 
have originated from the detection bias, as discussed earlier. However, our findings 
should warn clinicians that even with low daily doses of oral GCs, the patients are at risk 
of a vertebral fracture. This certainly comes along our other message that low-dose oral 
GC therapy does not pose a risk for non-vertebral OP fractures including the hip, making 
daily doses ≤7.5 mg PED perhaps a clinically safe exposure in RA patients respecting a 
non-vertebral fracture risk. A novel research idea in this topic would be a study design 
that investigates this association by means of a spline regression analysis to find a more 
exact cut-off point of a daily GC dose for a significantly elevated fracture risk in various 
sites. Another idea is to evaluate this association in various subgroups of patients with RA 
who had different baseline fracture risks, as recommended by the EULAR task force.16  
On a same line, the key message in Chapter 6 is relevant for clinicians and patients with 
RA. From our analyses it is understood that the OP fracture risk associated with 
concomitant use of oral GCs and PPIs has probably an additive nature, stemming from the 
individual risks related to each of these drugs. Therefore, more attention should be paid 
to those RA patients who are prescribed both drugs, with routine fracture risk 
assessment and proper preventative anti-osteoporotic therapies. This recommendation 
would be more important for elderly patients, possibly with a more advanced disease, 
who are at a higher risk of OP fractures due to other risk factors.17 We could not 
unfortunately match the PPI findings with any of the previously proposed biological 
mechanisms of action of PPIs on bone or falling. This is still an unsolved enigma, and thus 
an interesting realm for future studies to find a clear and sound mechanism, which can 
hopefully explain the associations that we and others found in real-world data. 
The results of the last project of this thesis in Chapter 7 are also interesting for clinicians 
and patients with RA. In the past two decades, biological drugs have become a pivotal 
therapy for many chronic inflammatory diseases including RA,79 but their comprehensive 
safety profile and any effect on the risk of OP fracture is still a matter of debate.38 The 





“treat-to-target” strategy of RA management in a real-world setting, which means 
comparable improvement of disease activity in both comparison groups in the study. We 
believe, this still conforms with the previously reported beneficial effects of bDMARDs on 
BMD identified in single-arm before-after trials.30,32,80 Moreover, a side message of our 
study was evidence for the safety of bDMARDs regarding OP fracture risk, compared to 
the adverse effect of other anti-inflammatory drugs used in RA, in particular GCs. While 
biologicals were not associated with a reduced risk of OP fractures, they still did not incur 
an increased risk. There is also strong evidence from systematic reviews of RCTs that 
bDMARDs are efficacious therapies for those RA patients who were not responding to a 
first-line csDMARD to control the RA disease activity and progression.81 As this is a 
relatively young research area, more investigation is needed to inform on alternative 
mechanisms or various pleiotropic effects that biologicals might have on different 
cytokines or bone active molecules. 
 
d. Conclusion 
In conclusion, there was an overall decreasing trend in IRs of MOFs in Denmark between 
1995 and 2010. These changes were more pronounced in women, while there was a lower 
decrease of hip fracture and an increasing trend in clinical vertebral fracture among men. 
Oral BPs had apparently no beneficial effect on mortality reduction in patients with a 
MOF, although our results were probably impacted by healthy-user bias and confounding 
by selective prescribing. However, oral BPs are first-line treatment for osteoporosis and 
as preventative therapy for a recurrent OP fracture, as supported by strong evidence. 
Furthermore, we showed that the threshold for a marked increased risk of hip and clinical 
vertebral fracture in high daily oral GC users is the cumulative use ≥1.0 g PED, which is a 
hallmark of long-term GC therapy. 
Low-dose oral GC therapy (≤7.5 mg PED/day) in RA patients was associated with an 
increased risk of clinical vertebral fracture, while there was no association with risk of 
non-vertebral OP fractures. Hence, more attention should be paid to an imminent 
vertebral fracture in patients with RA who receive low daily doses of GCs. We also 
showed that there was an increased and additive risk of OP fractures by concomitant use 
of oral GCs and PPIs in patients with RA, although the risk did not increase with increasing 
daily doses or longer duration of PPI use. Thus, we recommend adequate fracture risk 
assessment and anti-osteoporotic treatment for RA patients who are co-prescribed both 
oral GCs and PPIs. Finally, we found that bDMARDs had no independent beneficial effect 
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on reducing the risk of OP fractures in patients with RA. Nevertheless, bDMARDs are 
recommended as second-line pharmacotherapy in RA because of their potent effect on 
suppressing disease activity. Additionally, the combined data from clinical trials on BMD 
and observational studies on fracture risk point to their protective effect on bone health, 
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Osteoporosis is a chronic disease with loss of bone mass and increased risk of 
osteoporotic (OP) fractures. It is predominantly a disease of elderly or postmenopausal 
women, with substantial personal and societal impact, mainly because of the associated 
fractures. Osteoporosis and OP fractures can occur secondary to other morbidities (such 
as rheumatoid arthritis [RA]) or use of some medications (for instance, glucocorticoids 
[GCs]). Diagnosis of osteoporosis is based on measurements of bone mineral density 
(BMD) by dual-energy X-ray absorptiometry (DXA). Main OP fracture sites include hip, 
vertebrae, humerus, forearm, pelvis and ribs. Among the OP fractures, vertebral fracture 
is the most prevalent, and hip is the most problematic with high morbidity, mortality and 
societal costs. 
Absolute number of OP fractures is increasing due to the global increase in life 
expectancies and the ageing trajectory. On the other hand, awareness about the disease, 
improved lifestyles and fracture prevention by anti-osteoporotic medications, might have 
resulted in reduced fracture rates. On that line, previous studies have shown a decrease 
in incidence rates (IRs) of hip fracture, especially in North European or North American 
countries in the past decades. However, there is little known about the secular trend in all 
OP fractures globally, not especially from a Northern European country with traditionally 
high incidence of OP fractures. 
OP fractures are devastating outcomes due to their associated high morbidity and 
mortality rates. Previous literature has shown that anti-osteoporotic therapies (such as 
bisphosphonates [BPs]) can prevent a subsequent fracture. There is also evidence that 
BPs could have some anti-atherosclerotic effects, which might confer a mortality benefit. 
However, whether BPs would have a beneficial effect against mortality after a fracture is 
unsolved and highly controversial in the literature. 
Oral GCs are one of the most potent anti-inflammatory medications with relatively high 
frequency of use in many chronic inflammatory diseases. Effects on bone quality and 
induction of an increased risk of OP fracture is one of the most established side effects of 
oral GCs. Previous literature has shown a role for daily or cumulative dose of oral GCs in 
developing an OP fracture. However, the association between various exposure patterns 
of oral GCs and risk of OP fractures is less clear, particularly in patients with a chronic 





RA is a chronic inflammatory musculoskeletal disease, which is characterised by synovitis 
in the small joints of hands and feet, pain, morning stiffness, and limited range of motion. 
It is most prevalent among middle-aged and older women. A set of clinical signs and 
symptoms in physical examination, laboratory tests, and imaging determine the diagnosis 
of RA. Based on the European Alliance of Associations for Rheumatology (EULAR) 
recommendations, pharmacotherapy of RA includes conventional synthetic disease-
modifying antirheumatic drugs (csDMARDs) with or without short-term low-dose GC 
therapy in early disease, and biological DMARDs (bDMARD) and targeted synthetic 
DMARDs (tsDMARDs) in case of failure of csDMARDs. Patients with RA are at an 
increased risk of OP fractures compared to the general population due to the 
inflammatory process of the disease and reduced mobility. 
Some of the medications that are recommended for use in RA have known and 
sometimes compound effects on fracture risk. For instance, oral GCs especially in low 
doses might have some local beneficial effects on bone by supressing the background 
inflammation and increasing the mobility of patient. But the effect of low-dose oral GCs 
(≤7.5 mg prednisolone equivalent dose [PED]/day) on OP fracture risk in RA is not yet 
clear. Furthermore, patients with RA, especially elderly patients, frequently use proton 
pump inhibitors (PPIs), which have been reported to increase the fracture risk in 
observational studies, although the exact mechanism has never been established. Thus, it 
would be of interest to investigate the effect of concomitant use of oral GCs and PPIs on 
OP fracture risk. Likewise, previous studies have shown that bDMARDs may have 
protective effects on BMD in patients with RA. But there are few studies who 
investigated the association between use of bDMARDs and OP fracture risk in RA. 
Pharmacoepidemiology is an interdisciplinary field studying the effectiveness of 
medications and their adverse effects in real-world setting. The pharmacoepidemiological 
research is observational in essence, and generally uses previously collected anonymised 
patient data in electronic healthcare databases (EHDs). The randomisation performed in 
randomised controlled trials (RCTs) is lacking in pharmacoepidemiological studies and 
hence should be mimicked by means of complicated study designs. This can bring up 
major limitations, such as confounding and bias, in order to have a fair comparison 
between the studying groups. We took advantage of pharmacoepidemiological 
methodologies to investigate the above-mentioned knowledge gaps in the literature.  
In this thesis, we aimed to study the OP fractures, and their relation to mortality, 
medication use and RA. The first section of this thesis evaluated various attributes of OP 





mortality after fracture with oral BP use, and the association between various exposure 
patterns of oral GCs and OP fracture risk. The second section focused on the role of 
medication use in risk of OP fractures among patients with RA, which included low-dose 
oral GCs, oral GCs and PPIs concomitantly, and bDMARDs. 
 
Section 1, Osteoporotic fractures in the general population 
An investigation of recent secular trends in IRs of OP fractures in the general population 
of Denmark was performed in Chapter 2. We found a general decline in IRs of major OP 
fractures (MOF) for 50+ adults in Denmark between 1995 and 2010 (from 169.8 to 148.0 
per 10,000 person years). All OP fractures were decreasing in women, however, a lower 
decrease of hip fracture in addition to increasing rates for clinical vertebral and steady 
rates for humerus fracture were observed in men. Our observed trends were generally in 
line with previous studies from Denmark, Canada and US. Based on these findings, we 
recommend appropriate screening for OP fractures (by fracture risk assessment and BMD 
measurements if needed), in addition to proper use of anti-osteoporotic treatments not 
only in postmenopausal women, but also in older men. 
The association between oral BP use and mortality risk following a MOF was evaluated in 
Chapter 3, using a cohort of patients with a MOF in the UK Clinical Practice Research 
Datalink (CPRD) between 2000 and 2018. We found a 7% increased risk of all-cause 
mortality after non-hip MOF, and a 28% reduced risk after hip fracture with current use of 
oral BPs versus never use. Both the timing and effect size of an association based on anti-
atherosclerotic properties of BPs were not supported by our results. Instead, unknown 
distortion due to healthy-user bias and selective prescribing, or unknown pleiotropic 
properties of BPs might explain our findings. Future in vitro and in vivo studies are 
recommended to elaborate on the alternative mechanisms or pleiotropic properties of 
BPs, which confer a mortality benefit. 
The role of daily and cumulative doses of oral GCs in OP fracture risk in the general 
population of Denmark was studied in Chapter 4, with a case-control study between 1996 
and 2011. The remarkable finding was a distinctive elevated risk of hip and clinical 
vertebral fracture with heavy use of oral GCs, defined as average daily doses ≥15.0  mg 
PED/day and a cumulative use ≥1.0 g PED, as in clear contrast to short course users (those 
with high average daily doses but cumulative use <1.0 g PED). Presumably, the threshold 
for a marked increased fracture risk in high daily oral GC users is the cumulative use ≥1.0 g 





doses of oral GCs, adequate fracture assessment and timely anti-osteoporotic therapy are 
all recommended in patients with a chronic inflammatory disease who need long-term GC 
therapy, to avoid the catastrophic consequences of an imminent fracture. 
 
Section 2, Osteoporotic fracture risk with medication use in rheumatoid arthritis 
The association between low-dose oral GC use (≤7.5 mg PED/day) and OP fracture risk in 
patients with RA was evaluated in Chapter 5, in a cohort of patients with RA from the 
CPRD between 1997 and 2017. Current use of low-dose oral GCs was not associated with 
overall risk of OP fractures compared with past GC use; however, it incurred a 59% 
increased risk of clinical vertebral fracture. The main results remained unchanged 
regardless of a short-term (with a cumulative use <1 g PED) or a long-term (≥1 g PED) use. 
Apparently, the beneficial effect of low-dose GC therapy on suppressing the background 
inflammation of RA could probably be enough to offset its negative effect on bone 
synthesis in most fracture sites but not in vertebrae. Thus, clinicians should be aware that 
even in RA patients who use low daily doses of oral GCs, the risk of clinical vertebral 
fracture is increased.  
The association between concomitant use of oral GCs and PPIs and OP fracture risk in 
patients with RA was studied in Chapter 6, using the CPRD with all RA patients from 1997 
to 2017. We observed a 1.6-fold increased risk of OP fractures with concomitant current 
use of oral GCs and PPIs in RA patients compared to non-use of both drugs. This was 
statistically different from a 1.2-fold increased fracture risk associated with single use of 
oral GCs or PPIs. We did not observe an increasing trend in fracture risk with higher daily 
doses or longer durations of PPI use, which is in contrast to older observational studies. 
More attention should be paid to those RA patients who are prescribed both drugs, with 
routine fracture risk assessment and proper preventative anti-osteoporotic therapies. As 
we could not match the PPI findings with any of the previously proposed biological 
mechanisms of action of PPIs on bone or falling, more studies are recommended to 
investigate the associations that we and others found in real-world data. 
The association between use of bDMARDs and OP fracture risk in patients with RA was 
evaluated in Chapter 7, using nationwide registries in Denmark including all RA patients 
between 2006 and 2016. We found no reduced risk of OP fractures with bDMARD use in 
patients with RA compared with no treatment with biologicals. The only known 
mechanism of action of bDMARDs on bone health is supposed to be through the 





could be due to the “treat-to-target” strategy of RA management in a real-world setting, 
which means comparable control of disease activity in both comparison groups in the 
study. We believe, this still conforms with the previously reported beneficial effects of 
bDMARDs on BMD identified in single-arm before-after trials. More investigation is 
needed to inform on alternative mechanisms or various pleiotropic effects that 
biologicals might have on different cytokines or bone active molecules. 
 
General discussion and conclusion 
The main findings of the studies in this thesis, in addition to putting them into the 
broader context of the previous literature are presented in Chapter 8. Moreover, the 
major limitations in pharmacoepidemiological studies, i.e., confounding and bias, have 
been described with potential examples that we might have encountered in our studies, 
the strategies embraced to tackle them, and any possible impact on our results. Finally, 
the clinical implications of our findings and some novel ideas for future research have 
been presented. 
In conclusion, there was an overall decreasing trend in IRs of MOFs in Denmark between 
1995 and 2010, while there was an increasing trend in clinical vertebral fracture among 
men. Oral BPs had apparently no beneficial effect on mortality reduction in patients with 
a MOF, although our results were probably impacted by healthy-user bias and 
confounding by selective prescribing. Furthermore, we showed that the threshold for a 
marked increased risk of hip and clinical vertebral fracture in high daily oral GC users is the 
cumulative use ≥1.0 g PED, which is a hallmark of long-term GC therapy. 
Low-dose oral GC therapy (≤7.5 mg PED/day) in RA patients was associated with an 
increased risk of clinical vertebral fracture, while there was no association with risk of 
non-vertebral OP fractures. We also found an increased and additive risk of OP fractures 
by concomitant use of oral GCs and PPIs in patients with RA, although the risk did not 
increase with increasing daily doses or longer duration of PPI use. Finally, we found that 
bDMARDs had no independent beneficial effect on reducing the risk of OP fractures in 
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iii. Impact Paragraph 
The main objective of this thesis was to study the fragility or osteoporotic (OP) fractures, 
both in the general population and among the patients with rheumatoid arthritis (RA), 
and in relation to death after fracture and medication use.  
Our key messages in Chapters 5 and 6 are more relevant for the healthcare setting, 
clinicians and patients with RA, but also possibly for the future therapeutic guidelines. We 
found that low-dose oral glucocorticoid (GC) therapy was not associated with risk of non-
vertebral OP fractures in patients with RA; however, it incurred a 59% increased risk of 
clinical vertebral fracture. This means an additional two clinical vertebral fractures per 
1000 patients with RA in the UK who took low-dose oral GCs in one year. And we know 
that only one third of vertebral fractures would come into clinical attention, so another 
four vertebral fractures per 1000 patients with RA in the UK have been caused by low-
dose GC therapy in a year and would have been missed in practice. This is an important 
finding, which warns clinicians that even in RA patients who take low daily GC doses, the 
risk of vertebral fracture is increased. Furthermore, we found that use of both oral GCs 
and proton pump inhibitors (PPIs, drugs that reduce stomach acid production) together 
incurred a 60% higher risk of OP fractures in patients with RA. This means an additional 14 
OP fractures per 1000 patients with RA in the UK who took both drugs for one year, 
compared to non-use of both medications. Thus, more attention should be paid to those 
RA patients who are prescribed both drugs, with routine fracture risk assessment and 
proper preventative anti-osteoporotic therapies. This recommendation would be more 
important for elderly patients, possibly with a more advanced disease, who are at a 
higher risk of OP fractures due to other risk factors.  
The main findings in Chapters 2 and 4 could be more relevant for policymakers, clinicians 
and inclusion in therapeutic guidelines. Here, we found a decreasing trend for all four 
major OP fractures (MOFs) including hip, clinical vertebral, humerus and forearm among 
women between 1995 and 2010 in Denmark. A slower rate of decrease of hip fracture, 
steady rate for humerus, and an increasing rate for clinical vertebral fracture was 
observed among men. Thus, we recommend appropriate screening for OP fractures (by 
fracture risk assessment and bone mineral density [BMD] measurements if needed), in 
addition to proper use of anti-osteoporotic treatments not only in postmenopausal 
women, but also in older men. On the other hand, we showed that there was a clear 





vertebral fracture, in those patients who were taking high daily doses. The threshold of 
cumulative GC use of 1.0 g prednisolone equivalent dose, as the hallmark of long-term GC 
therapy, is important for both the prescribing clinician and patients, who due to a chronic 
inflammatory disease, need long-term GC treatment in moderate to high average daily 
doses. Therefore, avoiding unnecessary high doses of oral GCs, adequate fracture risk 
assessment and timely anti-osteoporotic therapy are all recommended in order to avoid 
the catastrophic consequences of an imminent fracture in such patients. 
The findings in Chapters 3, 6 and 7 would ideally inspire the future research in the 
respecting field. Based on our findings, oral bisphosphonates (BPs) had apparently no 
beneficial effect on reducing the number of deaths in patients with a MOF. Oral BPs are 
highly recommended as first-line treatment in patients with osteoporosis or those who 
already had an OP fracture, in order to avoid a future fracture. However, our results did 
not support their hypothetical beneficial effect on hardening of the arteries. Instead, 
some limitations of the observational studies might explain our findings. Thus, we 
recommend further studies that could explain the alternative biological mechanisms or 
some properties of BPs that produce multiple effects, which confer a mortality benefit. 
Additionally, we did not observe an increasing fracture risk with higher daily doses or 
longer use of PPIs, which is in contrast to some previous observational studies. To date, 
few biological mechanisms have been proposed for an effect of PPIs on bone or falling, 
such as not enough production of stomach acid and calcium malabsorption, or an 
increased fall risk due to malabsorption of magnesium or vitamin B12, but our results did 
not support them. This is still an unsolved enigma, and thus an interesting realm for 
future studies to find a clear and sound mechanism, which can hopefully explain the 
associations that we and others found in real-world data. Furthermore, we found that 
biological disease-modifying antirheumatic drugs (bDMARDs) had no independent 
beneficial effect on reducing the risk of OP fractures in patients with RA. As the only 
known mechanism of biologic drugs for an effect on bone health is through the 
inflammatory cycle and considering a “treat-to-target” strategy of RA management in the 
real-world setting, our results are consenting with the protective effect of bDMARDs on 
BMD identified by clinical trials. However, more research is recommended to investigate 
the association between bDMARDs, BMD and OP fracture risk in patients with RA. 
Our research projects had also considerable scientific impact. The results of the study in 
Chapter 2 were published in one of the top journals in the bone field, i.e., Osteoporosis 
International in 2019. We also presented our findings in poster in the 34th International 
Conference on Pharmacoepidemiology (ICPE) in August 2018 at Prague, Czech Republic. 
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We published our results of Chapter 3 in one of the top journals in the gerontology and 
geriatrics field, i.e., Journal of the American Medical Directors Association in 2020. This 
project was also orally presented at the Dutch Epidemiological Conference - WEON in July 
2019 at Groningen, the Netherlands. The results of the project in Chapter 4 have been 
published in Archives of Osteoporosis in 2018. The paper from Chapter 5 has been 
published in one of the top ranked journals in the field of rheumatology, i.e., 
Rheumatology (Oxford) in 2021. The findings were also orally presented at the American 
Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting - virtual edition, 
oral presentation at the ASBMR Dutch days 2020 - virtual event, and in poster at the ICPE 
All Access 2020 - virtual event. We published our findings from Chapter 6 in Annals of the 
Rheumatic Diseases in 2021, which is the rank 1 rheumatology journal in the world. This 
publication was followed by an especially tailored editorial in the same issue, a couple of 
correspondences published in the same journal, a lay summary in the British Medical 
Journal Patient Summaries Blog, and a wide media coverage in medical news services and 
online bulletins. This project was also presented in poster at the Dutch Epidemiological 
Conference - WEON in July 2019 in Groningen, the Netherlands, and also in poster at the 
ASBMR 2020 Annual Meeting - virtual edition. The project in Chapter 7 has been currently 
submitted, with a list of target journals in the field of rheumatology, general medicine, 
and bone. The abstract has been also accepted for plenary poster presentation at the 

















































First of all, I would like to thank my lovely family, Maman Nasrin, Baba Aghanour, and my 
brother Alireza for their unrestricted love, care and accompaniment during the 4 years of 
this PhD position. My house in Maastricht was indeed warmer when you were coming to 
visit me, and I enjoyed a lot the Euro trips that we did together before the Covid-19 
pandemic! I would like to thank again my parents for their unlimited support and 
sponsorship, without which this PhD thesis could not be completed. 
I am also very proud of my supervisory team for this PhD position. Dear Frank, I learned a 
lot of things from you not only in pharmacoepidemiology, but also in professionalism, 
team management, and dedication to work. Your commitment to my PhD projects with 
all the difficulties you had in the past 2 years was just lovely and motivating. Dear 
Annelies, I was always fascinated how your specialty clinical input has helped me to 
interpret our results in various projects. Your encouraging words, in addition to your 
utmost kind attitude, great dedication to the projects, and wise advice have consistently 
helped me to accomplish the projects effectively and in time. Dear Andrea, I learned 
many things from you both in academic writing and in pharmacoepidemiology methods. I 
would not forget how wonderfully you helped me to get to know Maastricht and the new 
workplace during the early months of this position. Dear Annemariek, it was so lovely to 
work on our SAS codes together in addition to discussing and adjusting the nuances of 
methodological points in each project. Your positive attitude, dedication to work, and 
punctuality was exceptional. My dear team members, hartelijk bedankt and thank you 
very much!  
I truly appreciate the contribution of our other co-authors in the projects of this thesis, 
including Prof Dr Joop P van den Bergh, Prof Dr Tjeerd P van Staa, Prof Dr Piet Geusens, 
Prof Dr Pieter Vestergaard, Dr Patrick C Souverein, Dr Suzanne M Cadarette, and Dr 
Amine Amiche. Without your valuable work, our great publications were indeed 
impossible. 
I am also very grateful of the Members of the Assessment Committee for their time and 
for reading and evaluating this PhD thesis. This included Prof Dr Olaf H Klungel, Prof Dr 
Martijn Poeze, Prof Dr Matty P Weijenberg, Prof Dr Willem Lems, and Dr Sandrine P G 
Bours. 
I spent a very nice time with all my colleagues, pharmacists, older and newer PhD 





Toxicology of the Maastricht University Medical Center+. Dankjewel dear Ellen, Sander, 
Jan, Mieke, Diana, Jacqueline, Marlien, Ivo, Yannick, Femi, Judith (vD), Robin, Spencer, 
Richard, Lotte, Carlota, Ard, Sjoerd, Ken Ho, Nikki, Hans, Judith (G), and Veerle! 
I would also like to name those friends, cousins and other relatives, with whom I spent a 
wonderful time in the past 4 years, either in Maastricht, or in the Hague, or in Tehran, or 
in Istanbul, or via video calls during the Covid-19 pandemic! Merci dear Kaveh, Leila, 
Babak, Reza (S), Soroush, Mohammad (M), Fati, Razi, Bita, Raheleh, Soheila, Radu, Yin, 
Reza (E), Masoud, Farid, Fereshteh, Masoumeh, Mohammad (P), Hamidreza, Fatemeh 
(A), Sepideh, Elnaz, Mahtab, Nafiseh, Faraneh, Sanaz, Camila, Kelvin, Arjan, Esther and 
Dirk. I cannot wait to see you again!  
And last but not least, I would like to thank my previous Professors at the Tehran and 
Leiden Universities who taught me ‘Medicine’ and ‘Ageing’ as the scientific and 
educational base of this PhD position. My sincere gratitude would extend to Prof Dr 
Hassan Seirafi, Dr Reza Taslimi, Dr Mehdi Jalali, Dr Amirhoushang Ehsani, Dr Kamran 
Balighi, Prof Dr Rudi G J Westendorp, Prof Dr David van Bodegom, and Dr Jolanda 





 List of Publications 
 197 
v. List of Publications 
The publications as parts of this thesis are marked with an asterisk.  
 
* Abtahi S, Driessen JHM, Burden AM, Souverein PC, van den Bergh JP, van Staa TP, 
Boonen A, de Vries F. Low-dose oral glucocorticoid therapy and risk of osteoporotic 
fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice 
Research Datalink. Rheumatology (Oxford). 2021 Jul:keab548. 
 
Abtahi S, Driessen JHM, Burden AM, Souverein PC, van den Bergh JP, Boonen A. 
Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton 
pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid 
arthritis: a population-based cohort study' by Gong and Zhang and Lin et al. Ann Rheum 
Dis. 2021 May: annrheumdis-2021-220477. 
 
Abtahi S, Driessen JHM, Burden AM, Souverein PC, van den Bergh JP, van Staa TP, 
Boonen A, de Vries F. Response to: 'Correspondence on 'Concomitant use of oral 
glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among 
patients with rheumatoid arthritis: a population-based cohort study'' by Zheng. Ann 
Rheum Dis. 2021 Feb:annrheumdis-2021-219856. 
 
* Abtahi S, Driessen JHM, Burden AM, Souverein PC, van den Bergh JP, van Staa TP, 
Boonen A, de Vries F. Concomitant use of oral glucocorticoids and proton pump inhibitors 
and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-
based cohort study. Ann Rheum Dis. 2021 Mar;80:423-31.  
 
* Abtahi S, Burden AM, Geusens P, van den Bergh JP, van Staa T, de Vries F. The 
Association of oral bisphosphonate use with mortality risk following a major osteoporotic 
fracture in the United Kingdom: population-based cohort study. J Am Med Dir Assoc. 2020 
Jun;21(6):811-6. 
 
* Abtahi S, Driessen JHM, Vestergaard P, van den Bergh J, Boonen A, de Vries F, Burden 
AM. Secular trends in major osteoporotic fractures among 50+ adults in Denmark 





Abtahi S, Oshagbemi OA, van Veelen A, van Geel RMJM. The role of misclassification of 
exposure in the association between aspirin and nonsteroidal anti-inflammatory drug use 
and keratinocyte cancers. Br J Dermatol. 2019 Sep;181(3):642. 
 
Abtahi S. The role of long-term effects of allopurinol on cardiovascular outcomes and all-
cause mortality in diabetes. Diabetes Obes Metab. 2019 Sep;21(9):2180. 
 
Abtahi S, Oshagbemi OA, van Veelen A. Impact of average daily and cumulative dose of 
statins on mortality risk among healthy elderly. Am J Med. 2019 Jul;132(7):e621. 
 
Kamyab K, Rezvani M, Seirafi H, Mortazavi S, Teymourpour A, Abtahi S, Nasimi M. 
Distinguishing immunohistochemical features of alopecia areata from androgenic 
alopecia. J Cosmet Dermatol. 2019 Feb;18(1):422-6. 
 
Nasimi M, Abedini R, Daneshpazjooh M, Esmaeilpour A, Ghaedi F, Teimourpour A, Abtahi 
S. Illness perception of patients with pemphigus vulgaris. Int J Womens Dermatol. 2018 
Nov;5(2):96-9. 
 
* Amiche MA, Abtahi S, Driessen JHM, Vestergaard P, de Vries F, Cadarette SM, Burden 
AM. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in 
Denmark: a population-based case-control study. Arch Osteoporos. 2018 Mar;13(1):30. 
 
Abtahi S, Seirafi H, Balighi K, Ehsani AH, Farnaghi F, Mobasher P. Psoralen and UltraViolet 
A in atopic dermatitis. J Skin Stem Cell. 2017 Jun;4(2):e69286. 
 
Ebrahimifard F, Shirvani A, Abtahi S, Setayesh A. Internal jugular catheter malposition in a 
patient with end stage renal disease: a case report. Acta Med Iran. 2014;52(9):721-4. 
 
Rafiei M, Abtahi S, Fallahi M, Bastin H. [Cellular and Molecular Biology.] Eds. Tehran: Mir 







 Curriculum Vitae 
 199 
vi. Curriculum Vitae 
Shahab Abtahi was born in Tehran, Iran, on 19 May 1983. He went to the Moslem primary 
school in Tehranpars, before admitted to Allameh-Helli secondary and high schools as 
part of the National Organisation for Development of Exceptional Talents in Iran. At the 
final year of high school in 2000, he won the gold medal of 3rd National Biology 
Olympiad, followed a year later by winning the bronze medal of 12th International Biology 
Olympiad in Brussels, Belgium in 2001 as a member of Iran’s national team. In doing this, 
he received scholarships from the Young Scholars Club and the Ministry of Education of 
Iran (2000-2001). 
Shahab studied ‘General Medicine’ at the Tehran University of Medical Sciences and 
received his Medical Doctorate’s degree (MD) in 2011. During these years and besides 
medical school, he was teaching biology to college and high school students across Iran, 
as well as strengthening his English and learning French and German. He received the 
First-Class Member’s scholarship from the Iran’s National Elites Foundation between 2004 
and 2006. Furthermore, he received scholarship for and participated in the summer 
school for biomedical imaging at the Swiss Federal Institute of Technology- ETH Zurich in 
2009.  
After a few years of working as a general physician, teacher, and medical advisor in a 
pharmaceutical company, Shahab moved to the Netherlands in 2014 to enrol at the 
master course of ‘Vitality and Ageing’ at the Leyden Academy. For doing this, he 
benefited from a scholarship from the board of Academy. He obtained his Master of 
Science (MSc) in this discipline from the Leiden University in 2016. Shahab then started 
this PhD position in ‘Pharmacoepidemiology’ at the Department of Clinical Pharmacy and 
Toxicology of the Maastricht University Medical Center+ in 2017. Additionally, he was 
appointed as a visiting researcher at the Division of Pharmacoepidemiology and Clinical 
Pharmacology of the Utrecht Institute for Pharmaceutical Sciences, Utrecht University. 
During his studies as a PhD candidate at the Maastricht University, he presented his 
works at several national and international conferences and symposia, for which he has 
also been awarded a few scholarships and prizes. These included the 34th International 
Conference on Pharmacoepidemiology (ICPE) in 2018 at Prague, the Dutch 
Epidemiological Conference - WEON 2019 in Groningen, and the American Society for 





also attended the Summer Course of Pharmacoepidemiology and Drug Safety at the 
Utrecht University in 2019. 
Shahab is currently appointed as the ‘Postdoctoral Fellow in Pharmacoepidemiology’ at 
the Division of Pharmacoepidemiology and Clinical Pharmacology of the Utrecht Institute 
for Pharmaceutical Sciences, Utrecht University. 
 
 
 
